

CITATION REPORT

List of articles citing

Naturally secreted oligomers of amyloid beta protein
potently inhibit hippocampal long-term potentiation
in vivo

DOI: 10.1038/416535a
Nature, 2002, 416, 535-9.

Source: <https://exaly.com/paper-pdf/34729706/citation-report.pdf>

Version: 2024-04-10

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
2290	Alzheimers Disease Non-amyloidogenic p3 Peptide Revisited: A Case for Amyloid.		
2289	Protein misfolding, aggregation, and degradation in disease. 2003 , 232, 3-16		15
2288	Disease mechanism for retinitis pigmentosa (RP11) caused by mutations in the splicing factor gene PRPF31. 2002 , 11, 3209-19		56
2287	Methionine 35 oxidation reduces fibril assembly of the amyloid abeta-(1-42) peptide of Alzheimer's disease. 2002 , 277, 40173-6		172
2286	Huntingtin spheroids and protofibrils as precursors in polyglutamine fibrilization. 2002 , 277, 41032-7		288
2285	Molecular chaperones as modulators of polyglutamine protein aggregation and toxicity. 2002 , 99 Suppl 4, 16412-8		190
2284	Deciphering the genetic basis of Alzheimer's disease. 2002 , 3, 67-99		226
2283	Studies of the aggregation of mutant proteins in vitro provide insights into the genetics of amyloid diseases. 2002 , 99 Suppl 4, 16419-26		246
2282	Oligomeric and fibrillar species of amyloid-beta peptides differentially affect neuronal viability. 2002 , 277, 32046-53		1117
2281	New class of inhibitors of amyloid-beta fibril formation. Implications for the mechanism of pathogenesis in Alzheimer's disease. 2002 , 277, 42881-90		115
2280	Chaperoning brain degeneration. 2002 , 99 Suppl 4, 16407-11		179
2279	Presenilin and nicastrin regulate each other and determine amyloid beta-peptide production via complex formation. 2002 , 99, 8666-71		222
2278	Passive immunization against beta-amyloid peptide protects central nervous system (CNS) neurons from increased vulnerability associated with an Alzheimer's disease-causing mutation. 2002 , 277, 33012-7		50
2277	Genetic modulation of polyglutamine toxicity by protein conjugation pathways in Drosophila. 2002 , 11, 2895-904		131
2276	Therapeutics in Alzheimer's and prion diseases. 2002 , 30, 574-8		5
2275	Evidence for early cytotoxic aggregates in transgenic mice for human transthyretin Leu55Pro. 2002 , 161, 1935-48		93
2274	Toxic proteins in neurodegenerative disease. 2002 , 296, 1991-5		957

2273	Alzheimer's disease is a synaptic failure. 2002 , 298, 789-91	3246
2272	In vitro studies of Flemish, Dutch, and wild-type beta-amyloid provide evidence for two-staged neurotoxicity. 2002 , 11, 330-40	37
2271	Amyloid beta-peptide (1-42)-induced oxidative stress and neurotoxicity: implications for neurodegeneration in Alzheimer's disease brain. A review. 2002 , 36, 1307-13	575
2270	The search for an amyloid solution. 2002 , 298, 962-4; author reply 962-4	26
2269	The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. 2002 , 297, 353-6	10460
2268	Molecular Modeling and Simulation. 2002 ,	318
2267	Abeta(25-35) and Abeta(1-40) act on different calcium channels in CA1 hippocampal neurons. 2002 , 296, 1317-21	55
2266	Mutations that reduce aggregation of the Alzheimer's Abeta42 peptide: an unbiased search for the sequence determinants of Abeta amyloidogenesis. 2002 , 319, 1279-90	198
2265	A long CAG repeat in the mouse Sca1 locus replicates SCA1 features and reveals the impact of protein solubility on selective neurodegeneration. 2002 , 34, 905-19	250
2264	Protein misfolding, amyloid formation, and neurodegeneration: a critical role for molecular chaperones?. 2002 , 35, 9-12	262
2263	Bradykinin receptor modulation in cellular models of aging and Alzheimer's disease. 2002 , 2, 1833-40	19
2262	Amyloid beta-peptide alters the distribution of early endosomes and inhibits phosphorylation of Akt in the presence of 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT). 2002 , 106, 94-100	11
2261	Alzheimer's disease and the basal forebrain cholinergic system: relations to beta-amyloid peptides, cognition, and treatment strategies. 2002 , 68, 209-45	527
2260	Amyloid beta -peptide inhibition of the PKA/CREB pathway and long-term potentiation: reversibility by drugs that enhance cAMP signaling. 2002 , 99, 13217-21	426
2259	Chapter 4. Emerging themes in Alzheimer's disease research: Paradigm shift in drug discovery. 2002 , 37, 31-40	1
2258	The degradation of Abeta(25-35) by the serine protease plasmin is inhibited by aluminium. 2002 , 4, 357-67	12
2257	Ideas of order for amyloid fibril structure. 2002 , 10, 1031-6	125
2256	Amyloid-beta and tau serve antioxidant functions in the aging and Alzheimer brain. 2002 , 33, 1194-9	169

2255	Paradigm shifts in Alzheimer's disease and other neurodegenerative disorders: the emerging role of oligomeric assemblies. 2002 , 69, 567-77	493
2254	Age-related deficits in long-term potentiation are insensitive to hydrogen peroxide: coincidence with enhanced autophosphorylation of Ca ²⁺ /calmodulin-dependent protein kinase II. 2002 , 70, 298-308	36
2253	Neuroplasticity in Alzheimer's disease. 2002 , 70, 402-37	87
2252	Immunization treatment approaches in Alzheimer's and prion diseases. 2002 , 2, 400-4	5
2251	The neuropathogenic contributions of lysosomal dysfunction. 2002 , 83, 481-9	170
2250	Structural, kinetic and cytotoxicity aspects of 12-28 beta-amyloid protein fragment: a reappraisal. 2002 , 8, 578-88	21
2249	Medicine: danger--misfolding proteins. <i>Nature</i> , 2002 , 416, 483-4	50.4 136
2248	Astrophysics: the evidence in the afterglow. <i>Nature</i> , 2002 , 416, 484-5	50.4 3
2247	Targeted transfection by femtosecond laser. <i>Nature</i> , 2002 , 418, 290-1	50.4 501
2246	Neurodegenerative disease: amyloid pores from pathogenic mutations. <i>Nature</i> , 2002 , 418, 291	50.4 1046
2245	New hope for Alzheimer disease vaccine. 2002 , 8, 1195-6	18
2244	Converting p53 from a killer into a healer. 2002 , 8, 1196-8	40
2243	Generation of antibodies specific for beta-amyloid by vaccination of patients with Alzheimer disease. 2002 , 8, 1270-5	243
2242	Therapeutically effective antibodies against amyloid-beta peptide target amyloid-beta residues 4-10 and inhibit cytotoxicity and fibrillogenesis. 2002 , 8, 1263-9	362
2241	The early results of misfolding. 2002 , 1, 329-329	
2240	The nature of the beast. 2002 , 1, 410-410	
2239	Therapeutic strategies for Alzheimer's disease. 2002 , 1, 859-66	144
2238	The early results of misfolding. 2002 , 3, 314-314	

2237 The early results of misfolding. **2002**, 3, 335-335

2236 Towards an understanding of amyloidogenesis. **2002**, 9, 323-5

73

2235 Picture story. Locked but not loaded. **2002**, 9, 325

2234 Altered aggregation properties of mutant gamma-crystallins cause inherited cataract. **2002**, 21, 6005-14

136

2233 Intracellular A-beta amyloid, a sign for worse things to come?. **2002**, 26, 299-316

63

2232 Presenilins and APP in neuritic and synaptic plasticity: implications for the pathogenesis of Alzheimer's disease. **2002**, 2, 167-96

31

2231 Femtomole immunodetection of synthetic and endogenous amyloid-beta oligomers and its application to Alzheimer's disease drug candidate screening. **2003**, 20, 305-13

66

2230 What can rodent models tell us about cognitive decline in Alzheimer's disease?. **2003**, 27, 249-76

21

2229 Mechanisms of Abeta clearance and catabolism. **2003**, 4, 147-60

26

2228 Usefulness of behavioral and electrophysiological studies in transgenic models of Alzheimer's disease. **2003**, 28, 1009-15

14

2227 Neuritic alterations and neural system dysfunction in Alzheimer's disease and dementia with Lewy bodies. **2003**, 28, 1683-91

27

2226 Aging, amyloid, and Alzheimer's disease: a perspective in honor of Carl Cotman. **2003**, 28, 1705-13

65

2225 From Alzheimer to Huntington: why is a structural understanding so difficult?. **2003**, 22, 355-61

125

2224 Methionine oxidation: Implications for the mechanism of toxicity of the β amyloid peptide from Alzheimer's disease. **2003**, 10, 413-417

13

2223 Guinea pigs as a nontransgenic model for APP processing in vitro and in vivo. **2003**, 28, 637-44

36

2222 Amyloid beta -protein (Abeta) assembly: Abeta 40 and Abeta 42 oligomerize through distinct pathways. **2003**, 100, 330-5

1077

2221 Alzheimer's disease-affected brain: presence of oligomeric A beta ligands (ADDLs) suggests a molecular basis for reversible memory loss. **2003**, 100, 10417-22

906

2220 Protein aggregation and aggregate toxicity: new insights into protein folding, misfolding diseases and biological evolution. **2003**, 81, 678-99

1272

2219	The neuroprotective effects of Cerebrolysin in a transgenic model of Alzheimer's disease are associated with improved behavioral performance. 2003 , 110, 1313-27	73
2218	Emerging ideas on the molecular basis of protein and peptide aggregation. 2003 , 13, 146-59	289
2217	Soluble oligomers for the diagnosis of neurodegenerative diseases. 2003 , 2, 461-2	40
2216	Alzheimer's disease, normal-pressure hydrocephalus, and senescent changes in CSF circulatory physiology: a hypothesis. 2003 , 2, 506-11	320
2215	NMDA receptor regulation by amyloid-beta does not account for its inhibition of LTP in rat hippocampus. 2003 , 968, 263-72	80
2214	Repair of amyloid beta(25-35)-induced memory impairment and synaptic loss by a Kampo formula, Zokumei-to. 2003 , 990, 141-7	47
2213	Stress proteins and glial functions: possible therapeutic targets for neurodegenerative disorders. 2003 , 97, 35-53	51
2212	Cholinergic neuropathology in a mouse model of Alzheimer's disease. 2003 , 462, 371-81	83
2211	Protein-folding kinetics and mechanisms studied by pulse-labeling and mass spectrometry. 2003 , 22, 1-26	145
2210	Amyloid beta protein toxicity mediated by the formation of amyloid-beta protein precursor complexes. 2003 , 54, 781-9	82
2209	Alzheimer vaccine: amyloid-beta on trial. 2003 , 25, 283-8	22
2208	Alzheimer's amyloid beta oligomers and lipoprotein apoA β : mistaken identity is possible. 2003 , 25, 1024; author reply 1025	3
2207	Predicting the conformations of carvedilol based on its pharmacophore fragments: a gas phase and solvation ab initio and density functional study. 2003 , 666-667, 537-545	5
2206	Co-incorporation of A β 40 and A β 42 to form mixed pre-fibrillar aggregates. 2003 , 270, 654-63	35
2205	Truncated beta-amyloid peptide species in pre-clinical Alzheimer's disease as new targets for the vaccination approach. 2003 , 85, 1581-91	176
2204	Amyloid beta-protein (A β)1-40 protects neurons from damage induced by A β 1-42 in culture and in rat brain. 2003 , 87, 609-19	116
2203	Oligomerization and neurotoxicity of the amyloid ADan peptide implicated in familial Danish dementia. 2004 , 88, 281-90	30
2202	Lack of amyloid plaque formation in the central nervous system of a patient with Werner syndrome. 2003 , 23, 51-6	14

2201	Time scale of protein aggregation dictated by liquid-liquid demixing. 2003 , 51, 147-53	32
2200	Protein folding and misfolding. <i>Nature</i> , 2003 , 426, 884-90	50.4 3716
2199	Folding proteins in fatal ways. <i>Nature</i> , 2003 , 426, 900-4	50.4 1191
2198	Therapeutic approaches to protein-misfolding diseases. <i>Nature</i> , 2003 , 426, 905-9	50.4 726
2197	Hypotrichosis simplex of the scalp is associated with nonsense mutations in CDSN encoding corneodesmosin. 2003 , 34, 151-3	141
2196	A welcoming environment for amyloid plaques. 2003 , 6, 328-30	9
2195	Unfolding the role of protein misfolding in neurodegenerative diseases. 2003 , 4, 49-60	1072
2194	Conformational restriction via cyclization in beta-amyloid peptide Abeta(1-28) leads to an inhibitor of Abeta(1-28) amyloidogenesis and cytotoxicity. 2003 , 10, 149-59	34
2193	Self-assembly of Abeta(1-42) into globular neurotoxins. 2003 , 42, 12749-60	462
2192	A molecular switch in amyloid assembly: Met35 and amyloid beta-protein oligomerization. 2003 , 125, 15359-65	143
2191	Hydrogen exchange-mass spectrometry analysis of beta-amyloid peptide structure. 2003 , 42, 9507-14	55
2190	Prevention of peptide fibril formation in an aqueous environment by mutation of a single residue to Aib. 2003 , 42, 4492-8	25
2189	Abeta protofibrils possess a stable core structure resistant to hydrogen exchange. 2003 , 42, 14092-8	116
2188	The intact human acetylcholinesterase C-terminal oligomerization domain is alpha-helical in situ and in isolation, but a shorter fragment forms beta-sheet-rich amyloid fibrils and protofibrillar oligomers. 2003 , 42, 10863-73	22
2187	Humoral immune response to fibrillar beta-amyloid peptide. 2003 , 42, 11682-92	30
2186	Neurodegeneration in familial amyloid polyneuropathy: from pathology to molecular signaling. 2003 , 71, 385-400	104
2185	Alpha-synuclein oligomerization: a role for lipids?. 2003 , 26, 517-9	27
2184	Alzheimer's disease: molecular understanding predicts amyloid-based therapeutics. 2003 , 43, 545-84	717

2183	Prevention of transthyretin amyloid disease by changing protein misfolding energetics. 2003 , 299, 713-6	434
2182	Protofibrils, pores, fibrils, and neurodegeneration: separating the responsible protein aggregates from the innocent bystanders. 2003 , 26, 267-98	1439
2181	Methionine oxidation: Implications for the mechanism of toxicity of the β -amyloid peptide from Alzheimer's disease. 2003 , 10, 413-417	3
2180	Alternate aggregation pathways of the Alzheimer beta-amyloid peptide: Abeta association kinetics at endosomal pH. 2003 , 325, 743-57	87
2179	Mixtures of wild-type and a pathogenic (E22G) form of Abeta40 in vitro accumulate protofibrils, including amyloid pores. 2003 , 332, 795-808	213
2178	Role of high mobility group protein-1 (HMG1) in amyloid-beta homeostasis. 2003 , 301, 699-703	68
2177	Mutant SOD1 linked to familial amyotrophic lateral sclerosis, but not wild-type SOD1, induces ER stress in COS7 cells and transgenic mice. 2003 , 303, 496-503	111
2176	Part II: alpha-synuclein and its molecular pathophysiological role in neurodegenerative disease. 2003 , 45, 14-44	226
2175	Roles of amyloid precursor protein and its fragments in regulating neural activity, plasticity and memory. 2003 , 70, 1-32	545
2174	Human neprilysin is capable of degrading amyloid beta peptide not only in the monomeric form but also the pathological oligomeric form. 2003 , 350, 113-6	186
2173	Oxidative stress precedes fibrillar deposition of Alzheimer's disease amyloid beta-peptide (1-42) in a transgenic <i>Caenorhabditis elegans</i> model. 2003 , 24, 415-20	297
2172	Altered auditory-evoked potentials in mice carrying mutated human amyloid precursor protein and presenilin-1 transgenes. 2003 , 116, 511-7	10
2171	Ubiquitin and synaptic dysfunction: ataxic mice highlight new common themes in neurological disease. 2003 , 26, 4-7	21
2170	The metallobiology of Alzheimer's disease. 2003 , 26, 207-14	1074
2169	'Unfolding' pathways in neurodegenerative disease. 2003 , 26, 407-10	161
2168	Neuronal fibrillogenesis: amyloid fibrils from primary neuronal cultures impair long-term memory in the crab <i>Chasmagnathus</i> . 2003 , 147, 73-82	8
2167	Molecular mechanisms of amyloidosis. 2003 , 349, 583-96	1335
2166	Protein aggregation and the ubiquitin proteasome pathway: gaining the UPPer hand on neurodegeneration. 2003 , 13, 253-61	155

2165	The formation of highly soluble oligomers of alpha-synuclein is regulated by fatty acids and enhanced in Parkinson's disease. 2003 , 37, 583-95	448
2164	APP processing and synaptic function. 2003 , 37, 925-37	1248
2163	Parkin suppresses dopaminergic neuron-selective neurotoxicity induced by Pael-R in Drosophila. 2003 , 37, 911-24	317
2162	Triple-transgenic model of Alzheimer's disease with plaques and tangles: intracellular Abeta and synaptic dysfunction. 2003 , 39, 409-21	3031
2161	Enhanced proteolysis of beta-amyloid in APP transgenic mice prevents plaque formation, secondary pathology, and premature death. 2003 , 40, 1087-93	604
2160	Amyloid precursor protein (APP) and the biology of proteolytic processing: relevance to Alzheimer's disease. 2003 , 35, 1505-35	152
2159	Immunotherapy for Alzheimer's disease: will vaccination work?. 2003 , 9, 85-7	21
2158	Protofibrils of amyloid beta-protein inhibit specific K ⁺ currents in neocortical cultures. 2003 , 13, 177-90	67
2157	Synaptic plasticity in animal models of early Alzheimer's disease. 2003 , 358, 821-8	155
2156	Protein folding and misfolding: a paradigm of self-assembly and regulation in complex biological systems. 2003 , 361, 1205-22	95
2155	Human neurodegenerative disease modeling using Drosophila. 2003 , 26, 627-56	132
2154	In vitro characterization of conditions for amyloid-beta peptide oligomerization and fibrillogenesis. 2003 , 278, 11612-22	749
2153	The glutamatergic system and Alzheimer's disease: therapeutic implications. 2003 , 17, 641-52	177
2152	Kinetics of amyloid beta-protein degradation determined by novel fluorescence- and fluorescence polarization-based assays. 2003 , 278, 37314-20	93
2151	Dentate gyrus volume is reduced before onset of plaque formation in PDAPP mice: a magnetic resonance microscopy and stereologic analysis. 2003 , 100, 1381-6	164
2150	Cholesterol: from heart attacks to Alzheimer's disease. 2003 , 44, 1423-30	56
2149	Inhibition of receptor-mediated endocytosis demonstrates generation of amyloid beta-protein at the cell surface. 2003 , 278, 51035-43	94
2148	Parkin cleaves intracellular alpha-synuclein inclusions via the activation of calpain. 2003 , 278, 41890-9	60

2147	Specific compositions of amyloid-beta peptides as the determinant of toxic beta-aggregation. 2003 , 278, 23648-55	81
2146	Molecular distinction between pathogenic and infectious properties of the prion protein. 2003 , 77, 7611-22	121
2145	Alzheimer beta-amyloid homodimers facilitate A beta fibrillization and the generation of conformational antibodies. 2003 , 278, 35317-24	60
2144	Identification of a mutant amyloid peptide that predominantly forms neurotoxic protofibrillar aggregates. 2003 , 278, 23187-95	36
2143	Genetic programming by the proteolytic fragments of the amyloid precursor protein: somewhere between confusion and clarity. 2003 , 14, 317-41	23
2142	Molecular analyses of Machado-Joseph disease. 2003 , 100, 261-75	22
2141	Protein Misfolding and Disease. 2003 ,	
2140	Antibody therapy for Alzheimer's disease. 2003 , 2, 53-9	5
2139	Alzheimer's disease: from molecular pathogenesis to innovative therapies. 2003 , 3, 619-30	7
2138	Glycation of the amyloid beta-protein by a nicotine metabolite: a fortuitous chemical dynamic between smoking and Alzheimer's disease. 2003 , 100, 8182-7	52
2137	Activation of the c-Jun N-terminal kinase signaling cascade mediates the effect of amyloid-beta on long term potentiation and cell death in hippocampus: a role for interleukin-1beta?. 2003 , 278, 27971-80	94
2136	Stereoselective interactions of peptide inhibitors with the beta-amyloid peptide. 2003 , 278, 34874-81	117
2135	The peptide KLVFF-K(6) promotes beta-amyloid(1-40) protofibril growth by association but does not alter protofibril effects on cellular reduction of 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT). 2003 , 64, 1160-8	22
2134	Neurotoxic, redox-competent Alzheimer's beta-amyloid is released from lipid membrane by methionine oxidation. 2003 , 278, 42959-65	156
2133	Selective neuronal degeneration induced by soluble oligomeric amyloid beta protein. 2003 , 17, 118-20	179
2132	Nuclear localization of a non-caspase truncation product of atrophin-1, with an expanded polyglutamine repeat, increases cellular toxicity. 2003 , 278, 13047-55	68
2131	The selective inhibition of serpin aggregation by the molecular chaperone, alpha-crystallin, indicates a nucleation-dependent specificity. 2003 , 278, 48644-50	33
2130	Differential degradation of amyloid beta genetic variants associated with hereditary dementia or stroke by insulin-degrading enzyme. 2003 , 278, 23221-6	67

2129	Lithostathine quadruple-helical filaments form proteinase K-resistant deposits in Creutzfeldt-Jakob disease. 2003 , 278, 51770-8	35
2128	Nicastrin interacts with gamma-secretase complex components via the N-terminal part of its transmembrane domain. 2003 , 278, 52519-23	52
2127	Elucidation of primary structure elements controlling early amyloid beta-protein oligomerization. 2003 , 278, 34882-9	246
2126	Mutant huntingtin promotes the fibrillogenesis of wild-type huntingtin: a potential mechanism for loss of huntingtin function in Huntington's disease. 2003 , 278, 41452-61	95
2125	Spherical aggregates of beta-amyloid (amylospheroid) show high neurotoxicity and activate tau protein kinase I/glycogen synthase kinase-3beta. 2003 , 100, 6370-5	417
2124	Inhibition of proteasomal activity causes inclusion formation in neuronal and non-neuronal cells overexpressing Parkin. 2003 , 14, 4541-56	109
2123	Expansion of polyglutamine induces the formation of quasi-aggregate in the early stage of protein fibrillization. 2003 , 278, 34717-24	42
2122	Neurotoxicity and physicochemical properties of Abeta mutant peptides from cerebral amyloid angiopathy: implication for the pathogenesis of cerebral amyloid angiopathy and Alzheimer's disease. 2003 , 278, 46179-87	182
2121	An Alzheimer's disease hypothesis based on transcriptional dysregulation. 2003 , 10, 80-5	30
2120	Amyloidkrankheiten - kleine Fortschritte, groÙ Fragen. 2003 , 51, 1261-1263	
2119	Converging pathogenic mechanisms in vascular and neurodegenerative dementia. 2003 , 34, 335-7	163
2118	Amyloid beta-peptide [1-42]-associated free radical-induced oxidative stress and neurodegeneration in Alzheimer's disease brain: mechanisms and consequences. 2003 , 10, 2651-9	141
2117	Environmental enrichment exacerbates amyloid plaque formation in a transgenic mouse model of Alzheimer disease. 2003 , 62, 1220-7	165
2116	Proposed pathogenetic cascade of inclusion-body myositis: importance of amyloid-beta, misfolded proteins, predisposing genes, and aging. 2003 , 15, 737-44	59
2115	Possible involvement of small oligomers of amyloid-beta peptides in 15-deoxy-delta 12,14 prostaglandin J2-sensitive microglial activation. 2003 , 91, 330-3	28
2114	??-?. 2003 , 77, 1124-1126	
2113	Neprilysin gene transfer reduces human amyloid pathology in transgenic mice. 2003 , 23, 1992-6	326
2112	In vivo assessment of brain interstitial fluid with microdialysis reveals plaque-associated changes in amyloid-beta metabolism and half-life. 2003 , 23, 8844-53	369

2111	Age-dependent cerebrovascular abnormalities and blood flow disturbances in APP23 mice modeling Alzheimer's disease. 2003 , 23, 8453-9	127
2110	A beta 25-35-induced depression of long-term potentiation in area CA1 in vivo and in vitro is attenuated by verapamil. 2003 , 89, 3061-9	55
2109	Incubation of nerve endings with a physiological concentration of Abeta1-42 activates CaV2.2(N-Type)-voltage operated calcium channels and acutely increases glutamate and noradrenaline release. 2004 , 6, 243-55	40
2108	Attenuated hippocampus-dependent learning and memory decline in transgenic TgAPPswe Fischer-344 rats. 2004 , 10, 36-44	36
2107	Live discussion: Protein folding and neurodegeneration: biophysics to the rescue?. 2004 , 6, 99-105	
2106	Alzheimer disease: mechanistic understanding predicts novel therapies. 2004 , 140, 627-38	206
2105	The Amyloid Hypothesis and the clearance and degradation of Alzheimer's beta-peptide. 2004 , 6, 303-14	19
2104	The role of ubiquitin-protein ligases in neurodegenerative disease. 2004 , 1, 71-87	57
2103	Abeta(25-35)-induced memory impairment, axonal atrophy, and synaptic loss are ameliorated by M1, A metabolite of protopanaxadiol-type saponins. 2004 , 29, 860-8	119
2102	Minute quantities of misfolded mutant superoxide dismutase-1 cause amyotrophic lateral sclerosis. 2004 , 127, 73-88	211
2101	Using antibodies to analyze polyglutamine stretches. 2004 , 277, 103-28	21
2100	Immunotherapy for Alzheimer's disease. 2004 , 101 Suppl 2, 14657-62	142
2099	Thermodynamics of beta-amyloid fibril formation. 2004 , 120, 8307-17	26
2098	Self-assembly of peptides into a beta-barrel motif. 2004 , 120, 5809-23	30
2097	Targeting the neurotoxic species in Alzheimer's disease: inhibitors of Abeta oligomerization. 2004 , 18, 1366-72	177
2096	Block of long-term potentiation by naturally secreted and synthetic amyloid beta-peptide in hippocampal slices is mediated via activation of the kinases c-Jun N-terminal kinase, cyclin-dependent kinase 5, and p38 mitogen-activated protein kinase as well as metabotropic glutamate receptor type 5. 2004 , 24, 3370-8	398
2095	Enhanced toxicity and cellular binding of a modified amyloid beta peptide with a methionine to valine substitution. 2004 , 279, 42528-34	92
2094	Age-dependent neurodegeneration and Alzheimer-amyloid plaque formation in transgenic Drosophila. 2004 , 24, 3899-906	212

2093	Tyrosine gated electron transfer is key to the toxic mechanism of Alzheimer's disease beta-amyloid. 2004 , 18, 1427-9	231
2092	Cortical synaptic integration in vivo is disrupted by amyloid-beta plaques. 2004 , 24, 4535-40	179
2091	A nontransgenic mouse model shows inducible amyloid-beta (Abeta) peptide deposition and elucidates the role of apolipoprotein E in the amyloid cascade. 2004 , 101, 13909-14	93
2090	Mouse models of Alzheimer's disease: insight into treatment. 2004 , 15, 353-69	87
2089	Presynaptic localization of neprilysin contributes to efficient clearance of amyloid-beta peptide in mouse brain. 2004 , 24, 991-8	201
2088	Abnormality of G-protein-coupled receptor kinases at prodromal and early stages of Alzheimer's disease: an association with early beta-amyloid accumulation. 2004 , 24, 3444-52	53
2087	Memantine improves spatial learning in a transgenic mouse model of Alzheimer's disease. 2004 , 311, 677-82	157
2086	A strategy for designing inhibitors of alpha-synuclein aggregation and toxicity as a novel treatment for Parkinson's disease and related disorders. 2004 , 18, 1315-7	146
2085	Active immunization of mice with an Abeta-Hsp70 vaccine. 2004 , 1, 20-8	18
2084	3' untranslated region in a light neurofilament (NF-L) mRNA triggers aggregation of NF-L and mutant superoxide dismutase 1 proteins in neuronal cells. 2004 , 24, 2716-26	24
2083	Systemic catabolism of Alzheimer's Abeta40 and Abeta42. 2004 , 279, 45897-908	125
2082	Calcium dyshomeostasis in beta-amyloid and tau-bearing skeletal myotubes. 2004 , 279, 53524-32	25
2081	Amyloid nucleation and hierarchical assembly of Ure2p fibrils. Role of asparagine/glutamine repeat and nonrepeat regions of the prion domains. 2004 , 279, 3361-9	47
2080	Increased soluble amyloid-beta peptide and memory deficits in amyloid model mice overexpressing the low-density lipoprotein receptor-related protein. 2004 , 101, 1075-80	120
2079	Aggregation of the Acylphosphatase from Sulfolobus solfataricus: the folded and partially unfolded states can both be precursors for amyloid formation. 2004 , 279, 14111-9	89
2078	Beta-amyloid-mediated inhibition of NMDA receptor-dependent long-term potentiation induction involves activation of microglia and stimulation of inducible nitric oxide synthase and superoxide. 2004 , 24, 6049-56	168
2077	In silico study of amyloid beta-protein folding and oligomerization. 2004 , 101, 17345-50	305
2076	Dissecting the pathological effects of human Abeta40 and Abeta42 in Drosophila: a potential model for Alzheimer's disease. 2004 , 101, 6623-8	380

2075	Huntingtin bodies sequester vesicle-associated proteins by a polyproline-dependent interaction. 2004 , 24, 269-81	142
2074	Fibrillogenesis and cytotoxic activity of the amyloid-forming apomyoglobin mutant W7FW14F. 2004 , 279, 13183-9	64
2073	Trinucleotide Repeat Protocols. 2004 ,	3
2072	Novel ventriculo-peritoneal shunt in Alzheimer's disease cerebrospinal fluid biomarkers. 2004 , 4, 97-107	15
2071	Inhibition of beta-amyloid toxicity by short peptides containing N-methyl amino acids. 2004 , 63, 324-8	44
2070	Soluble Arctic amyloid beta protein inhibits hippocampal long-term potentiation in vivo. 2004 , 19, 2839-46	103
2069	Protein misfolding in neurodegenerative diseases. 2004 , 30, 215-24	80
2068	Clearing amyloid through the blood-brain barrier. 2004 , 89, 807-11	298
2067	In vivo inhibition of Abeta production by memapsin 2 (beta-secretase) inhibitors. 2004 , 89, 1409-16	100
2066	MAPK recruitment by beta-amyloid in organotypic hippocampal slice cultures depends on physical state and exposure time. 2004 , 91, 349-61	97
2065	A modified beta-amyloid hypothesis: intraneuronal accumulation of the beta-amyloid peptide--the first step of a fatal cascade. 2004 , 91, 513-20	304
2064	Macrophage colony stimulatory factor and interferon-gamma trigger distinct mechanisms for augmentation of beta-amyloid-induced microglia-mediated neurotoxicity. 2004 , 91, 623-33	33
2063	Dietary supplementation with melatonin reduces levels of amyloid beta-peptides in the murine cerebral cortex. 2004 , 36, 224-31	88
2062	Cell biology of protein misfolding: the examples of Alzheimer's and Parkinson's diseases. 2004 , 6, 1054-61	697
2061	Protein aggregation and neurodegenerative disease. 2004 , 10 Suppl, S10-7	2281
2060	Molecular pathways to neurodegeneration. 2004 , 10 Suppl, S2-9	555
2059	Neurodegenerative diseases: a decade of discoveries paves the way for therapeutic breakthroughs. 2004 , 10, 1055-63	547
2058	Beta-sheet breaker peptide prevents Abeta-induced spatial memory impairments with partial reduction of amyloid deposits. 2004 , 9, 953-61	116

2057	Neurovascular regulation in the normal brain and in Alzheimer's disease. 2004 , 5, 347-60	1662
2056	Strategies for disease modification in Alzheimer's disease. 2004 , 5, 677-85	361
2055	Pathway complexity of Alzheimer's beta-amyloid Abeta16-22 peptide assembly. 2004 , 12, 1245-55	121
2054	Age, apolipoprotein E4, and the risk of HIV dementia: the Hawaii Aging with HIV Cohort. 2004 , 157, 197-202	106
2053	Amyloid-beta precursor protein processing in neurodegeneration. 2004 , 14, 582-8	194
2052	Mechanisms of the inhibitory effects of amyloid beta-protein on synaptic plasticity. 2004 , 39, 1661-7	50
2051	Effects of amyloid-beta on cholinergic and acetylcholinesterase-positive cells in cultured basal forebrain neurons of embryonic rat brain. 2004 , 998, 73-82	14
2050	Proteomics: a new approach to investigate oxidative stress in Alzheimer's disease brain. 2004 , 1000, 1-7	191
2049	Proteases and lipoprotein receptors in Alzheimer's disease. 2004 , 41, 139-78	4
2048	ApoE and Abeta1-42 interactions: effects of isoform and conformation on structure and function. 2004 , 23, 235-46	72
2047	Human amylin oligomer growth and fibril elongation define two distinct phases in amyloid formation. 2004 , 279, 12206-12	127
2046	Redox-active metals, oxidative stress, and Alzheimer's disease pathology. 2004 , 1012, 153-63	329
2045	NSAID and antioxidant prevention of Alzheimer's disease: lessons from in vitro and animal models. 2004 , 1035, 68-84	103
2044	Glial reactions and the clearance of amyloid beta protein in the brains of patients with hereditary cerebral hemorrhage with amyloidosis-Dutch type. 2004 , 107, 389-98	26
2043	Trace metal contamination initiates the apparent auto-aggregation, amyloidosis, and oligomerization of Alzheimer's Abeta peptides. 2004 , 9, 954-60	195
2042	Linking DJ-1 to neurodegeneration offers novel insights for understanding the pathogenesis of Parkinson's disease. 2004 , 82, 163-74	106
2041	Proteolytic generation and aggregation of peptides from transmembrane regions: lung surfactant protein C and amyloid beta-peptide. 2004 , 61, 326-35	25
2040	Unraveling the pathogenesis of Parkinson's disease--the contribution of monogenic forms. 2004 , 61, 1729-50	41

2039	Amyloid peptide channels. 2004 , 202, 1-10	148
2038	Irreversible formation of intermediate BSA oligomers requires and induces conformational changes. 2004 , 55, 1053-62	37
2037	Interaction between amyloid beta-protein aggregates and membranes. 2004 , 10, 612-21	57
2036	Amyloid beta-peptide interactions with neuronal and glial cell plasma membrane: binding sites and implications for Alzheimer's disease. 2004 , 10, 229-48	231
2035	Interactions of Alzheimer amyloid peptides with cultured cells and brain tissue, and their biological consequences. 2004 , 76, 4-14	16
2034	The proteomics of positron emission tomography. 2004 , 55, 303-5	11
2033	Progressive age-related development of Alzheimer-like pathology in APP/PS1 mice. 2004 , 55, 801-14	280
2032	Residues 17-20 and 30-35 of beta-amyloid play critical roles in aggregation. 2004 , 75, 162-71	140
2031	High mobility group box protein-1 inhibits microglial Abeta clearance and enhances Abeta neurotoxicity. 2004 , 78, 880-91	64
2030	Amyloidosis of Alzheimer's Abeta peptides: solid-state nuclear magnetic resonance, electron paramagnetic resonance, transmission electron microscopy, scanning transmission electron microscopy and atomic force microscopy studies. 2004 , 42, 231-46	62
2029	Alzheimer's beta-peptide oligomer formation at physiologic concentrations. 2004 , 335, 81-90	100
2028	Kinetic control of dimer structure formation in amyloid fibrillogenesis. 2004 , 101, 12916-21	160
2027	Metabolite-initiated protein misfolding may trigger Alzheimer's disease. 2004 , 101, 4752-7	195
2026	Proteolytic antibody light chains alter beta-amyloid aggregation and prevent cytotoxicity. 2004 , 43, 9999-10007	37
2025	Prefibrillar amyloid protein aggregates share common features of cytotoxicity. 2004 , 279, 31374-82	315
2024	Resolution of Carvedilol's Conformational Surface via Gas and Solvent Phase Density Functional Theory Optimizations and NMR Spectroscopy. 2004 , 108, 7719-7729	7
2023	Solution NMR studies of the A beta(1-40) and A beta(1-42) peptides establish that the Met35 oxidation state affects the mechanism of amyloid formation. 2004 , 126, 1992-2005	430
2022	Pharmacophore Fragment-Based Prediction and Gas-Phase ab Initio Optimization of Carvedilol Conformations. 2004 , 108, 6239-6247	4

2021	Peroxidase activity of cyclooxygenase-2 (COX-2) cross-links beta-amyloid (Abeta) and generates Abeta-COX-2 hetero-oligomers that are increased in Alzheimer's disease. 2004 , 279, 14673-8	38
2020	Small assemblies of unmodified amyloid Eprotein are the proximate neurotoxin in Alzheimer's disease. 2004 , 25, 569-569	
2019	Prevention of domain swapping inhibits dimerization and amyloid fibril formation of cystatin C: use of engineered disulfide bridges, antibodies, and carboxymethylpapain to stabilize the monomeric form of cystatin C. 2004 , 279, 24236-45	91
2018	In silico assembly of Alzheimer's Abeta16-22 peptide into beta-sheets. 2004 , 126, 11509-16	125
2017	Inhibitors of beta-amyloid aggregation: still an issue of structure and function?. 2004 , 1, 7-12	1
2016	Beta-amyloid peptide at sublethal concentrations downregulates brain-derived neurotrophic factor functions in cultured cortical neurons. 2004 , 24, 6799-809	191
2015	Modeling amyloid beta-peptide insertion into lipid bilayers. 2004 , 86, 3585-97	47
2014	Molecular dynamics simulation of amyloid beta dimer formation. 2004 , 87, 2310-21	177
2013	Oligomerization of amyloid Abeta16-22 peptides using hydrogen bonds and hydrophobicity forces. 2004 , 87, 3657-64	123
2012	Diflunisal analogues stabilize the native state of transthyretin. Potent inhibition of amyloidogenesis. 2004 , 47, 355-74	211
2011	Per-6-substituted-per-6-deoxy beta-cyclodextrins inhibit the formation of beta-amyloid peptide derived soluble oligomers. 2004 , 47, 3329-33	41
2010	Physiological roles of amyloid-beta and implications for its removal in Alzheimer's disease. 2004 , 21, 621-30	39
2009	Synaptic targeting by Alzheimer's-related amyloid beta oligomers. 2004 , 24, 10191-200	805
2008	A Localized Surface Plasmon Resonance Biosensor: First Steps toward an Assay for Alzheimer's Disease. 2004 , 4, 1029-1034	596
2007	Transthyretin aggregation under partially denaturing conditions is a downhill polymerization. 2004 , 43, 7365-81	281
2006	Therapeutic targets from a Drosophila model of Alzheimer's disease. 2004 , 4, 513-6	13
2005	Methionine 35 oxidation reduces toxic effects of the amyloid beta-protein fragment (31-35) on human red blood cell. 2004 , 36, 2066-76	28
2004	The presenilin-1 familial Alzheimer disease mutant P117L impairs neurogenesis in the hippocampus of adult mice. 2004 , 188, 224-37	147

2003	Exaggerated polymerisation of beta-amyloid 40 stimulated by plasma lipoproteins results in fibrillar Abeta preparations that are ineffective in promoting ADP-induced platelet aggregation. 2004 , 1674, 305-11	3
2002	Experimental investigation of protein folding and misfolding. 2004 , 34, 4-14	110
2001	Ubiquitin-proteasome-mediated local protein degradation and synaptic plasticity. 2004 , 73, 311-57	119
2000	Structure and function of amyloid in Alzheimer's disease. 2004 , 74, 323-49	119
1999	Cognitive impairment in PDAPP mice depends on ApoE and ACT-catalyzed amyloid formation. 2004 , 25, 1153-67	64
1998	Alzheimer's amyloid beta-peptide (1-42): involvement of methionine residue 35 in the oxidative stress and neurotoxicity properties of this peptide. 2004 , 25, 563-8	118
1997	Lethal weapon: amyloid beta-peptide, role in the oxidative stress and neurodegeneration of Alzheimer's disease. 2004 , 25, 581-7	21
1996	Small assemblies of unmodified amyloid beta-protein are the proximate neurotoxin in Alzheimer's disease. 2004 , 25, 569-80	437
1995	LRP/amyloid beta-peptide interaction mediates differential brain efflux of Abeta isoforms. 2004 , 43, 333-44	661
1994	Deciphering the molecular basis of memory failure in Alzheimer's disease. 2004 , 44, 181-93	1004
1993	Methionine 35 oxidation reduces toxic and pro-apoptotic effects of the amyloid beta-protein fragment (31-35) on isolated brain mitochondria. 2004 , 126, 297-303	27
1992	Principles of protein folding, misfolding and aggregation. 2004 , 15, 3-16	689
1991	Roles of molecular chaperones in protein misfolding diseases. 2004 , 15, 17-29	236
1990	Staying connected: synapses in Alzheimer disease. 2004 , 165, 1461-4	15
1989	The endocytotic pathway is required for increased A beta 42 secretion during apoptosis. 2004 , 128, 201-11	12
1988	Microglial activation facilitates Abeta plaque removal following intracranial anti-Abeta antibody administration. 2004 , 15, 11-20	166
1987	Normal induction but accelerated decay of LTP in APP + PS1 transgenic mice. 2004 , 15, 188-95	98
1986	Deposition of amyloid fibrils promotes cell-surface accumulation of amyloid beta precursor protein. 2004 , 16, 617-29	26

1985	Activation of the neuronal c-Abl tyrosine kinase by amyloid-beta-peptide and reactive oxygen species. 2004 , 17, 326-36	96
1984	Amyloid beta-protein induced electrophysiological changes are dependent on aggregation state: N-methyl-D-aspartate (NMDA) versus non-NMDA receptor/channel activation. 2004 , 366, 320-5	66
1983	Soluble beta-amyloid (A beta) 40 causes attenuation or potentiation of noradrenaline-induced vasoconstriction in rats depending upon the concentration employed. 2004 , 367, 129-32	14
1982	Familial Alzheimer disease associated with A713T mutation in APP. 2004 , 370, 241-3	24
1981	Age-related myelin breakdown: a developmental model of cognitive decline and Alzheimer's disease. 2004 , 25, 5-18; author reply 49-62	681
1980	Silent prions lying in wait: a two-hit model of prion/amyloid formation and infection. 2004 , 336, 775-86	68
1979	Monitoring the process of HypF fibrillization and liposome permeabilization by protofibrils. 2004 , 338, 943-57	96
1978	Atomic force microscopy reveals defects within mica supported lipid bilayers induced by the amyloidogenic human amylin peptide. 2004 , 342, 877-87	134
1977	Biophysical alterations of hippocampal pyramidal neurons in learning, ageing and Alzheimer's disease. 2004 , 3, 383-406	72
1976	Targets for Alzheimer's disease: lessons learnt from flies. 2004 , 3, 64-70	2
1975	BACE1 deficiency rescues memory deficits and cholinergic dysfunction in a mouse model of Alzheimer's disease. 2004 , 41, 27-33	457
1974	A disintegrin-metalloproteinase prevents amyloid plaque formation and hippocampal defects in an Alzheimer disease mouse model. 2004 , 113, 1456-64	438
1973	Emerging principles of conformation-based prion inheritance. 2004 , 73, 617-56	294
1972	Transmissible spongiform encephalopathies. 2004 , 363, 51-61	192
1971	Enhancement of NMDA responses by beta-amyloid peptides in the hippocampus in vivo. 2004 , 15, 1649-52	49
1970	Amyloid beta peptide-induced cerebral neuronal loss is mediated by caspase-3 in vivo. 2004 , 63, 255-61	51
1969	Soluble oligomeric Abeta disrupts the protein kinase C signaling pathway. 2004 , 15, 503-7	7
1968	Amyloid-beta down-regulates XIAP expression in human SH-SY5Y neuroblastoma cells. 2004 , 15, 851-4	7

1967	Do antiangiogenic protein fragments have amyloid properties?. 2004 , 104, 1601-5	23
1966	Amyloid beta prevents activation of calcium/calmodulin-dependent protein kinase II and AMPA receptor phosphorylation during hippocampal long-term potentiation. 2004 , 92, 2853-8	123
1965	Amyloid beta degradation: a challenging task for brain peptidases. 2005 , 38, 129-45	17
1964	Amyloid- β as a Biologically Active Peptide in CNS. 2005 , 529-538	0
1963	Dementia update 2005. 2005 , 19, 100-17	44
1962	Reduction of NR1 and phosphorylated Ca ²⁺ /calmodulin-dependent protein kinase II levels in Alzheimer's disease. 2005 , 16, 1809-13	42
1961	An Overview of Protein Misfolding Diseases. 1093-1113	3
1960	HIV-1 Tat inhibits neprilysin and elevates amyloid beta. 2005 , 19, 127-35	142
1959	The Amyloid β Protein. 384-491	2
1958	Disease modifying strategies for the treatment of Alzheimer's disease targeted at modulating levels of the beta-amyloid peptide. 2005 , 33, 553-8	50
1957	Synaptic plasticity disruption by amyloid beta protein: modulation by potential Alzheimer's disease modifying therapies. 2005 , 33, 563-7	63
1956	Mechanisms of memory loss in Abeta and tau mouse models. 2005 , 33, 591-4	38
1955	The role of cell-derived oligomers of A β in Alzheimer's disease and avenues for therapeutic intervention. 2005 , 33, 1087-1090	97
1954	Structure and neurotoxicity of novel amyloids derived from the BRI gene. 2005 , 33, 1111-1112	6
1953	Protein aggregation, metals and oxidative stress in neurodegenerative diseases. 2005 , 33, 1082-6	49
1952	Structure and neurotoxicity of novel amyloids derived from the BRI gene. 2005 , 33, 1111-2	8
1951	The production of hydrogen peroxide during early-stage protein aggregation: a common pathological mechanism in different neurodegenerative diseases?. 2005 , 33, 548-50	41
1950	Protein aggregation, metals and oxidative stress in neurodegenerative diseases. 2005 , 33, 1082-1086	82

1949	Understanding molecular mechanisms of proteolysis in Alzheimer's disease: progress toward therapeutic interventions. 2005 , 1751, 60-7	56
1948	Imaging amyloid beta peptide oligomeric particles in solution. 2005 , 13, 5213-7	14
1947	The physics of the interactions governing folding and association of proteins. 2005 , 1066, 34-53	12
1946	Protein denaturation and aggregation: Cellular responses to denatured and aggregated proteins. 2005 , 1066, 181-221	83
1945	In vitro study of stability and amyloid-fibril formation of two mutants of human stefin B (cystatin B) occurring in patients with EPM1. 2005 , 14, 2713-22	33
1944	Virosome-based active immunization targets soluble amyloid species rather than plaques in a transgenic mouse model of Alzheimer's disease. 2005 , 27, 157-66	17
1943	Protein misfolding, aggregation, and degradation in disease. 2005 , 31, 141-50	44
1942	Calcium-regulated signaling pathways: role in amyloid beta-induced synaptic dysfunction. 2004 , 6, 53-64	48
1941	Oxidative metabolites accelerate Alzheimer's amyloidogenesis by a two-step mechanism, eliminating the requirement for nucleation. 2005 , 44, 4977-83	125
1940	Reduced neuronal expression of synaptic transmission modulator HNK-1/neural cell adhesion molecule as a potential consequence of amyloid beta-mediated oxidative stress: a proteomic approach. 2005 , 92, 705-17	27
1939	A 13 kDa carboxy-terminal fragment of ApoE stabilizes Abeta hexamers. 2005 , 94, 1351-60	20
1938	Globular amyloid beta-peptide oligomer - a homogenous and stable neuropathological protein in Alzheimer's disease. 2005 , 95, 834-47	467
1937	Aggregating interests in aggregates: mechanistic, diagnostic and therapeutic implications of brain amyloidosis in neurodegenerative disorders among the elderly. 2005 , 5, 117-121	
1936	Beta-amyloid inhibition of long-term potentiation is mediated via tumor necrosis factor. 2005 , 22, 2827-32	115
1935	Contributors to white matter damage in the frontal lobe in Alzheimer's disease. 2005 , 31, 623-31	38
1934	Modulation of neurodegeneration by molecular chaperones. 2005 , 6, 11-22	852
1933	The crucial role of metal ions in neurodegeneration: the basis for a promising therapeutic strategy. 2005 , 146, 1041-59	290
1932	Amyloid beta protein immunotherapy neutralizes Abeta oligomers that disrupt synaptic plasticity in vivo. 2005 , 11, 556-61	443

1931	The synaptic Abeta hypothesis of Alzheimer disease. 2005 , 8, 977-9	176
1930	Beyond migration: Dlx1 regulates interneuron differentiation. 2005 , 8, 979-81	14
1929	Natural oligomers of the amyloid-beta protein specifically disrupt cognitive function. 2005 , 8, 79-84	1436
1928	Targeting BACE1 with siRNAs ameliorates Alzheimer disease neuropathology in a transgenic model. 2005 , 8, 1343-9	344
1927	Opinion: What is the role of protein aggregation in neurodegeneration?. 2005 , 6, 891-8	488
1926	A case for a non-transgenic animal model of Alzheimer's disease. 2005 , 4, 157-72	47
1925	Genetic and molecular aspects of Alzheimer's disease shed light on new mechanisms of transcriptional regulation. 2005 , 4, 134-46	60
1924	Behavioral phenotypes of amyloid-based genetically modified mouse models of Alzheimer's disease. 2005 , 4, 173-96	152
1923	The immune system, amyloid-beta peptide, and Alzheimer's disease. 2005 , 205, 244-56	51
1922	Role of water-soluble amyloid-beta in the pathogenesis of Alzheimer's disease. 2005 , 86, 139-45	30
1921	Amyloid-beta in Alzheimer's disease: the horse or the cart? Pathogenic or protective?. 2005 , 86, 133-8	48
1920	Metals and amyloid-beta in Alzheimer's disease. 2005 , 86, 147-59	254
1919	Calcium dysregulation in Alzheimer's disease: recent advances gained from genetically modified animals. 2005 , 38, 427-37	127
1918	Up-regulation of nicotinic acetylcholine receptors by central-type acetylcholinesterase inhibitors in rat cortical neurons. 2005 , 527, 77-85	50
1917	Reductions in beta-amyloid concentrations in vivo by the gamma-secretase inhibitors BMS-289948 and BMS-299897. 2005 , 69, 689-98	93
1916	Soluble Abeta oligomers ultrastructurally localize to cell processes and might be related to synaptic dysfunction in Alzheimer's disease brain. 2005 , 1031, 222-8	102
1915	Protective effect of donepezil against Abeta(1-40) neurotoxicity in rat septal neurons. 2005 , 1047, 72-84	69
1914	The last neuronal division: a unifying hypothesis for the pathogenesis of Alzheimer's disease. 2005 , 9, 531-41	51

1913	Beta-amyloid accumulation in APP mutant neurons reduces PSD-95 and GluR1 in synapses. 2005 , 20, 187-98	304
1912	Metabolism of amyloid-beta peptide and Alzheimer's disease. 2005 , 108, 129-48	161
1911	CLPM: a cross-linked peptide mapping algorithm for mass spectrometric analysis. 2005 , 6 Suppl 2, S9	31
1910	Lattice models of peptide aggregation: evaluation of conformational search algorithms. 2005 , 26, 1638-46	7
1909	Synaptic transmission and synchronous activity is disrupted in hippocampal slices taken from aged TAS10 mice. 2005 , 15, 110-7	30
1908	Amyloid-beta aggregates formed at polar-nonpolar interfaces differ from amyloid-beta protofibrils produced in aqueous buffers. 2005 , 67, 164-74	30
1907	Hydrolysis of the amyloid beta-peptide (A beta) 1-40 between Asp23-Val24 produces non-aggregating fragments. An electrospray mass spectrometric study. 2005 , 40, 142-5	7
1906	Oligomerization of amyloid beta-protein occurs during the isolation of lipid rafts. 2005 , 80, 114-9	24
1905	Fluorescence resonance energy transfer analysis of apolipoprotein E C-terminal domain and amyloid beta peptide (1-42) interaction. 2005 , 80, 877-86	21
1904	Aluminum-triggered structural modifications and aggregation of beta-amyloids. 2005 , 62, 1724-33	109
1903	What is the dominant Abeta species in human brain tissue? A review. 2005 , 7, 29-41	39
1902	A computational positron emission tomography simulation model for imaging beta-amyloid in mice. 2005 , 7, 69-77	8
1901	beta-Amyloid peptides impair PKC-dependent functions of metabotropic glutamate receptors in prefrontal cortical neurons. 2005 , 93, 3102-11	41
1900	The neuropathology of Alzheimer's disease in the year 2005. 2005 , 433-440	11
1899	The role of beta-amyloid in Alzheimer's disease. 2005 , 452-458	
1898	Alzheimer's Disease: Clinical Features, Neuropathologies and Biochemical Abnormalities, Genetics, Models, and Experimental Therapeutics. 2005 , 445-458	2
1897	Dendritic spine abnormalities in amyloid precursor protein transgenic mice demonstrated by gene transfer and intravital multiphoton microscopy. 2005 , 25, 7278-87	458
1896	Ubiquitin-proteasome pathway components as therapeutic targets for CNS maladies. 2005 , 11, 3807-28	25

1895	Synaptic fatigue is more pronounced in the APP/PS1 transgenic mouse model of Alzheimer's disease. 2005 , 2, 137-40	21
1894	Beta-amyloid immunotherapy prevents synaptic degeneration in a mouse model of Alzheimer's disease. 2005 , 25, 9096-101	146
1893	Protofibril formation of amyloid beta-protein at low pH via a non-cooperative elongation mechanism. 2005 , 280, 30001-8	96
1892	Alzheimer's Abeta40 studied by NMR at low pH reveals that sodium 4,4-dimethyl-4-silapentane-1-sulfonate (DSS) binds and promotes beta-ball oligomerization. 2005 , 280, 3675-85	30
1891	Copper-dependent inhibition of human cytochrome c oxidase by a dimeric conformer of amyloid-beta1-42. 2005 , 25, 672-9	291
1890	Transmembrane glycine zippers: physiological and pathological roles in membrane proteins. 2005 , 102, 14278-83	199
1889	Autoantibodies to redox-modified oligomeric Abeta are attenuated in the plasma of Alzheimer's disease patients. 2005 , 280, 17458-63	71
1888	RNA-binding protein is involved in aggregation of light neurofilament protein and is implicated in the pathogenesis of motor neuron degeneration. 2005 , 14, 3643-59	35
1887	Reversible mechanical unzipping of amyloid beta-fibrils. 2005 , 280, 8464-70	72
1886	Interaction of presenilins with FKBP38 promotes apoptosis by reducing mitochondrial Bcl-2. 2005 , 14, 1889-902	74
1885	Formation of morphologically similar globular aggregates from diverse aggregation-prone proteins in mammalian cells. 2005 , 102, 10887-92	61
1884	Transgenic <i>C. elegans</i> as a model in Alzheimer's research. 2005 , 2, 37-45	66
1883	Protein aggregation in Alzheimer's disease and other neuropathological disorders. 2005 , 2, 19-28	30
1882	A beta immunotherapy: Lessons learned for potential treatment of Alzheimer's disease. 2005 , 2, 255-60	58
1881	The role of cell-derived oligomers of Abeta in Alzheimer's disease and avenues for therapeutic intervention. 2005 , 33, 1087-90	171
1880	Reversal of amyloid-induced heart disease in desmin-related cardiomyopathy. 2005 , 102, 13592-7	93
1879	Folding events in the 21-30 region of amyloid beta-protein (Abeta) studied in silico. 2005 , 102, 6015-20	113
1878	Soluble beta-amyloid1-40 induces NMDA-dependent degradation of postsynaptic density-95 at glutamatergic synapses. 2005 , 25, 11061-70	246

1877	Beta-secretase-cleaved amyloid precursor protein accumulates at actin inclusions induced in neurons by stress or amyloid beta: a feedforward mechanism for Alzheimer's disease. 2005 , 25, 11313-21	105
1876	Alzheimer's Disease. 2005 ,	7
1875	Conformational transition of amyloid beta-peptide. 2005 , 102, 5403-7	222
1874	Akt-dependent expression of NAIP-1 protects neurons against amyloid- β toxicity. 2005 , 280, 24941-7	48
1873	beta-amyloid is different in normal aging and in Alzheimer disease. 2005 , 280, 34186-92	148
1872	Hydrogen peroxide is generated during the very early stages of aggregation of the amyloid peptides implicated in Alzheimer disease and familial British dementia. 2005 , 280, 35789-92	180
1871	Amyloid-beta protofibrils differ from amyloid-beta aggregates induced in dilute hexafluoroisopropanol in stability and morphology. 2005 , 280, 2471-80	86
1870	The Materials Science of Protein Aggregation. 2005 , 30, 452-457	21
1869	Nucleation-dependent polymerization is an essential component of amyloid-mediated neuronal cell death. 2005 , 25, 1071-80	185
1868	BACE1, a major determinant of selective vulnerability of the brain to amyloid-beta amyloidogenesis, is essential for cognitive, emotional, and synaptic functions. 2005 , 25, 11693-709	436
1867	Amyloid ion channels: a common structural link for protein-misfolding disease. 2005 , 102, 10427-32	799
1866	Insights into the molecular basis of the differing susceptibility of varying cell types to the toxicity of amyloid aggregates. 2005 , 118, 3459-70	83
1865	Acute gamma-secretase inhibition improves contextual fear conditioning in the Tg2576 mouse model of Alzheimer's disease. 2005 , 25, 8898-902	189
1864	LRP and Alzheimer's disease. 2005 , 16, 123-35	50
1863	Bax deletion prevents neuronal loss but not neurological symptoms in a transgenic model of inherited prion disease. 2005 , 102, 238-43	86
1862	Solvent and mutation effects on the nucleation of amyloid beta-protein folding. 2005 , 102, 18258-63	107
1861	Sequence determinants of enhanced amyloidogenicity of Alzheimer A β 42 peptide relative to A β 40. 2005 , 280, 35069-76	95
1860	Physicochemical characteristics of soluble oligomeric A β and their pathologic role in Alzheimer's disease. 2005 , 27, 869-81	100

1859	Effects of chronic glucocorticoid administration on insulin-degrading enzyme and amyloid-beta peptide in the aged macaque. 2005 , 64, 139-46	73
1858	The expression of p75 neurotrophin receptor protects against the neurotoxicity of soluble oligomers of beta-amyloid. 2005 , 311, 126-34	29
1857	Structure of beta-amyloid fibrils and its relevance to their neurotoxicity: implications for the pathogenesis of Alzheimer's disease. 2005 , 99, 437-47	76
1856	Binding of endostatin to phosphatidylserine-containing membranes and formation of amyloid-like fibers. 2005 , 44, 2857-63	84
1855	Curcumin inhibits formation of amyloid beta oligomers and fibrils, binds plaques, and reduces amyloid in vivo. 2005 , 280, 5892-901	1668
1854	Oxidative stress in Alzheimer's disease: implications for prevention and therapy. 2005 , 38, 65-78	67
1853	Refining an Alzheimer's vaccine to avoid an inflammatory response. 2005 , 5, 809-16	5
1852	The development of anti-amyloid therapy for Alzheimer's disease : from secretase modulators to polymerisation inhibitors. 2005 , 19, 989-96	68
1851	Single-site mutations in a hyperthermophilic variant of the B1 domain of protein G result in self-assembled oligomers. 2005 , 44, 2360-8	11
1850	Aggregation of a slow-folding mutant of a beta-clam protein proceeds through a monomeric nucleus. 2005 , 44, 7266-74	57
1849	Promotion of oxidative lipid membrane damage by amyloid beta proteins. 2005 , 44, 12606-13	101
1848	Kinetic stabilization of an oligomeric protein by a single ligand binding event. 2005 , 127, 5540-51	89
1847	Conformational dynamics of amyloid beta-protein assembly probed using intrinsic fluorescence. 2005 , 44, 13365-76	58
1846	Dimeric transthyretin variant assembles into spherical neurotoxins. 2005 , 44, 3280-8	24
1845	Exploring the early steps of amyloid peptide aggregation by computers. 2005 , 38, 885-91	81
1844	Efficient inhibition of prion replication by PrP-Fc(2) suggests that the prion is a PrP(Sc) oligomer. 2005 , 345, 1243-51	29
1843	Reversal of protein aggregation provides evidence for multiple aggregated States. 2005 , 346, 603-16	82
1842	ApoE isoform-specific effects on LTP: blockade by oligomeric amyloid-beta1-42. 2005 , 18, 75-82	74

1841	Differential effects of oligomeric and fibrillar amyloid-beta 1-42 on astrocyte-mediated inflammation. 2005 , 18, 459-65	181
1840	Amyloid-beta fibril formation is not necessarily required for microglial activation by the peptides. 2005 , 47, 369-76	28
1839	Mechanism of impairment of long-term potentiation by amyloid beta is independent of NMDA receptors or voltage-dependent calcium channels in hippocampal CA1 pyramidal neurons. 2005 , 391, 1-6	39
1838	Altered intracellular signaling and reduced viability of Alzheimer's disease neuronal cybrids is reproduced by beta-amyloid peptide acting through receptor for advanced glycation end products (RAGE). 2005 , 29, 333-43	49
1837	An unusual soluble beta-turn-rich conformation of prion is involved in fibril formation and toxic to neuronal cells. 2005 , 328, 292-305	52
1836	A hybrid molecule that prohibits amyloid fibrils and alleviates neuronal toxicity induced by beta-amyloid (1-42). 2005 , 328, 816-23	35
1835	Induction of anti-inflammatory immune response by an adenovirus vector encoding 11 tandem repeats of Abeta1-6: toward safer and effective vaccines against Alzheimer's disease. 2005 , 336, 84-92	31
1834	Biochemical and medical aspects of the indoleamine 2,3-dioxygenase-initiated L-tryptophan metabolism. 2005 , 338, 12-9	258
1833	Effect of beta-amyloid peptide on behavior and synaptic plasticity in terrestrial snail. 2005 , 67, 40-5	9
1832	Are mitochondria critical in the pathogenesis of Alzheimer's disease?. 2005 , 49, 618-32	222
1831	Amyloid-beta causes apoptosis of neuronal cells via caspase cascade, which can be prevented by amyloid-beta-derived short peptides. 2005 , 196, 282-9	76
1830	The aggravating role of the ubiquitin-proteasome system in neurodegeneration. 2005 , 579, 571-6	42
1829	Neutron diffraction reveals sequence-specific membrane insertion of pre-fibrillar islet amyloid polypeptide and inhibition by rifampicin. 2005 , 579, 1143-8	23
1828	Charge substitution shows that repulsive electrostatic interactions impede the oligomerization of Alzheimer amyloid peptides. 2005 , 579, 3574-8	46
1827	The insect homologue of the amyloid precursor protein interacts with the heterotrimeric G protein Go alpha in an identified population of migratory neurons. 2005 , 288, 160-78	29
1826	Induction of a Th2 immune response by co-administration of recombinant adenovirus vectors encoding amyloid beta-protein and GM-CSF. 2005 , 23, 2977-86	28
1825	Neurodegenerative diseases: insights into pathogenic mechanisms from atherosclerosis. 2005 , 26, 293-302	43
1824	Mean age of onset in familial Alzheimer's disease is determined by amyloid beta 42. 2005 , 26, 785-8	87

1823	Searching for the role and the most suitable biomarkers of oxidative stress in Alzheimer's disease and in other neurodegenerative diseases. 2005 , 26, 587-95	104
1822	Prevention of Alzheimer's disease: Omega-3 fatty acid and phenolic anti-oxidant interventions. 2005 , 26 Suppl 1, 133-6	167
1821	Intraneuronal Abeta, non-amyloid aggregates and neurodegeneration in a Drosophila model of Alzheimer's disease. 2005 , 132, 123-35	285
1820	Endogenous beta-amyloid peptide synthesis modulates cAMP response element-regulated gene expression in PC12 cells. 2005 , 135, 1193-202	23
1819	Novel Abeta peptide immunogens modulate plaque pathology and inflammation in a murine model of Alzheimer's disease. 2005 , 2, 28	29
1818	Protein aggregation determinants from a simplified model: cooperative folders resist aggregation. 2005 , 14, 653-62	22
1817	Detection of a biomarker for Alzheimer's disease from synthetic and clinical samples using a nanoscale optical biosensor. 2005 , 127, 2264-71	716
1816	Neurotoxic protein oligomers--what you see is not always what you get. 2005 , 12, 88-95	189
1815	Pathophysiology of Alzheimer's disease. 2005 , 15, 727-53, ix	52
1814	Formation and stabilization model of the 42-mer Abeta radical: implications for the long-lasting oxidative stress in Alzheimer's disease. 2005 , 127, 15168-74	137
1813	Certain inhibitors of synthetic amyloid beta-peptide (Abeta) fibrillogenesis block oligomerization of natural Abeta and thereby rescue long-term potentiation. 2005 , 25, 2455-62	262
1812	Inhibition of amyloid fibril formation and cytotoxicity by hydroxyindole derivatives. 2006 , 45, 4727-35	131
1811	Polymorphism of Alzheimer's Aβ Amyloid Fibrils. 2008 , 19-27	2
1810	Are amyloid diseases caused by protein aggregates that mimic bacterial pore-forming toxins?. 2006 , 39, 167-201	325
1809	Antioxidant protection and neurodegenerative disease: the role of amyloid-beta and tau. 2006 , 21, 126-30	49
1808	Tetracycline inhibits W7FW14F apomyoglobin fibril extension and keeps the amyloid protein in a pre-fibrillar, highly cytotoxic state. 2006 , 20, 346-7	32
1807	Exogenous induction of cerebral beta-amyloidogenesis is governed by agent and host. 2006 , 313, 1781-4	749
1806	Aggregation of partially unfolded Myosin subfragment-1 into spherical oligomers with amyloid-like dye-binding properties. 2006 , 139, 989-96	5

1805	Alzheimer: 100 Years and Beyond. 2006 ,	5
1804	A Drosophila model of Alzheimer's disease. 2006 , 412, 234-55	47
1803	Current Topics in Complement. 2006 ,	1
1802	Cytotoxic Intermediates in the Fibrillation Pathway: Aβ Oligomers in Alzheimer's Disease as a Case Study. 2006 , 60-81	1
1801	A high-throughput screen for compounds that inhibit aggregation of the Alzheimer's peptide. 2006 , 1, 461-9	143
1800	Amyloid-beta1-42 reduces neuronal excitability in mouse dentate gyrus. 2006 , 403, 162-5	45
1799	Amyloid fibrils of mammalian prion protein are highly toxic to cultured cells and primary neurons. 2006 , 281, 13828-13836	203
1798	Commentary on "Challenges to demonstrating disease-modifying effects in Alzheimer's disease clinical trials". 2006 , 2, 272-4	7
1797	Absent event-related potential (ERP) word repetition effects in mild Alzheimer's disease. 2006 , 117, 1319-30	66
1796	Mitochondria are a direct site of A beta accumulation in Alzheimer's disease neurons: implications for free radical generation and oxidative damage in disease progression. 2006 , 15, 1437-49	852
1795	Alzheimer amyloid beta(1-40) peptide: interactions with cationic gemini and single-chain surfactants. 2006 , 110, 18040-5	26
1794	P4069: Modeling amyloid β peptide transport across the blood-brain barrier in TRBBB cells. 2006 , 2, S533-S534	
1793	P4071: Nuclear magnetic resonance studies of beta-amyloid peptide interactions with the ganglioside GM1. 2006 , 2, S534-S534	
1792	Oligomerization and aggregation of bovine pancreatic ribonuclease A: characteristic events observed by FTIR spectroscopy. 2006 , 90, 2525-33	33
1791	Detection of oligomeric forms of alpha-synuclein protein in human plasma as a potential biomarker for Parkinson's disease. 2006 , 20, 419-25	541
1790	When it runs in the family: putting susceptibility genes in perspective. 2006 , 15, 277-300	47
1789	Synaptic targeting by A beta oligomers (ADDLS) as a basis for memory loss in early Alzheimer's disease. 2006 , 2, 43-55	86
1788	Different conformations of amyloid beta induce neurotoxicity by distinct mechanisms in human cortical neurons. 2006 , 26, 6011-8	408

1787	Secondary structure and interfacial aggregation of amyloid-beta(1-40) on sodium dodecyl sulfate micelles. 2006 , 45, 8639-48	67
1786	Interactions between fatty acids and alpha-synuclein. 2006 , 47, 1714-24	41
1785	Fibrillation of human insulin A and B chains. 2006 , 45, 9342-53	63
1784	Prefibrillar amyloid aggregates could be generic toxins in higher organisms. 2006 , 26, 8160-7	199
1783	From green bacteria to human dementia: a novel model for discovering amyloid assembly inhibitors. 2006 , 1, 417-9	6
1782	Slow aggregation of lysozyme in alkaline pH monitored in real time employing the fluorescence anisotropy of covalently labelled dansyl probe. 2006 , 580, 2097-101	25
1781	Ubiquitin hydrolase Uch-L1 rescues beta-amyloid-induced decreases in synaptic function and contextual memory. 2006 , 126, 775-88	338
1780	Improving synaptic function in a mouse model of AD. 2006 , 126, 655-7	14
1779	Soluble Abeta and cognitive function in aged F-344 rats and Tg2576 mice. 2006 , 173, 62-75	17
1778	Over-expression of two different forms of the alpha-secretase ADAM10 affects learning and memory in mice. 2006 , 175, 278-84	39
1777	Amelioration of amyloid load by anti-Abeta single-chain antibody in Alzheimer mouse model. 2006 , 344, 79-86	37
1776	Inducible expression of Tau repeat domain in cell models of tauopathy: aggregation is toxic to cells but can be reversed by inhibitor drugs. 2006 , 281, 1205-14	255
1775	Amyloid beta-peptide oligomerization in silico: dimer and trimer. 2006 , 110, 1955-8	62
1774	Involvement of apoptosis and cholinergic dysfunction in Alzheimer's disease. 2006 , 6, S57-S63	1
1773	Alzheimer's disease, the nematode <i>Caenorhabditis elegans</i> , and ginkgo biloba leaf extract. 2006 , 78, 2066-72	50
1772	Polyglutamine and polyalanine expansions in ataxin7 result in different types of aggregation and levels of toxicity. 2006 , 31, 438-45	17
1771	Retention of misfolded mutant transthyretin by the chaperone BiP/GRP78 mitigates amyloidogenesis. 2006 , 356, 469-82	38
1770	High-resolution atomic force microscopy of soluble Abeta42 oligomers. 2006 , 358, 106-19	188

1769	Amino-terminal domain stability mediates apolipoprotein E aggregation into neurotoxic fibrils. 2006 , 361, 932-44	68
1768	Direct observation of oligomeric species formed in the early stages of amyloid fibril formation using electrospray ionisation mass spectrometry. 2006 , 364, 9-19	130
1767	Alzheimer's amyloid story finds its star. 2006 , 12, 395-6	12
1766	Distinct destructive signal pathways of neuronal death in Alzheimer's disease. 2006 , 12, 574-9	40
1765	Novel approaches for immunotherapeutic intervention in Alzheimer's disease. 2006 , 49, 113-26	33
1764	Metabolism of amyloid beta peptide and pathogenesis of Alzheimer's disease. Towards presymptomatic diagnosis, prevention and therapy. 2006 , 54, 235-53	82
1763	Metal exposure and Alzheimer's pathogenesis. 2006 , 155, 45-51	106
1762	High resolution scanning tunnelling microscopy of the beta-amyloid protein (Abeta1-40) of Alzheimer's disease suggests a novel mechanism of oligomer assembly. 2006 , 155, 104-10	50
1761	The Arctic Alzheimer mutation facilitates early intraneuronal Abeta aggregation and senile plaque formation in transgenic mice. 2006 , 27, 67-77	185
1760	Insulin, insulin-degrading enzyme and amyloid-beta peptide in Alzheimer's disease: review and hypothesis. 2006 , 27, 190-8	398
1759	Mapping cellular transcriptosomes in autopsied Alzheimer's disease subjects and relevant animal models. 2006 , 27, 1060-77	59
1758	Common mechanisms of amyloid oligomer pathogenesis in degenerative disease. 2006 , 27, 570-5	457
1757	Apoptosis is secondary to non-apoptotic axonal degeneration in neurons exposed to Abeta in distal axons. 2006 , 27, 1224-38	38
1756	Early neuropathology of somatostatin/NPY GABAergic cells in the hippocampus of a PS1xAPP transgenic model of Alzheimer's disease. 2006 , 27, 1658-72	136
1755	siRNA targeted against amyloid precursor protein impairs synaptic activity in vivo. 2006 , 27, 1740-50	44
1754	Antiamyloidogenic and neuroprotective functions of cathepsin B: implications for Alzheimer's disease. 2006 , 51, 703-14	300
1753	A hundred years of Alzheimer's disease research. 2006 , 52, 3-13	365
1752	AMPA removal underlies Abeta-induced synaptic depression and dendritic spine loss. 2006 , 52, 831-43	812

1751	Visuospatial function in the beagle dog: an early marker of cognitive decline in a model of human aging and dementia. 2006 , 86, 197-204	90
1750	AbetaPP-overexpression and proteasome inhibition increase alphaB-crystallin in cultured human muscle: relevance to inclusion-body myositis. 2006 , 16, 839-44	24
1749	Synaptic plasticity: one STEP at a time. 2006 , 29, 452-8	100
1748	Lipoprotein receptors in Alzheimer's disease. 2006 , 29, 687-94	38
1747	The nucleation growth and reversibility of Amyloid-beta deposition in vivo. 2006 , 10, 291-301	11
1746	Pathogenesis of Alzheimer's Dementia. 2006 , 49, 717	
1745	Dysfunction of TGF-beta signaling in Alzheimer's disease. 2006 , 116, 2855-7	37
1744	Neurine, an acetylcholine autolysis product, elevates secreted amyloid-beta protein precursor and amyloid-beta peptide levels, and lowers neuronal cell viability in culture: a role in Alzheimer's disease?. 2006 , 10, 9-16	10
1743	Soluble amyloid-beta in the brain: the scarlet pimpernel. 2006 , 9, 127-32	8
1742	Genetics and pathology of alpha-secretase site AbetaPP mutations in the understanding of Alzheimer's disease. 2006 , 9, 389-98	6
1741	Circulating amyloidogenic free light chains and serum N-terminal natriuretic peptide type B decrease simultaneously in association with improvement of survival in AL. 2006 , 107, 3854-8	209
1740	La lunga attesa: towards a molecular approach to neuroimaging and therapeutics in Alzheimer's disease. 2006 , 19, 453-74	11
1739	Synaptic vulnerability in neurodegenerative disease. 2006 , 65, 733-9	146
1738	Lessons from a crab: molecular mechanisms in different memory phases of Chasmagnathus. 2006 , 210, 280-8	34
1737	Of mice and men: more neurobiology in dementia. 2006 , 19, 555-63	21
1736	Targeting cell death in dementia. 2006 , 20, S3-7	13
1735	New developments in mild cognitive impairment and Alzheimer's disease. 2006 , 19, 552-8	17
1734	Protein Aggregation, Ion Channel Formation, and Membrane Damage. 2006 , 223-236	

1733	Chaperone Suppression of Aggregated Protein Toxicity. 2006 , 137-164	1
1732	Metals and Alzheimer's disease. 2006 , 10, 145-63	265
1731	[Amyloid-beta protein vaccine therapy for alzheimer's disease]. 2006 , 95, 1122-8	
1730	Autoinsertion of soluble oligomers of Alzheimer's Abeta(1-42) peptide into cholesterol-containing membranes is accompanied by relocation of the sterol towards the bilayer surface. 2006 , 6, 21	37
1729	ABCB1 genotypes and haplotypes in patients with dementia and age-matched non-demented control patients. 2006 , 1, 13	9
1728	Molecular dynamics studies of hexamers of amyloid-beta peptide (16-35) and its mutants: influence of charge states on amyloid formation. 2007 , 66, 575-87	20
1727	Amyloid beta-protein fragment 31-35 suppresses long-term potentiation in hippocampal CA1 region of rats in vivo. 2006 , 60, 307-13	34
1726	Temporal memory deficits in Alzheimer's mouse models: rescue by genetic deletion of BACE1. 2006 , 23, 251-60	221
1725	Withanoside IV and its active metabolite, sominone, attenuate Abeta(25-35)-induced neurodegeneration. 2006 , 23, 1417-26	107
1724	Non-fibrillar beta-amyloid abates spike-timing-dependent synaptic potentiation at excitatory synapses in layer 2/3 of the neocortex by targeting postsynaptic AMPA receptors. 2006 , 23, 2035-47	69
1723	Protective effects of EUK4010 on beta-amyloid(1-42) induced degeneration of neuronal cells. 2006 , 24, 1011-9	7
1722	Intracellular and extracellular Abeta, a tale of two neuropathologies. 2005 , 15, 66-71	53
1721	Cyclooxygenase-dependent lipid-modification of brain proteins. 2005 , 15, 139-42	26
1720	Genetic alterations of the BRI2 gene: familial British and Danish dementias. 2006 , 16, 71-9	38
1719	A presenilin-independent aspartyl protease prefers the gamma-42 site cleavage. 2006 , 96, 118-25	22
1718	PGH2-derived levuglandin adducts increase the neurotoxicity of amyloid beta1-42. 2006 , 96, 917-23	39
1717	Mutations in amyloid precursor protein and presenilin-1 genes increase the basal oxidative stress in murine neuronal cells and lead to increased sensitivity to oxidative stress mediated by amyloid beta-peptide (1-42), HO and kainic acid: implications for Alzheimer's disease. 2006 , 96, 1322-35	90
1716	The transcription factor Yin Yang 1 is an activator of BACE1 expression. 2006 , 96, 1696-707	58

1715	Molecular mechanisms for Alzheimer's disease: implications for neuroimaging and therapeutics. 2006 , 97, 1700-25	190
1714	Toxicity mediated by soluble oligomers of beta-amyloid(1-42) on cholinergic SN56.B5.G4 cells. 2006 , 98, 1930-45	43
1713	Alois Alzheimer and Alzheimer's disease: a centennial perspective. 2006 , 99, 708-10	57
1712	FAD mutants unable to increase neurotoxic Abeta 42 suggest that mutation effects on neurodegeneration may be independent of effects on Abeta. 2007 , 101, 674-81	65
1711	Overexpression of Abeta is associated with acceleration of onset of motor impairment and superoxide dismutase 1 aggregation in an amyotrophic lateral sclerosis mouse model. 2006 , 5, 153-65	32
1710	Abeta star: a light onto synaptic dysfunction?. 2006 , 12, 760-1; discussion 761	11
1709	A transgenic triple scores a home run. 2006 , 12, 762-3; discussion 763	3
1708	Highly cited clinical and epidemiological papers on Alzheimer disease published in 2004. 2006 , 12, 763	
1707	Alzheimer protease hitches a ride. 2006 , 12, 1352-4	1
1706	Cancer gets the Chk'ered flag. 2006 , 12, 1354-6	0
1705	Reelin, lipoprotein receptors and synaptic plasticity. 2006 , 7, 850-9	405
1704	A specific amyloid-beta protein assembly in the brain impairs memory. <i>Nature</i> , 2006 , 440, 352-7	50.4 2406
1703	A network dysfunction perspective on neurodegenerative diseases. <i>Nature</i> , 2006 , 443, 768-73	50.4 489
1702	A century-old debate on protein aggregation and neurodegeneration enters the clinic. <i>Nature</i> , 2006 , 443, 774-9	50.4 554
1701	Hyperforin prevents beta-amyloid neurotoxicity and spatial memory impairments by disaggregation of Alzheimer's amyloid-beta-deposits. 2006 , 11, 1032-48	84
1700	Effects of secreted oligomers of amyloid beta-protein on hippocampal synaptic plasticity: a potent role for trimers. 2006 , 572, 477-92	472
1699	Tuning amyloidogenic conformations through cosolvents and hydrostatic pressure: when the soft matter becomes even softer. 2006 , 1764, 470-80	19
1698	All-atom molecular dynamics studies of the full-length E-amyloid peptides. 2006 , 323, 138-147	35

1697	Localized surface plasmon resonance biosensors. 2006 , 1, 219-28	374
1696	Linking molecular motors to Alzheimer's disease. 2006 , 99, 193-200	25
1695	Solution state characterization of amyloid beta-derived diffusible ligands. 2006 , 45, 15157-67	165
1694	LRP in amyloid-beta production and metabolism. 2006 , 1086, 35-53	89
1693	The significance of the cholinergic system in the brain during aging and in Alzheimer's disease. 2006 , 113, 1625-44	392
1692	Relative paucity of tau accumulation in the small areas with abundant Abeta42-positive capillary amyloid angiopathy within a given cortical region in the brain of patients with Alzheimer pathology. 2006 , 111, 510-8	15
1691	Neuropathology of Alzheimer disease: pathognomonic but not pathogenic. 2006 , 111, 503-9	108
1690	Rubinstein-Taybi syndrome: molecular findings and therapeutic approaches to improve cognitive dysfunction. 2006 , 63, 1725-35	46
1689	The various aggregation states of beta-amyloid 1-42 mediate different effects on oxidative stress, neurodegeneration, and BACE-1 expression. 2006 , 41, 202-12	95
1688	Alzheimer's disease and post-operative cognitive dysfunction. 2006 , 41, 346-59	132
1687	Inflammation in Alzheimer's disease. 2006 , 6, 247-260	22
1686	Protein homeostasis in neurons and its pathological alterations. 2006 , 16, 270-4	14
1685	A decade of modeling Alzheimer's disease in transgenic mice. 2006 , 22, 281-9	241
1684	To be or not to be toxic: aggregations in Huntington and Alzheimer disease. 2006 , 22, 408-11	29
1683	Pharmacological and molecular enhancement of learning in aging and Alzheimer's disease. 2006 , 99, 180-92	52
1682	Development of new screening system for Alzheimer disease, in vitro Abeta sink assay, to identify the dissociation of soluble Abeta from fibrils. 2006 , 22, 487-95	7
1681	Soluble oligomers of amyloid-beta peptide induce neuronal apoptosis by activating a cPLA2-dependent sphingomyelinase-ceramide pathway. 2006 , 23, 178-89	163
1680	Anti-Abeta single-chain antibody delivery via adeno-associated virus for treatment of Alzheimer's disease. 2006 , 23, 502-11	79

1679	Cholesterol depletion reduces aggregation of amyloid-beta peptide in hippocampal neurons. 2006 , 23, 573-7	66
1678	The modular systems biology approach to investigate the control of apoptosis in Alzheimer's disease neurodegeneration. 2006 , 7 Suppl 1, S2	36
1677	The alpha-to-beta conformational transition of Alzheimer's Abeta-(1-42) peptide in aqueous media is reversible: a step by step conformational analysis suggests the location of beta conformation seeding. 2006 , 7, 257-67	314
1676	Amyloid beta oligomerization is induced by brain lipid rafts. 2006 , 99, 878-89	88
1675	Antibodies against beta-amyloid reduce Abeta oligomers, glycogen synthase kinase-3beta activation and tau phosphorylation in vivo and in vitro. 2006 , 83, 374-84	114
1674	Absence of synaptophysin near cortical neurons containing oligomer Abeta in Alzheimer's disease brain. 2006 , 84, 632-6	35
1673	Lack of neprilysin suffices to generate murine amyloid-like deposits in the brain and behavioral deficit in vivo. 2006 , 84, 1871-8	65
1672	Orally available compound prevents deficits in memory caused by the Alzheimer amyloid-beta oligomers. 2006 , 60, 668-76	148
1671	Isoflurane-induced apoptosis: a potential pathogenic link between delirium and dementia. 2006 , 61, 1300-6	90
1670	Posttranslational modifications and receptor-associated proteins in AMPA receptor trafficking and synaptic plasticity. 2006 , 15, 266-82	49
1669	Disulphide-reduced superoxide dismutase-1 in CNS of transgenic amyotrophic lateral sclerosis models. 2006 , 129, 451-64	198
1668	Early diagnostics and therapeutics for Alzheimer's disease--how early can we get there?. 2006 , 6, 1293-306	19
1667	Inclusion-body myositis: a myodegenerative conformational disorder associated with Abeta, protein misfolding, and proteasome inhibition. 2006 , 66, S39-48	127
1666	Inclusion-body myositis and Alzheimer disease: two sides of the same coin, or different currencies altogether?. 2006 , 66, S65-8	14
1665	Fibrillar beta-amyloid impairs the late phase of long term potentiation. 2006 , 3, 179-83	22
1664	Tau-dependent microtubule disassembly initiated by prefibrillar beta-amyloid. 2006 , 175, 541-6	180
1663	Vaccine development for Alzheimer's disease. 2006 , 12, 4283-93	13
1662	Oxidative stress, mitochondrial dysfunction, and stress signaling in Alzheimer's disease. 2006 , 3, 339-49	101

1661	A partial failure of membrane protein turnover may cause Alzheimer's disease: a new hypothesis. 2006 , 3, 81-90	54
1660	Alzheimer's disease--an interactive perspective. 2006 , 3, 109-21	41
1659	Computer simulations of Alzheimer's amyloid beta-protein folding and assembly. 2006 , 3, 493-504	33
1658	Filling the gaps in the abeta cascade hypothesis of Alzheimer's disease. 2006 , 3, 421-30	111
1657	Proteolytic degradation of the amyloid beta-protein: the forgotten side of Alzheimer's disease. 2006 , 3, 431-5	17
1656	The role of beta-amyloid protein in synaptic function: implications for Alzheimer's disease therapy. 2006 , 4, 149-63	34
1655	Views on amyloid hypothesis and secretase inhibitors for treating Alzheimer's disease: progress and problems. 2006 , 12, 4295-312	37
1654	Genetically modified mice models for Alzheimer's disease. 2006 , 6, 609-27	13
1653	Role of toll-like receptor signalling in Abeta uptake and clearance. 2006 , 129, 3006-19	389
1652	Cerebral arachidonate cascade in dementia: Alzheimer's disease and vascular dementia. 2006 , 4, 87-100	31
1651	Vicious cycles within the neuropathophysiologic mechanisms of Alzheimer's disease. 2006 , 3, 95-108	41
1650	Pathways by which Abeta facilitates tau pathology. 2006 , 3, 437-48	148
1649	Genetic and pharmacological basis for therapeutic inhibition of beta- and gamma-secretases in mouse models of Alzheimer's memory deficits. 2006 , 17, 429-54	25
1648	Therapeutic approaches to polyglutamine diseases: combating protein misfolding and aggregation. 2006 , 12, 2543-55	33
1647	The role of amyloid-beta derived diffusible ligands (ADDLs) in Alzheimer's disease. 2006 , 6, 597-608	96
1646	Mapping genetic modulators of amyloid plaque deposition in TgCRND8 transgenic mice. 2006 , 15, 2313-23	22
1645	Reduction of soluble Abeta and tau, but not soluble Abeta alone, ameliorates cognitive decline in transgenic mice with plaques and tangles. 2006 , 281, 39413-23	227
1644	Docosahexaenoic acid protects from amyloid and dendritic pathology in an Alzheimer's disease mouse model. 2006 , 18, 249-59	78

1643	Evidence that Perutz's double-beta-stranded subunit structure for beta-amyloids also applies to their channel-forming structures in membranes. 2006 , 103, 1546-50	49
1642	Soluble amyloid oligomers increase bilayer conductance by altering dielectric structure. 2006 , 128, 637-47	177
1641	Toxicity of recombinant beta-amyloid prefibrillar oligomers on the morphogenesis of the sea urchin <i>Paracentrotus lividus</i> . 2006 , 20, 1916-7	44
1640	Blocking the apolipoprotein E/amyloid-beta interaction as a potential therapeutic approach for Alzheimer's disease. 2006 , 103, 18787-92	134
1639	Protein aggregation in crowded environments. 2006 , 387, 485-97	281
1638	Involvement of the nitric oxide pathway in synaptic dysfunction following amyloid elevation in Alzheimer's disease. 2006 , 17, 497-523	42
1637	Acute impairment of mitochondrial trafficking by beta-amyloid peptides in hippocampal neurons. 2006 , 26, 10480-7	196
1636	Generic hydrophobic residues are sufficient to promote aggregation of the Alzheimer's Abeta42 peptide. 2006 , 103, 15824-9	147
1635	Formation, structure, and dissociation of the ribonuclease S three-dimensional domain-swapped dimer. 2006 , 281, 9400-6	22
1634	Parkin protects against mitochondrial toxins and beta-amyloid accumulation in skeletal muscle cells. 2006 , 281, 12809-16	68
1633	Acceleration of amyloid beta-peptide aggregation by physiological concentrations of calcium. 2006 , 281, 27916-23	109
1632	Neuronal cell death in Alzheimer's disease and a neuroprotective factor, humanin. 2006 , 4, 139-47	93
1631	Opposing activities protect against age-onset proteotoxicity. 2006 , 313, 1604-10	701
1630	Heat shock proteins 70 and 90 inhibit early stages of amyloid beta-(1-42) aggregation in vitro. 2006 , 281, 33182-91	293
1629	The Generic Nature of Protein Folding and Misfolding. 2006 , 21-41	10
1628	The double-edged flower: roles of complement protein C1q in neurodegenerative diseases. 2006 , 586, 153-76	26
1627	AMPA receptor downscaling at the onset of Alzheimer's disease pathology in double knockin mice. 2006 , 103, 3410-5	175
1626	Neuroserpin binds Abeta and is a neuroprotective component of amyloid plaques in Alzheimer disease. 2006 , 281, 29268-77	65

1625	Early-onset behavioral and synaptic deficits in a mouse model of Alzheimer's disease. 2006 , 103, 5161-6	550
1624	Differential modulation of plasma beta-amyloid by insulin in patients with Alzheimer disease. 2006 , 66, 1506-10	78
1623	Alzheimer precursor protein interaction with the Nogo-66 receptor reduces amyloid-beta plaque deposition. 2006 , 26, 1386-95	110
1622	Neprilysin-sensitive synapse-associated amyloid-beta peptide oligomers impair neuronal plasticity and cognitive function. 2006 , 281, 17941-51	134
1621	Temporal profile of amyloid-beta (Abeta) oligomerization in an in vivo model of Alzheimer disease. A link between Abeta and tau pathology. 2006 , 281, 1599-604	303
1620	beta-Amyloid-induced dynamin 1 degradation is mediated by N-methyl-D-aspartate receptors in hippocampal neurons. 2006 , 281, 28079-89	198
1619	Conformation-sensitive antibodies against alzheimer amyloid-beta by immunization with a thioredoxin-constrained B-cell epitope peptide. 2007 , 282, 11436-45	54
1618	Protein Misfolding, Aggregation, and Conformational Diseases. 2007 ,	13
1617	Angiotensin-converting enzyme converts amyloid beta-protein 1-42 (Abeta(1-42)) to Abeta(1-40), and its inhibition enhances brain Abeta deposition. 2007 , 27, 8628-35	139
1616	Oligomeric amyloid decreases basal levels of brain-derived neurotrophic factor (BDNF) mRNA via specific downregulation of BDNF transcripts IV and V in differentiated human neuroblastoma cells. 2007 , 27, 2628-35	137
1615	Abeta oligomer-mediated long-term potentiation impairment involves protein phosphatase 1-dependent mechanisms. 2007 , 27, 7648-53	109
1614	Identification of anti-prion compounds as efficient inhibitors of polyglutamine protein aggregation in a zebrafish model. 2007 , 282, 9195-203	76
1613	Interruption of CryAB-amyloid oligomer formation by HSP22. 2007 , 282, 555-63	53
1612	Structural basis for the recognition and cross-linking of amyloid fibrils by human apolipoprotein E. 2007 , 282, 35831-41	22
1611	Accumulation of pathological tau species and memory loss in a conditional model of tauopathy. 2007 , 27, 3650-62	389
1610	The experimental Alzheimer's disease drug posiphen [(+)-phenserine] lowers amyloid-beta peptide levels in cell culture and mice. 2007 , 320, 386-96	103
1609	Immunotherapy as treatment for Alzheimer's disease. 2007 , 7, 1535-48	25
1608	Self assembly of short aromatic peptides into amyloid fibrils and related nanostructures. 2007 , 1, 32-5	99

1607	Minocycline attenuates neuronal cell death and improves cognitive impairment in Alzheimer's disease models. 2007 , 32, 2393-404	219
1606	Advances on the understanding of the origins of synaptic pathology in AD. 2007 , 8, 486-508	28
1605	Structural reorganisation and potential toxicity of oligomeric species formed during the assembly of amyloid fibrils. 2007 , 3, 1727-38	178
1604	Oligomers of beta-amyloid peptide inhibit BDNF-induced arc expression in cultured cortical Neurons. 2007 , 4, 518-21	24
1603	Amyloid beta protein modulates glutamate-mediated neurotransmission in the rat basal forebrain: involvement of presynaptic neuronal nicotinic acetylcholine and metabotropic glutamate receptors. 2007 , 27, 9262-9	47
1602	N-phenylamine derivatives as aggregation inhibitors in cell models of tauopathy. 2007 , 4, 397-402	45
1601	Nogo receptor interacts with brain APP and Abeta to reduce pathologic changes in Alzheimer's transgenic mice. 2007 , 4, 568-70	24
1600	Natural oligomers of the Alzheimer amyloid-beta protein induce reversible synapse loss by modulating an NMDA-type glutamate receptor-dependent signaling pathway. 2007 , 27, 2866-75	1232
1599	Computational simulations of the early steps of protein aggregation. 2007 , 1, 3-8	59
1598	Involvement of beta-site APP cleaving enzyme 1 (BACE1) in amyloid precursor protein-mediated enhancement of memory and activity-dependent synaptic plasticity. 2007 , 104, 8167-72	101
1597	Detection of polyglutamine protein oligomers in cells by fluorescence correlation spectroscopy. 2007 , 282, 24039-48	80
1596	Memories: Molecules and Circuits. 2007 ,	2
1595	Valsartan lowers brain beta-amyloid protein levels and improves spatial learning in a mouse model of Alzheimer disease. 2007 , 117, 3393-402	235
1594	Brain slices as models for neurodegenerative disease and screening platforms to identify novel therapeutics. 2007 , 5, 19-33	173
1593	Synapse-associated protein-97 mediates alpha-secretase ADAM10 trafficking and promotes its activity. 2007 , 27, 1682-91	148
1592	Beta-amyloid modulation of synaptic transmission and plasticity. 2007 , 27, 11832-7	94
1591	A ganglioside-induced toxic soluble Abeta assembly. Its enhanced formation from Abeta bearing the Arctic mutation. 2007 , 282, 2646-55	60
1590	Oligomerization and transglutaminase cross-linking of the cystatin CRES in the mouse epididymal lumen: potential mechanism of extracellular quality control. 2007 , 282, 32912-23	20

1589 [Actin cytoskeletal abnormality in Alzheimer's disease]. **2007**, 130, 358-61

1588 Environmental enrichment delays the onset of memory deficits and reduces neuropathological hallmarks in a mouse model of Alzheimer-like neurodegeneration. **2007**, 11, 359-70

91

1587 Chapter 1 Amyloid and Amyloid-Like Protein Aggregates in Neurodegenerative Disease. **2007**, 30, 1-32

1586 Native and oxidized low-density lipoproteins modulate the vasoactive actions of soluble beta-amyloid peptides in rat aorta. **2007**, 113, 427-34

7

1585 Detection of amyloid-beta oligomers in human cerebrospinal fluid by flow cytometry and fluorescence resonance energy transfer. **2007**, 11, 117-25

57

1584 Acide docosahexaénoïque et maladie d'Alzheimer : des raisons d'espérer ?. **2007**, 14, 16-24

1583 Liaisons dangereuses? General anaesthetics and long-term toxicity in the CNS. **2007**, 24, 107-15

18

1582 Inverse correlation between amyloid precursor protein and synaptic plasticity in transgenic mice. **2007**, 18, 1083-7

22

1581 Therapeutic potential of amyloid β -degrading enzymes in Alzheimer's disease. **2007**, 2, 133-137

1580 Molecular determinants of Alzheimer's disease A β peptide neurotoxicity. **2007**, 2, 397-409

8

1579 Structure and functions of the human amyloid precursor protein: the whole is more than the sum of its parts. **2007**, 82, 11-32

135

1578 Chronic dietary alpha-lipoic acid reduces deficits in hippocampal memory of aged Tg2576 mice. **2007**, 28, 213-25

130

1577 Targeting soluble Abeta peptide with Tramiprosate for the treatment of brain amyloidosis. **2007**, 28, 537-47

221

1576 Dendrimeric Abeta1-15 is an effective immunogen in wildtype and APP-tg mice. **2007**, 28, 813-23

52

1575 Increased susceptibility to amyloid toxicity in familial Alzheimer's fibroblasts. **2007**, 28, 863-76

45

1574 Long-term soluble Abeta1-40 activates CaM kinase II in organotypic hippocampal cultures. **2007**, 28, 1388-95

10

1573 Intracellular Abeta and cognitive deficits precede beta-amyloid deposition in transgenic arcAbeta mice. **2007**, 28, 1297-306

196

1572 Targeting cellular prion protein reverses early cognitive deficits and neurophysiological dysfunction in prion-infected mice. **2007**, 53, 325-35

204

1571	Overview: the long and winding road to understanding Alzheimer's disease. 2007 , 53, 477-9	7
1570	Aberrant excitatory neuronal activity and compensatory remodeling of inhibitory hippocampal circuits in mouse models of Alzheimer's disease. 2007 , 55, 697-711	1038
1569	The HMG-CoA reductase inhibitor, atorvastatin, attenuates the effects of acute administration of amyloid-beta1-42 in the rat hippocampus in vivo. 2007 , 52, 136-45	56
1568	Memantine: a NMDA receptor antagonist that improves memory by restoration of homeostasis in the glutamatergic system--too little activation is bad, too much is even worse. 2007 , 53, 699-723	509
1567	Beta-amyloid disrupted synaptic vesicle endocytosis in cultured hippocampal neurons. 2007 , 147, 60-70	69
1566	Soluble amyloid beta1-42 reduces dopamine levels in rat prefrontal cortex: relationship to nitric oxide. 2007 , 147, 652-63	33
1565	Intrahippocampal administration of A beta(1-40) impairs spatial learning and memory in hyperglycemic mice. 2007 , 87, 483-94	38
1564	The cell biology of synaptic plasticity: AMPA receptor trafficking. 2007 , 23, 613-43	755
1563	Novel therapeutic strategies for the treatment of protein-misfolding diseases. 2007 , 9, 1-34	93
1562	Methylene blue inhibits amyloid Abeta oligomerization by promoting fibrillization. 2007 , 46, 8850-60	183
1561	Mitochondrial dysfunction: the first domino in brain aging and Alzheimer's disease?. 2007 , 9, 1659-75	160
1560	Preferential accumulation of Abeta(1-42) on gel phase domains of lipid bilayers: an AFM and fluorescence study. 2007 , 1768, 146-54	77
1559	Inhibitors of amyloid beta-protein aggregation mediated by GM1-containing raft-like membranes. 2007 , 1768, 122-30	61
1558	The redox chemistry of the Alzheimer's disease amyloid beta peptide. 2007 , 1768, 1976-90	458
1557	Physicochemical interactions of amyloid beta-peptide with lipid bilayers. 2007 , 1768, 1935-42	166
1556	Amyloid beta ion channel: 3D structure and relevance to amyloid channel paradigm. 2007 , 1768, 1966-75	141
1555	A mechanistic link between oxidative stress and membrane mediated amyloidogenesis revealed by infrared spectroscopy. 2007 , 1768, 1913-22	26
1554	ATF4 regulates gamma-secretase activity during amino acid imbalance. 2007 , 352, 722-7	41

1553	Monomeric A beta and metals reduce their cytotoxicities to each other. 2007 , 358, 540-4	2
1552	The binding constant for amyloid Abeta40 peptide interaction with human serum albumin. 2007 , 364, 714-8	52
1551	Amyloid, memory and neurogenesis. 2007 , 205, 330-5	19
1550	Effects of the single point genetic mutation D54G on muscle creatine kinase activity, structure and stability. 2007 , 39, 392-401	38
1549	Depletion of Complexin II does not affect disease progression in a mouse model of Huntington's disease (HD); support for role for complexin II in behavioural pathology in a mouse model of HD. 2007 , 72, 108-20	15
1548	Lysozyme amyloid oligomers and fibrils induce cellular death via different apoptotic/necrotic pathways. 2007 , 365, 1337-49	174
1547	Early kinetics of amyloid fibril formation reveals conformational reorganisation of initial aggregates. 2007 , 366, 1351-63	56
1546	Abeta40 protects non-toxic Abeta42 monomer from aggregation. 2007 , 369, 909-16	73
1545	Formation of toxic fibrils of Alzheimer's amyloid beta-protein-(1-40) by monosialoganglioside GM1, a neuronal membrane component. 2007 , 371, 481-9	97
1544	Rapid, concurrent alterations in pre- and postsynaptic structure induced by naturally-secreted amyloid-beta protein. 2007 , 35, 183-93	100
1543	Overexpression of DSCR1 blocks zinc-induced neuronal cell death through the formation of nuclear aggregates. 2007 , 35, 585-95	16
1542	Mechanisms of mitochondrial dysfunction and energy deficiency in Alzheimer's disease. 2007 , 7, 297-310	203
1541	Greater frequency of subcortical lesions in severely demented patients with early onset Alzheimer's disease. 2007 , 3, 54-7	6
1540	beta-Sheet structured beta-amyloid(1-40) perturbs phosphatidylcholine model membranes. 2007 , 368, 982-97	71
1539	Oxidative DNA damage in mild cognitive impairment and late-stage Alzheimer's disease. 2007 , 35, 7497-504	350
1538	Investigations of the molecular mechanism of metal-induced Abeta (1-40) amyloidogenesis. 2007 , 46, 13523-32	62
1537	Structure, stability, and activity of myoglobin adsorbed onto phosphate-grafted zirconia nanoparticles. 2007 , 23, 13007-12	30
1536	Sensitive ELISA detection of amyloid-beta protofibrils in biological samples. 2007 , 103, 334-45	122

1535 Metal Ions and Alzheimer's Disease. **2007**, 333-361

1534 Abeta Peptide and Alzheimer's Disease. **2007**,

1

1533 Pharmacological Mechanisms in Alzheimer's Therapeutics. **2007**,

1

1532 Aspects of beta-amyloid as a biomarker for Alzheimer's disease. **2007**, 1, 59-78

65

1531 Mitochondria in aging and Alzheimer's disease. **2007**, 10, 349-57

45

1530 Amyloid-beta(1-42) rapidly forms protofibrils and oligomers by distinct pathways in low concentrations of sodium dodecylsulfate. **2007**, 46, 12451-62

126

1529 Amyloid β Peptide(1-42), Oxidative Stress, and Alzheimer's Disease. **2007**, 83-92

2

1528 Amyloid imaging in vivo: implications for Alzheimer's disease management. **2007**, 1, 337-49

3

1527 Zinc lowers amyloid-beta toxicity by selectively precipitating aggregation intermediates. **2007**, 46, 10655-63 89

1526 Modulation of fibrillogenesis of amyloid beta(1-40) peptide with cationic gemini surfactant. **2007**, 111, 13436-43

40

1525 The oxidative stress metabolite 4-hydroxynonenal promotes Alzheimer protofibril formation. **2007**, 46, 1503-10

129

1524 When conjugated polymers meet amyloid fibrils. **2007**, 2, 525-8

5

1523 An update on the amyloid hypothesis. **2007**, 25, 669-82, vi

34

1522 Generic cell dysfunction in neurodegenerative disorders: role of surfaces in early protein misfolding, aggregation, and aggregate cytotoxicity. **2007**, 13, 519-31

61

1521 Models of beta-amyloid ion channels in the membrane suggest that channel formation in the bilayer is a dynamic process. **2007**, 93, 1938-49

153

1520 Clinical aspects of indoleamine 2,3-dioxygenase (IDO)-initiated tryptophan metabolism: IDO is a target of drug discovery for various diseases. **2007**, 1304, 290-297

7

1519 Effects of Alzheimer's amyloid-beta and tau protein on mitochondrial function -- role of glucose metabolism and insulin signalling. **2007**, 113, 131-41

41

1518 The Pathogenesis of Alzheimer's Disease: General Overview. **2007**, 3-29

1

1517	Amyloid-beta aggregation. 2007 , 4, 13-27	244
1516	Alzheimer's Disease. 2007 ,	
1515	The Molecular Basis of Alzheimer's Disease. 2007 , 241-255	
1514	Alzheimer's Disease. 2007 , 779-789	1
1513	Diseases of protein misfolding. 113-131	
1512	Membrane protein stoichiometry determined from the step-wise photobleaching of dye-labelled subunits. 2007 , 8, 994-9	95
1511	Embedding the amyloid beta-peptide sequence in green fluorescent protein inhibits Abeta oligomerization. 2007 , 8, 985-8	19
1510	Distance measurement between Tyr10 and Met35 in amyloid beta by site-directed spin-labeling ESR spectroscopy: implications for the stronger neurotoxicity of Abeta42 than Abeta40. 2007 , 8, 2308-14	36
1509	IAPP mimic blocks Abeta cytotoxic self-assembly: cross-suppression of amyloid toxicity of Abeta and IAPP suggests a molecular link between Alzheimer's disease and type II diabetes. 2007 , 46, 1246-52	133
1508	Ein IAPP-Mimetikum blockiert die zytotoxische Aggregation von Aβ. Die Kreuzunterdrückung der Amyloidtoxizität von Aβ und IAPP deutet auf einen molekularen Zusammenhang zwischen Alzheimer-Krankheit und Typ-II-Diabetes hin. 2007 , 119, 1268-1274	31
1507	The complex relation between genotype and phenotype in motor neuron disease. 2007 , 62, 8-14	6
1506	Hippocampal slice cultures integrated with multi-electrode arrays: a model for study of long-term drug effects on synaptic activity. 2007 , 68, 84-93	7
1505	Molecules that target beta-amyloid. 2007 , 2, 1674-92	93
1504	beta-Secretase expression in normal and functionally deprived rat olfactory bulbs: inverse correlation with oxidative metabolic activity. 2007 , 501, 52-69	29
1503	Alzheimer's disease in Down syndrome: neurobiology and risk. 2007 , 13, 237-46	193
1502	Intracerebroventricular passive immunization with anti-oligoAbeta antibody in TgCRND8. 2007 , 85, 451-63	26
1501	Inter-individual variability in the expression of the mutated form of hPS1M146L determined the production of Abeta peptides in the PS1xAPP transgenic mice. 2007 , 85, 787-97	9
1500	Swedish amyloid precursor protein mutation increases phosphorylation of eIF2alpha in vitro and in vivo. 2007 , 85, 1528-37	35

1499	The use of conformation-specific ligands and assays to dissect the molecular mechanisms of neurodegenerative diseases. 2007 , 85, 2285-97	16
1498	N-(5-chloro-2-(hydroxymethyl)-N-alkyl-arylsulfonamides as gamma-secretase inhibitors. 2007 , 17, 4432-6	11
1497	Amino-caprolactam derivatives as gamma-secretase inhibitors. 2007 , 17, 5790-5	11
1496	Modification of nanostructured materials for biomedical applications. 2007 , 27, 579-594	101
1495	Role of the ubiquitin proteasome system in Alzheimer's disease. 2007 , 8 Suppl 1, S12	77
1494	Amyloid beta-peptide Abeta(1-42) but not Abeta(1-40) attenuates synaptic AMPA receptor function. 2007 , 61, 367-74	62
1493	Ccr2 deficiency impairs microglial accumulation and accelerates progression of Alzheimer-like disease. 2007 , 13, 432-8	674
1492	Drug development for CNS disorders: strategies for balancing risk and reducing attrition. 2007 , 6, 521-32	238
1491	Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid beta-peptide. 2007 , 8, 101-12	3692
1490	Loss-of-function presenilin mutations in Alzheimer disease. Talking Point on the role of presenilin mutations in Alzheimer disease. 2007 , 8, 141-6	266
1489	Intracellular amyloid-beta in Alzheimer's disease. 2007 , 8, 499-509	1474
1488	Evidence of fibril-like β -sheet structures in a neurotoxic amyloid intermediate of Alzheimer's β -amyloid. 2007 , 14, 1157-64	463
1487	Prion recognition elements govern nucleation, strain specificity and species barriers. <i>Nature</i> , 2007 , 447, 556-61	50.4 125
1486	Impairment of hippocampal gamma-frequency oscillations in vitro in mice overexpressing human amyloid precursor protein (APP). 2007 , 26, 1280-8	59
1485	A brief, but repeated, swimming protocol is sufficient to overcome amyloid beta-protein inhibition of hippocampal long-term potentiation. 2007 , 26, 1289-98	8
1484	Molecular mechanisms mediating pathological plasticity in Huntington's disease and Alzheimer's disease. 2007 , 100, 874-82	22
1483	IL-4 attenuates the neuroinflammation induced by amyloid-beta in vivo and in vitro. 2007 , 101, 771-81	98
1482	Effects of human apolipoprotein E isoforms on the amyloid beta-protein concentration and lipid composition in brain low-density membrane domains. 2007 , 101, 949-58	6

1481	A beta oligomers - a decade of discovery. 2007 , 101, 1172-84	1609
1480	Soluble oligomers from a non-disease related protein mimic Abeta-induced tau hyperphosphorylation and neurodegeneration. 2007 , 103, 736-48	71
1479	Modulation of amyloid-beta-induced and age-associated changes in rat hippocampus by eicosapentaenoic acid. 2007 , 103, 914-26	81
1478	The modulation of metal bio-availability as a therapeutic strategy for the treatment of Alzheimer's disease. 2007 , 274, 3775-83	56
1477	Conformational stability of Abeta-(25-35) in the presence of thiazolidine derivatives. 2007 , 69, 111-8	11
1476	Advancing translational research with the Semantic Web. 2007 , 8 Suppl 3, S2	165
1475	Requirement of aggregation propensity of Alzheimer amyloid peptides for neuronal cell surface binding. 2007 , 8, 29	29
1474	High content screen microscopy analysis of A beta 1-42-induced neurite outgrowth reduction in rat primary cortical neurons: neuroprotective effects of alpha 7 neuronal nicotinic acetylcholine receptor ligands. 2007 , 1151, 227-35	53
1473	Neurotrophins, synaptic plasticity and dementia. 2007 , 17, 325-30	142
1472	The role of amyloid beta peptide 42 in Alzheimer's disease. 2007 , 116, 266-86	233
1471	Reduced CXCL12/CXCR4 results in impaired learning and is downregulated in a mouse model of Alzheimer disease. 2007 , 28, 143-53	60
1470	Inflammatory processes in Alzheimer's disease. 2007 , 184, 69-91	575
1469	Differential neuroimmune markers to the onset of Alzheimer's disease neurodegeneration and dementia: autoantibodies to Abeta((25-35)) oligomers, S100b and neurotransmitters. 2007 , 186, 181-92	82
1468	Various dendritic abnormalities are associated with fibrillar amyloid deposits in Alzheimer's disease. 2007 , 1097, 30-9	106
1467	Fibrillar and oligomeric beta-amyloid as distinct local biomarkers for Alzheimer's disease. 2007 , 1097, 239-58	16
1466	Prion protein aggregation and neurotoxicity in cortical neurons. 2007 , 1096, 220-9	17
1465	Thermodynamics and kinetics of aggregation for the GNNQQNY peptide. 2007 , 129, 16005-14	139
1464	Thermodynamic studies on the interaction of antibodies with beta-amyloid peptide. 2007 , 111, 1238-43	17

1463	The conjugation of amyloid beta protein on the gold colloidal nanoparticles surfaces. 2007 , 18, 105101	72
1462	Role of aggregation conditions in structure, stability, and toxicity of intermediates in the Abeta fibril formation pathway. 2007 , 16, 723-32	96
1461	Soluble protein oligomers as emerging toxins in Alzheimer's and other amyloid diseases. 2007 , 59, 332-45	257
1460	Glial cell dysregulation: a new perspective on Alzheimer disease. 2007 , 12, 215-32	106
1459	Cofilin-mediated neurodegeneration in Alzheimer's disease and other amyloidopathies. 2007 , 35, 21-44	91
1458	Large size fibrillar bundles of the Alzheimer amyloid beta-protein. 2007 , 36, 701-9	12
1457	Metals ions and neurodegeneration. 2007 , 20, 639-54	153
1456	Plaques, tangles, and memory loss in mouse models of neurodegeneration. 2007 , 37, 79-100	113
1455	Alzheimer disease models and human neuropathology: similarities and differences. 2008 , 115, 5-38	299
1454	Targeting beta-amyloid pathology in Alzheimer's disease with Abeta immunotherapy. 2008 , 5, 415-20	52
1453	Disruption of Calcium Homeostasis in Alzheimer's Disease. 2008 , 40, 385-392	8
1452	Delineating the mechanism of Alzheimer's disease A beta peptide neurotoxicity. 2008 , 33, 526-32	92
1451	Differentiation increases the resistance of neuronal cells to amyloid toxicity. 2008 , 33, 2516-31	24
1450	Behavior of neural stem cells in the Alzheimer brain. 2008 , 65, 2372-84	76
1449	Neurotoxicity in Alzheimer's disease: is covalently crosslinked A beta responsible?. 2008 , 37, 265-8	13
1448	Acridine derivatives inhibit lysozyme aggregation. 2008 , 37, 1261-70	59
1447	Oligomeric and fibrillar species of beta-amyloid (A beta 42) both impair mitochondrial function in P301L tau transgenic mice. 2008 , 86, 1255-67	98
1446	Abinding molecules: Possible application as imaging probes and as anti-aggregation agents. 2008 , 51, 801-807	6

1445	Maximizing the potential of plasma amyloid-beta as a diagnostic biomarker for Alzheimer's disease. 2008 , 10, 195-207	28
1444	Dendritic spine loss and synaptic alterations in Alzheimer's disease. 2008 , 37, 73-82	209
1443	The ART of loss: Abeta imaging in the evaluation of Alzheimer's disease and other dementias. 2008 , 38, 1-15	81
1442	Therapeutic strategies for Alzheimer's disease. 2008 , 37, 171-86	102
1441	Recombinant amyloid beta-peptide production by coexpression with an affibody ligand. 2008 , 8, 82	32
1440	Formation of soluble amyloid oligomers and amyloid fibrils by the multifunctional protein vitronectin. 2008 , 3, 16	42
1439	Ligand-induced flocculation of neurotoxic fibrillar Abeta(1-42) by noncovalent crosslinking. 2008 , 9, 748-57	5
1438	Switch-peptides: design and characterization of controllable super-amyloid-forming host-guest peptides as tools for identifying anti-amyloid agents. 2008 , 9, 2104-12	22
1437	Using model membranes for the study of amyloid beta:lipid interactions and neurotoxicity. 2008 , 99, 753-63	58
1436	Simultaneous monitoring of peptide aggregate distributions, structure, and kinetics using amide hydrogen exchange: application to Abeta(1-40) fibrillogenesis. 2008 , 100, 1214-27	29
1435	A new amyloid beta variant favoring oligomerization in Alzheimer's-type dementia. 2008 , 63, 377-87	329
1434	Measuring target effect of proposed disease-modifying therapies in Alzheimer's disease. 2008 , 5, 381-90	17
1433	Abeta(1-42) reduces synapse number and inhibits neurite outgrowth in primary cortical and hippocampal neurons: a quantitative analysis. 2008 , 175, 96-103	46
1432	Globular and pre-fibrillar prion aggregates are toxic to neuronal cells and perturb their electrophysiology. 2008 , 1784, 873-81	22
1431	Design, synthesis, and biological evaluation of glycine-based molecular tongs as inhibitors of Abeta1-40 aggregation in vitro. 2008 , 16, 4810-22	22
1430	Influence of fluorinated and hydrogenated nanoparticles on the structure and fibrillogenesis of amyloid beta-peptide. 2008 , 137, 35-42	94
1429	Monitoring the earliest amyloid-beta oligomers via quantized photobleaching of dye-labeled peptides. 2008 , 382, 29-34	23
1428	Soluble Oligomers of the Amyloid EProtein: Impair Synaptic Plasticity and Behavior. 2008 , 89-102	4

1427	The Zyggregator method for predicting protein aggregation propensities. 2008 , 37, 1395-401	258
1426	Amyloid beta oligomers induce impairment of neuronal insulin receptors. 2008 , 22, 246-60	431
1425	Cerebral amyloid angiopathy: pathogenetic mechanisms and link to dense amyloid plaques. 2008 , 7 Suppl 1, 67-82	62
1424	Formation of highly toxic soluble amyloid beta oligomers by the molecular chaperone prefoldin. 2008 , 275, 5982-93	51
1423	Rapid appearance and local toxicity of amyloid-beta plaques in a mouse model of Alzheimer's disease. <i>Nature</i> , 2008 , 451, 720-4	50.4 774
1422	Substrate-targeting gamma-secretase modulators. <i>Nature</i> , 2008 , 453, 925-9	50.4 261
1421	Amyloid-beta protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory. 2008 , 14, 837-42	2779
1420	Oligomeric amyloid-beta peptide disrupts phosphatidylinositol-4,5-bisphosphate metabolism. 2008 , 11, 547-54	156
1419	Lipids revert inert Abeta amyloid fibrils to neurotoxic protofibrils that affect learning in mice. 2008 , 27, 224-33	266
1418	Developing preventive therapies for chronic diseases: lessons learned from Alzheimer's disease. 2007 , 65, S239-43	29
1417	The complement cascade: Yin-Yang in neuroinflammation--neuro-protection and -degeneration. 2008 , 107, 1169-87	130
1416	Selective induction of calcineurin activity and signaling by oligomeric amyloid beta. 2008 , 7, 824-35	75
1415	Cytoplasmic calcium mediates oxidative damage in an excitotoxic /energetic deficit synergic model in rats. 2008 , 27, 1075-85	28
1414	Effects of beta-amyloid peptide on the density of M2 muscarinic acetylcholine receptor protein in the hippocampus of the rat: relationship with GABA-, calcium-binding protein and somatostatin-containing cells. 2008 , 34, 506-22	11
1413	Upregulation of CRABP1 in human neuroblastoma cells overproducing the Alzheimer-typical Abeta42 reduces their differentiation potential. 2008 , 6, 38	12
1412	Similar toxicity of the oligomeric molten globule state and the prefibrillar oligomers. 2008 , 582, 203-9	26
1411	P3 peptide, a truncated form of A beta devoid of synaptotoxic effect, does not assemble into soluble oligomers. 2008 , 582, 1865-70	30
1410	Alcohol enhances Abeta42-induced neuronal cell death through mitochondrial dysfunction. 2008 , 582, 4185-90	4

1409	Cystatin B and its EPM1 mutants are polymeric and aggregate prone in vivo. 2008 , 1783, 312-22	23
1408	Inhibition of LTP in vivo by beta-amyloid peptide in different conformational states. 2008 , 1197, 135-42	25
1407	Phosphorylation of beta-amyloid precursor protein (APP) cytoplasmic tail facilitates amyloidogenic processing during apoptosis. 2008 , 1198, 204-12	16
1406	Females exhibit more extensive amyloid, but not tau, pathology in an Alzheimer transgenic model. 2008 , 1216, 92-103	205
1405	Amyloid flirting with synaptic failure: towards a comprehensive view of Alzheimer's disease pathogenesis. 2008 , 585, 109-18	47
1404	MAGUK proteins: new targets for pharmacological intervention in the glutamatergic synapse. 2008 , 585, 147-52	37
1403	The ubiquitin-proteasome system in Alzheimer's disease. 2008 , 12, 363-73	178
1402	Triptolide inhibits amyloid-beta1-42-induced TNF-alpha and IL-1beta production in cultured rat microglia. 2008 , 205, 32-6	55
1401	New structures help the modeling of toxic amyloidbeta ion channels. 2008 , 33, 91-100	123
1400	Abeta-globulomers are formed independently of the fibril pathway. 2008 , 30, 212-20	97
1399	A transgenic rat that develops Alzheimer's disease-like amyloid pathology, deficits in synaptic plasticity and cognitive impairment. 2008 , 31, 46-57	84
1398	Aggregation and catabolism of disease-associated intra-Abeta mutations: reduced proteolysis of AbetaA21G by neprilysin. 2008 , 31, 442-50	76
1397	Amyloid beta protein dimer-containing human CSF disrupts synaptic plasticity: prevention by systemic passive immunization. 2008 , 28, 4231-7	256
1396	General anesthetics and long-term neurotoxicity. 2008 , 143-57	20
1395	Investigating the mechanism of peptide aggregation: insights from mixed monte carlo-molecular dynamics simulations. 2008 , 94, 4414-26	44
1394	Soluble amyloid beta-oligomers affect dielectric membrane properties by bilayer insertion and domain formation: implications for cell toxicity. 2008 , 95, 4845-61	165
1393	Exercise alters the immune profile in Tg2576 Alzheimer mice toward a response coincident with improved cognitive performance and decreased amyloid. 2008 , 5, 13	156
1392	Interactions between APP secretases and inflammatory mediators. 2008 , 5, 25	127

1391	Clusters of hyperactive neurons near amyloid plaques in a mouse model of Alzheimer's disease. 2008 , 321, 1686-9	648
1390	Advances in Alzheimer's and Parkinson's Disease. 2008 ,	
1389	Amyloid beta-Cu ²⁺ complexes in both monomeric and fibrillar forms do not generate H ₂ O ₂ catalytically but quench hydroxyl radicals. 2008 , 47, 11653-64	101
1388	Designing peptide inhibitors for oligomerization and toxicity of Alzheimer's beta-amyloid peptide. 2008 , 47, 1984-92	123
1387	Beta-amyloid oligomers affect the structure and function of the postsynaptic region: role of the Wnt signaling pathway. 2008 , 5, 149-52	25
1386	Computational study on the structural diversity of amyloid Beta Peptide (abeta(10-35)) oligomers. 2008 , 112, 3479-84	49
1385	Central Nervous System Diseases and Inflammation. 2008 ,	5
1384	Apolipoprotein C-II amyloid fibrils assemble via a reversible pathway that includes fibril breaking and rejoining. 2008 , 376, 1116-29	61
1383	Mutations enhance the aggregation propensity of the Alzheimer's A beta peptide. 2008 , 377, 565-74	45
1382	New strategy for the generation of specific D-peptide amyloid inhibitors. 2008 , 377, 1372-81	27
1381	Formation of toxic Abeta(1-40) fibrils on GM1 ganglioside-containing membranes mimicking lipid rafts: polymorphisms in Abeta(1-40) fibrils. 2008 , 382, 1066-74	93
1380	Anti-oligomeric Abeta single-chain variable domain antibody blocks Abeta-induced toxicity against human neuroblastoma cells. 2008 , 384, 917-28	62
1379	Soluble amyloid beta oligomers may contribute to apoptosis of retinal ganglion cells in glaucoma. 2008 , 71, 77-80	25
1378	Calcium dysregulation in Alzheimer's disease. 2008 , 52, 621-33	147
1377	Type-2 alkenes mediate synaptotoxicity in neurodegenerative diseases. 2008 , 29, 871-82	41
1376	A polymer physics perspective on driving forces and mechanisms for protein aggregation. 2008 , 469, 132-41	127
1375	Alzheimer's disease-type neuronal tau hyperphosphorylation induced by A beta oligomers. 2008 , 29, 1334-47	341
1374	N-truncated amyloid-beta oligomers induce learning impairment and neuronal apoptosis. 2008 , 29, 1319-33	59

1373	Alpha v integrins mediate beta-amyloid induced inhibition of long-term potentiation. 2008 , 29, 1485-93	33
1372	Abeta inhibits the proteasome and enhances amyloid and tau accumulation. 2008 , 29, 1607-18	256
1371	Plaque-bearing mice with reduced levels of oligomeric amyloid-beta assemblies have intact memory function. 2008 , 151, 745-9	136
1370	A neuronal model of Alzheimer's disease: an insight into the mechanisms of oxidative stress-mediated mitochondrial injury. 2008 , 153, 120-30	111
1369	Neurotoxic effect of oligomeric and fibrillar species of amyloid-beta peptide 1-42: involvement of endoplasmic reticulum calcium release in oligomer-induced cell death. 2008 , 155, 725-37	173
1368	Effect on memory of acute administration of naturally secreted fibrils and synthetic amyloid-beta peptides in an invertebrate model. 2008 , 89, 407-18	6
1367	Wnt signaling in neuroprotection and stem cell differentiation. 2008 , 86, 281-96	166
1366	Human chorionic gonadotropin (a luteinizing hormone homologue) decreases spatial memory and increases brain amyloid-beta levels in female rats. 2008 , 54, 143-52	60
1365	Visualizing interaction of proteins relevant to Alzheimer's disease in intact cells. 2008 , 44, 299-303	11
1364	The aging brain. 2008 , 3, 41-66	425
1363	Age-dependent decline of neprilysin in Alzheimer's disease and normal brain: inverse correlation with A beta levels. 2008 , 29, 210-21	126
1362	Mechanisms of A beta mediated neurodegeneration in Alzheimer's disease. 2008 , 40, 181-98	198
1361	Beta-amyloid and glutamate receptors. 2008 , 212, 1-4	18
1360	A novel transgenic mouse expressing double mutant tau driven by its natural promoter exhibits tauopathy characteristics. 2008 , 212, 71-84	66
1359	Oligomer-specific Abeta toxicity in cell models is mediated by selective uptake. 2008 , 1782, 523-31	75
1358	Soluble oligomers of the amyloid beta-protein impair synaptic plasticity and behavior. 2008 , 192, 106-13	844
1357	Oligomers of the amyloid-beta protein disrupt working memory: confirmation with two behavioral procedures. 2008 , 193, 230-4	64
1356	Isomerization and/or racemization at Asp23 of Abeta42 do not increase its aggregative ability, neurotoxicity, and radical productivity in vitro. 2008 , 366, 745-51	17

1355	Design, synthesis, and biophysical properties of a helical Abeta1-42 analog: Inhibition of fibrillogenesis and cytotoxicity. 2008 , 371, 777-80	7
1354	Detection of Alzheimer's amyloid beta aggregation by capturing molecular trails of individual assemblies. 2008 , 377, 725-728	20
1353	The two faces of protein misfolding: gain- and loss-of-function in neurodegenerative diseases. 2008 , 27, 336-49	279
1352	Biochemistry and molecular biology of amyloid beta-protein and the mechanism of Alzheimer's disease. 2008 , 89, 245-60	100
1351	Amyloid plaque and neurofibrillary tangle pathology in a regulatable mouse model of Alzheimer's disease. 2008 , 173, 762-72	49
1350	Platform AY: Single Molecule Biophysics - III. 2008 , 94, 872-875	0
1349	Long-term effects of Abeta42 immunisation in Alzheimer's disease: follow-up of a randomised, placebo-controlled phase I trial. 2008 , 372, 216-23	1140
1348	Iron and the translation of the amyloid precursor protein (APP) and ferritin mRNAs: riboregulation against neural oxidative damage in Alzheimer's disease. 2008 , 36, 1282-7	100
1347	alpha-Synuclein: a therapeutic target for Parkinson's disease?. 2008 , 58, 271-80	31
1346	Active and passive immunotherapy for neurodegenerative disorders. 2008 , 31, 175-93	202
1345	Engineered antibody intervention strategies for Alzheimer's disease and related dementias by targeting amyloid and toxic oligomers. 2009 , 22, 199-208	39
1344	Alzheimer's Abeta peptides containing an isostructural backbone mutation afford distinct aggregate morphologies but analogous cytotoxicity. Evidence for a common low-abundance toxic structure(s)?. 2008 , 47, 50-9	35
1343	Stabilization of a beta-hairpin in monomeric Alzheimer's amyloid-beta peptide inhibits amyloid formation. 2008 , 105, 5099-104	324
1342	Amyloid-beta peptide (Abeta) neurotoxicity is modulated by the rate of peptide aggregation: Abeta dimers and trimers correlate with neurotoxicity. 2008 , 28, 11950-8	173
1341	Structural classification of toxic amyloid oligomers. 2008 , 283, 29639-43	622
1340	In situ Abeta pores in AD brain are cylindrical assembly of Abeta protofilaments. 2008 , 15, 223-33	28
1339	Methionine oxidation inhibits assembly and promotes disassembly of apolipoprotein C-II amyloid fibrils. 2008 , 47, 10208-17	33
1338	Cu(II) binding to monomeric, oligomeric, and fibrillar forms of the Alzheimer's disease amyloid-beta peptide. 2008 , 47, 5006-16	101

1337	How do surfactants and DTT affect the size, dynamics, activity and growth of soluble lysozyme aggregates?. 2008 , 415, 275-88	68
1336	Nanoscale size dependence in the conjugation of amyloid beta and ovalbumin proteins on the surface of gold colloidal particles. 2008 , 19, 375101	14
1335	Comparative molecular dynamics studies of wild-type and oxidized forms of full-length Alzheimer amyloid beta-peptides Abeta(1-40) and Abeta(1-42). 2008 , 112, 7123-31	55
1334	Faster forgetting contributes to impaired spatial memory in the PDAPP mouse: deficit in memory retrieval associated with increased sensitivity to interference?. 2008 , 15, 625-32	32
1333	Peripheral Abeta subspecies as risk biomarkers of Alzheimer's disease. 2008 , 105, 14052-7	193
1332	The molecular basis of functional bacterial amyloid polymerization and nucleation. 2008 , 283, 21530-9	98
1331	The low density lipoprotein receptor-related protein 1 mediates uptake of amyloid beta peptides in an in vitro model of the blood-brain barrier cells. 2008 , 283, 34554-62	79
1330	Amyloid-beta dynamics correlate with neurological status in the injured human brain. 2008 , 321, 1221-4	253
1329	Place cell firing correlates with memory deficits and amyloid plaque burden in Tg2576 Alzheimer mouse model. 2008 , 105, 7863-8	97
1328	Receptor for advanced glycation end product-dependent activation of p38 mitogen-activated protein kinase contributes to amyloid-beta-mediated cortical synaptic dysfunction. 2008 , 28, 3521-30	169
1327	Aggregated, wild-type prion protein causes neurological dysfunction and synaptic abnormalities. 2008 , 28, 13258-67	54
1326	Fluorescence detection of a lipid-induced tetrameric intermediate in amyloid fibril formation by apolipoprotein C-II. 2008 , 283, 35118-28	31
1325	Detection of elevated levels of soluble alpha-synuclein oligomers in post-mortem brain extracts from patients with dementia with Lewy bodies. 2009 , 132, 1093-101	168
1324	Amyloid beta-protein assembly as a therapeutic target of Alzheimer's disease. 2008 , 14, 3231-46	94
1323	Direct characterization of amyloidogenic oligomers by single-molecule fluorescence. 2008 , 105, 14424-9	165
1322	Retinoic acid attenuates beta-amyloid deposition and rescues memory deficits in an Alzheimer's disease transgenic mouse model. 2008 , 28, 11622-34	198
1321	Amyloid-beta binds to the extracellular cysteine-rich domain of Frizzled and inhibits Wnt/beta-catenin signaling. 2008 , 283, 9359-68	166
1320	Inhibition of gamma-secretase causes increased secretion of amyloid precursor protein C-terminal fragments in association with exosomes. 2008 , 22, 1469-78	205

1319	Platinum-based inhibitors of amyloid-beta as therapeutic agents for Alzheimer's disease. 2008 , 105, 6813-8	160
1318	Abeta oligomers induce neuronal cell cycle events in Alzheimer's disease. 2008 , 28, 10786-93	98
1317	Site-specific blockade of RAGE-Vd prevents amyloid-beta oligomer neurotoxicity. 2008 , 28, 5149-58	97
1316	Transglutaminase induces protofibril-like amyloid beta-protein assemblies that are protease-resistant and inhibit long-term potentiation. 2008 , 283, 16790-800	70
1315	Amyloid beta oligomers (A beta(1-42) globulomer) suppress spontaneous synaptic activity by inhibition of P/Q-type calcium currents. 2008 , 28, 788-97	180
1314	Structure-function relationships of pre-fibrillar protein assemblies in Alzheimer's disease and related disorders. 2008 , 5, 319-41	82
1313	Energy landscapes of the monomer and dimer of the Alzheimer's peptide Abeta(1-28). 2008 , 128, 125108	24
1312	The Alzheimer beta-amyloid (Abeta(1-39)) dimer in an implicit solvent. 2008 , 129, 195102	43
1311	Is covalently crosslinked Abeta responsible for synaptotoxicity in Alzheimer's disease?. 2008 , 5, 533-9	10
1310	Impact of Beta Amyloid on Excitatory Synaptic Transmission and Plasticity. 2008 , 63-68	1
1309	Amyloidogenesis of natively unfolded proteins. 2008 , 5, 260-87	147
1308	Role of the region 23-28 in Abeta fibril formation: insights from simulations of the monomers and dimers of Alzheimer's peptides Abeta40 and Abeta42. 2008 , 5, 244-50	91
1307	Protection mechanisms against Abeta42 aggregation. 2008 , 5, 548-54	9
1306	NF-kappaB-inducing kinase phosphorylates and blocks the degradation of Down syndrome candidate region 1. 2008 , 283, 3392-3400	34
1305	Structure-function implications in Alzheimer's disease: effect of Abeta oligomers at central synapses. 2008 , 5, 233-43	81
1304	A closer look at alpha-secretase. 2008 , 5, 179-86	95
1303	Processing of amyloid precursor protein and amyloid peptide neurotoxicity. 2008 , 5, 92-9	50
1302	The AbetaCs of Abeta-cleaving proteases. 2008 , 283, 29645-9	70

1301	Molecular and transmission characteristics of primary-passaged ovine scrapie isolates in conventional and ovine PrP transgenic mice. 2008 , 82, 11197-207	41
1300	Abeta predictor of Alzheimer disease symptoms. 2008 , 65, 875-6	
1299	p21-activated kinase-aberrant activation and translocation in Alzheimer disease pathogenesis. 2008 , 283, 14132-43	94
1298	CNI-1493 inhibits Abeta production, plaque formation, and cognitive deterioration in an animal model of Alzheimer's disease. 2008 , 205, 1593-9	20
1297	Enhanced clearance of Abeta in brain by sustaining the plasmin proteolysis cascade. 2008 , 105, 8754-9	101
1296	The beta-amyloid protein of Alzheimer's disease increases neuronal CRMP-2 phosphorylation by a Rho-GTP mechanism. 2008 , 131, 90-108	148
1295	The amyloid beta-peptide is imported into mitochondria via the TOM import machinery and localized to mitochondrial cristae. 2008 , 105, 13145-50	482
1294	The ratio of monomeric to aggregated forms of Abeta40 and Abeta42 is an important determinant of amyloid-beta aggregation, fibrillogenesis, and toxicity. 2008 , 283, 28176-89	197
1293	Clinical and neuropathological features of the arctic APP gene mutation causing early-onset Alzheimer disease. 2008 , 65, 499-505	78
1292	Cyclooxygenase-2 inhibition improves amyloid-beta-mediated suppression of memory and synaptic plasticity. 2008 , 131, 651-64	181
1291	Soluble amyloid-beta peptides potently disrupt hippocampal synaptic plasticity in the absence of cerebrovascular dysfunction in vivo. 2008 , 131, 2414-24	76
1290	[Therapeutic strategy by manipulating some protease activities for Alzheimer's disease]. 2008 , 131, 320-5	
1289	Metal-dependent generation of reactive oxygen species from amyloid proteins implicated in neurodegenerative disease. 2008 , 36, 1293-8	69
1288	[Neurotoxicity of amyloid beta proteins]. 2008 , 131, 326-32	
1287	The seed extract of Cassia obtusifolia offers neuroprotection to mouse hippocampal cultures. 2008 , 107, 380-92	53
1286	Spatial memory impairment without apoptosis induced by the combination of beta-amyloid oligomers and cerebral ischemia is related to decreased acetylcholine release in rats. 2008 , 106, 84-91	23
1285	[Clinical approach and pathological cascade of dementia]. 2008 , 48, 467-75	1
1284	Neuroimaging in dementia: in vivo amyloid imaging. 2008 , 215, 119-24	5

1283	A method for the detection of amyloid-beta1-40, amyloid-beta1-42 and amyloid-beta oligomers in blood using magnetic beads in combination with Flow cytometry and its application in the diagnostics of Alzheimer's disease. 2008 , 14, 127-31	16
1282	Conformational changes and aggregation of expanded polyglutamine proteins as therapeutic targets of the polyglutamine diseases: exposed beta-sheet hypothesis. 2008 , 14, 3267-79	50
1281	Amyloid-Targeted Metal Chelation, Anti-Oxidative Stress, and Anti- Inflammation as Potential Alzheimers Therapies. 2008 , 4, 140-149	8
1280	Drosophila models of Alzheimer's amyloidosis: the challenge of dissecting the complex mechanisms of toxicity of amyloid-beta 42. 2008 , 15, 523-40	48
1279	Validation of folate in a convenient yeast assay suited for identification of inhibitors of Alzheimer's amyloid-beta aggregation. 2008 , 15, 391-6	26
1278	Amyloid-beta E22Delta variant induces synaptic alteration in mouse hippocampal slices. 2008 , 19, 615-9	31
1277	Cyanidin 3-O-glucopyranoside protects and rescues SH-SY5Y cells against amyloid-beta peptide-induced toxicity. 2008 , 19, 1483-6	41
1276	Role of phosphodiesterase 5 in synaptic plasticity and memory. 2008 , 4, 371-87	68
1275	An update on the toxicity of Abeta in Alzheimer's disease. 2008 , 4, 1033-42	28
1274	In silico study on the effect of F19T mutation on amyloid-beta peptide (10-35). 2008 , 13, 3951-65	
1273	Molecular Aspects of Memory Dysfunction in Alzheimer's Disease. 2008 , 245-293	3
1272	Intracerebroventricular Administration of Amyloid β protein Oligomers Selectively Increases Dorsal Hippocampal Dialysate Glutamate Levels in the Awake Rat. 2008 , 8, 7428-7437	19
1271	Finite size effects in simulations of protein aggregation. 2008 , 3, e2641	7
1270	Amyloids: friend or foe?. 2008 , 13, 407-19	74
1269	Abeta-dependent Inhibition of LTP in different intracortical circuits of the visual cortex: the role of RAGE. 2009 , 17, 59-68	41
1268	Novel Pharmacotherapies for Alzheimer's Disease. 2009 , 52, 1059	9
1267	Zinc Inhibits Amyloid beta Production from Alzheimer's Amyloid Precursor Protein in SH-SY5Y Cells. 2009 , 13, 195-200	10
1266	Amyloid beta-peptide aggregation. What does it result in and how can it be prevented?. 2009 , 14, 1716-29	23

1265	nELAV proteins alteration in Alzheimer's disease brain: a novel putative target for amyloid-beta reverberating on AbetaPP processing. 2009 , 16, 409-19	50
1264	A natural squamosamide derivative FLZ reduces amyloid-beta production by increasing non-amyloidogenic AbetaPP processing. 2009 , 18, 153-65	8
1263	Intrinsic disorder in proteins associated with neurodegenerative diseases. 2009 , 14, 5188-238	169
1262	Synaptic retrogenesis and amyloid-beta in Alzheimer's disease. 2009 , 16, 1-14	50
1261	Interaction between Alzheimer's amyloid-beta and amyloid-beta-metal complexes with cell membranes. 2009 , 17, 81-90	16
1260	Improved learning and memory in aged mice deficient in amyloid beta-degrading neutral endopeptidase. 2009 , 4, e4590	29
1259	Disassembly of shank and homer synaptic clusters is driven by soluble beta-amyloid(1-40) through divergent NMDAR-dependent signalling pathways. 2009 , 4, e6011	65
1258	CCL2 accelerates microglia-mediated Abeta oligomer formation and progression of neurocognitive dysfunction. 2009 , 4, e6197	78
1257	New Alzheimer amyloid beta responsive genes identified in human neuroblastoma cells by hierarchical clustering. 2009 , 4, e6779	15
1256	Neurotoxicity of general anesthetics: cause for concern?. 2009 , 111, 1365-71	64
1255	Network features and pathway analyses of a signal transduction cascade. 2009 , 3,	
1254	Amyloid-ss Dynamics Correlate with Neurological Status in the Injured Human Brain. 2009 ,	
1253	Prion neurodegeneration: starts and stops at the synapse. 2009 , 3, 195-201	46
1252	Immunization with amyloid-beta attenuates inclusion body myositis-like myopathology and motor impairment in a transgenic mouse model. 2009 , 29, 6132-41	22
1251	Amino acid position-specific contributions to amyloid beta-protein oligomerization. 2009 , 284, 23580-91	71
1250	Paradoxical condensation of copper with elevated beta-amyloid in lipid rafts under cellular copper deficiency conditions: implications for Alzheimer disease. 2009 , 284, 21899-21907	48
1249	Prion protein and Alzheimer disease. 2009 , 3, 190-4	56
1248	Alpha-helix targeting reduces amyloid-beta peptide toxicity. 2009 , 106, 9191-6	113

1247	Role of amyloid-beta glycine 33 in oligomerization, toxicity, and neuronal plasticity. 2009 , 29, 7582-90	87
1246	Distinctive roles of different beta-amyloid 42 aggregates in modulation of synaptic functions. 2009 , 23, 1969-77	21
1245	Amyloid seeds formed by cellular uptake, concentration, and aggregation of the amyloid-beta peptide. 2009 , 106, 20324-9	284
1244	Increasing Cu bioavailability inhibits Abeta oligomers and tau phosphorylation. 2009 , 106, 381-6	227
1243	{beta}-Amyloid impairs AMPA receptor trafficking and function by reducing Ca ²⁺ /calmodulin-dependent protein kinase II synaptic distribution. 2009 , 284, 10639-49	140
1242	Isolation and characterization of patient-derived, toxic, high mass amyloid beta-protein (Abeta) assembly from Alzheimer disease brains. 2009 , 284, 32895-905	136
1241	Protection of synapses against Alzheimer's-linked toxins: insulin signaling prevents the pathogenic binding of Abeta oligomers. 2009 , 106, 1971-6	508
1240	Calcium dyshomeostasis and neurotoxicity of Alzheimer's beta-amyloid protein. 2009 , 9, 681-93	45
1239	Impaired balance of mitochondrial fission and fusion in Alzheimer's disease. 2009 , 29, 9090-103	816
1238	Molecular pathogenesis of Alzheimer's disease: reductionist versus expansionist approaches. 2009 , 10, 1386-406	37
1237	Self-assembly of bacteriophage-associated hyaluronate lyase (HYLP2) into an enzymatically active fibrillar film. 2009 , 284, 5240-9	4
1236	Amyloid beta-protein toxicity and the pathogenesis of Alzheimer disease. 2009 , 284, 4755-9	153
1235	High striatal amyloid beta-peptide deposition across different autosomal Alzheimer disease mutation types. 2009 , 66, 1537-44	133
1234	Genetic variation in N-methyl-D-aspartate receptor subunit NR3A but not NR3B influences susceptibility to Alzheimer's disease. 2009 , 28, 521-7	18
1233	Crosstalk between calcium, amyloid beta and the receptor for advanced glycation endproducts in Alzheimer's disease. 2009 , 20, 95-110	22
1232	AAV1/2-mediated CNS gene delivery of dominant-negative CCL2 mutant suppresses gliosis, beta-amyloidosis, and learning impairment of APP/PS1 mice. 2009 , 17, 803-9	52
1231	Neuronal protein trafficking associated with Alzheimer disease: from APP and BACE1 to glutamate receptors. 2009 , 3, 118-28	53
1230	Amyloid deposits: protection against toxic protein species?. 2009 , 8, 1668-74	111

1229	Antiparallel beta-sheet: a signature structure of the oligomeric amyloid beta-peptide. 2009 , 421, 415-23	354
1228	Oligomerization partially explains the lowering of Abeta42 in Alzheimer's disease cerebrospinal fluid. 2009 , 6, 139-47	40
1227	Pharmacology of the intracellular pathways activated by amyloid beta protein. 2009 , 9, 724-40	16
1226	To fold or not to fold: modulation and consequences of Hsp90 inhibition. 2009 , 1, 267-83	71
1225	Modulation of microglial innate immunity in Alzheimer's disease by activation of peroxisome proliferator-activated receptor gamma. 2009 , 16, 643-51	34
1224	Hereditary and sporadic forms of abeta-cerebrovascular amyloidosis and relevant transgenic mouse models. 2009 , 10, 1872-95	28
1223	Amyloidogenesis abolished by proline substitutions but enhanced by lipid binding. 2009 , 5, e1000357	36
1222	An ALS-linked mutant SOD1 produces a locomotor defect associated with aggregation and synaptic dysfunction when expressed in neurons of <i>Caenorhabditis elegans</i> . 2009 , 5, e1000350	141
1221	A role for synaptic zinc in activity-dependent Abeta oligomer formation and accumulation at excitatory synapses. 2009 , 29, 4004-15	189
1220	Antiamnesic and neuroprotective effects of the aminotetrahydrofuran derivative ANAVEX1-41 against amyloid beta(25-35)-induced toxicity in mice. 2009 , 34, 1552-66	84
1219	Translational, rotational and internal dynamics of amyloid beta-peptides (Abeta40 and Abeta42) from molecular dynamics simulations. 2009 , 131, 155103	15
1218	G protein-coupled receptors, cholinergic dysfunction, and Abeta toxicity in Alzheimer's disease. 2009 , 2, re8	38
1217	Cholesterol in Alzheimer's disease: unresolved questions. 2009 , 6, 15-29	116
1216	Oligomeric amyloid beta-protein as a therapeutic target in Alzheimer's disease: its significance based on its distinct localization and the occurrence of a familial variant form. 2009 , 6, 132-6	4
1215	Lysosomal modulatory drugs for a broad strategy against protein accumulation disorders. 2009 , 6, 438-45	13
1214	Omi is a mammalian heat-shock protein that selectively binds and detoxifies oligomeric amyloid-beta. 2009 , 122, 1917-26	19
1213	Reelin signaling antagonizes beta-amyloid at the synapse. 2009 , 106, 15938-43	117
1212	Epilepsy and cognitive impairments in Alzheimer disease. 2009 , 66, 435-40	458

1211	Cellular prion protein mediates the toxicity of beta-amyloid oligomers: implications for Alzheimer disease. 2009 , 66, 1325-8	57
1210	Oligomeric amyloid beta associates with postsynaptic densities and correlates with excitatory synapse loss near senile plaques. 2009 , 106, 4012-7	603
1209	Unique quadruplex structure and interaction of an RNA aptamer against bovine prion protein. 2009 , 37, 6249-58	78
1208	Nuclear signaling by the APP intracellular domain occurs predominantly through the amyloidogenic processing pathway. 2009 , 122, 3703-14	99
1207	Dysregulation of histone acetylation in the APP/PS1 mouse model of Alzheimer's disease. 2009 , 18, 131-9	218
1206	Driving amyloid toxicity in a yeast model by structural changes: a molecular approach. 2009 , 23, 2254-63	24
1205	Examination of potential mechanisms of amyloid-induced defects in neuronal transport. 2009 , 36, 11-25	39
1204	Biochemical and immunohistochemical analysis of an Alzheimer's disease mouse model reveals the presence of multiple cerebral Abeta assembly forms throughout life. 2009 , 36, 293-302	98
1203	Alzheimer's-associated Abeta oligomers show altered structure, immunoreactivity and synaptotoxicity with low doses of oleocanthal. 2009 , 240, 189-97	105
1202	Differential gene expression in ADAM10 and mutant ADAM10 transgenic mice. 2009 , 10, 66	30
1201	Chaperone signalling complexes in Alzheimer's disease. 2009 , 13, 619-30	96
1200	Membrane-targeted strategies for modulating APP and Abeta-mediated toxicity. 2009 , 13, 249-61	3
1199	Calcium in the initiation, progression and as an effector of Alzheimer's disease pathology. 2009 , 13, 2787-99	40
1198	Decreased acetylcholine release is correlated to memory impairment in the Tg2576 transgenic mouse model of Alzheimer's disease. 2009 , 1249, 222-8	62
1197	Oligomeric amyloid-beta(1-42) induces THP-1 human monocyte adhesion and maturation. 2009 , 1254, 109-19	12
1196	gamma-secretase processing of APLP1 leads to the production of a p3-like peptide that does not aggregate and is not toxic to neurons. 2009 , 1262, 89-99	14
1195	Stimulus pattern dependence of the Alzheimer's disease amyloid-beta 42 peptide's inhibition of long term potentiation in mouse hippocampal slices. 2009 , 1269, 176-84	25
1194	Excitatory amino acid transporter 2 associates with phosphorylated tau and is localized in neurofibrillary tangles of tauopathic brains. 2009 , 583, 2194-200	17

1193	L-3-n-butylphthalide improves cognitive impairment induced by intracerebroventricular infusion of amyloid-beta peptide in rats. 2009 , 621, 38-45	51
1192	The deficit in long-term potentiation induced by chronic administration of amyloid-beta is attenuated by treatment of rats with a novel phospholipid-based drug formulation, VP025. 2009 , 44, 300-4	8
1191	Cognitive-Performance Recovery of Alzheimer's Disease Model Mice by Modulation of Early Soluble Amyloid Assemblies. 2009 , 121, 2015-2020	15
1190	Die Alzheimer-Demenz: von der Pathologie zu therapeutischen Ansätzen. 2009 , 121, 3074-3105	37
1189	Age effects on the regulation of adult hippocampal neurogenesis by physical activity and environmental enrichment in the APP23 mouse model of Alzheimer disease. 2009 , 19, 1008-18	150
1188	Cytoskeletal pathologies of Alzheimer disease. 2009 , 66, 635-49	110
1187	Development of vaccination approaches for the treatment of neurological diseases. 2009 , 515, 4-14	11
1186	NMDA receptor-dependent signaling pathways that underlie amyloid beta-protein disruption of LTP in the hippocampus. 2009 , 87, 1729-36	109
1185	Deprivation-induced dendritic shrinkage might be oppositely affected by the expression of wild-type and mutated human amyloid precursor protein. 2009 , 87, 1813-22	7
1184	Cognitive-performance recovery of Alzheimer's disease model mice by modulation of early soluble amyloid assemblies. 2009 , 48, 1981-6	114
1183	Alzheimer's disease: from pathology to therapeutic approaches. 2009 , 48, 3030-59	467
1182	N-terminal truncated pyroglutamy beta amyloid peptide Abeta ₃₋₄₂ shows a faster aggregation kinetics than the full-length Abeta ₁₋₄₂ . 2009 , 91, 861-73	49
1181	Transient reduction of spontaneous neuronal network activity by sublethal amyloid beta (1-42) peptide concentrations. 2009 , 116, 351-5	10
1180	Cell-derived soluble oligomers of human amyloid-beta peptides disturb cellular homeostasis and induce apoptosis in primary hippocampal neurons. 2009 , 116, 1561-9	31
1179	Variations in the neuropathology of familial Alzheimer's disease. 2009 , 118, 37-52	96
1178	A fibril-specific, conformation-dependent antibody recognizes a subset of Abeta plaques in Alzheimer disease, Down syndrome and Tg2576 transgenic mouse brain. 2009 , 118, 505-17	37
1177	Classification and basic pathology of Alzheimer disease. 2009 , 118, 5-36	632
1176	Synaptic degeneration in Alzheimer's disease. 2009 , 118, 167-79	353

1175	Alzheimer's disease and blood-brain barrier function-Why have anti-beta-amyloid therapies failed to prevent dementia progression?. 2009 , 33, 1099-108	57
1174	A comparative study of beta-amyloid peptides Abeta1-42 and Abeta25-35 toxicity in organotypic hippocampal slice cultures. 2009 , 34, 295-303	76
1173	Oligodendrocytes are a novel source of amyloid peptide generation. 2009 , 34, 2243-50	21
1172	Influence of Cr Adhesion Layer on Detection of Amyloid-Derived Diffusible Ligands Based on Localized Surface Plasmon Resonance. 2009 , 4, 135-140	6
1171	Amyloid imaging in Alzheimer's disease and other dementias. 2009 , 3, 246-61	23
1170	Targeting the early steps of Abeta16-22 protofibril disassembly by N-methylated inhibitors: a numerical study. 2009 , 75, 442-52	63
1169	Neurons generated from APP/APLP1/APLP2 triple knockout embryonic stem cells behave normally in vitro and in vivo: lack of evidence for a cell autonomous role of the amyloid precursor protein in neuronal differentiation. 2010 , 28, 399-406	30
1168	Development of oligomeric prion-protein aggregates in a mouse model of prion disease. 2009 , 219, 123-30	19
1167	Discovery of amyloid-beta aggregation inhibitors using an engineered assay for intracellular protein folding and solubility. 2009 , 18, 277-86	39
1166	Bioluminescence imaging reveals inhibition of tumor cell proliferation by Alzheimer's amyloid beta protein. 2009 , 9, 15	21
1165	Calcium signaling in neurodegeneration. 2009 , 4, 20	179
1164	Alzheimer's disease: synaptic dysfunction and Abeta. 2009 , 4, 48	318
1163	Acute dosing of latrepirdine (Dimebon), a possible Alzheimer therapeutic, elevates extracellular amyloid-beta levels in vitro and in vivo. 2009 , 4, 51	29
1162	ZnT3 mRNA levels are reduced in Alzheimer's disease post-mortem brain. 2009 , 4, 53	45
1161	Does Alzheimer's disease begin in the brainstem?. 2009 , 35, 532-54	139
1160	Cellular prion protein mediates impairment of synaptic plasticity by amyloid-beta oligomers. <i>Nature</i> , 2009 , 457, 1128-32	50.4 1194
1159	Amyloid-beta protofibril levels correlate with spatial learning in Arctic Alzheimer's disease transgenic mice. 2009 , 276, 995-1006	66
1158	A new series of 1,3-dihidro-imidazo[1,5-c]thiazole-5,7-dione derivatives: synthesis and interaction with Abeta(25-35) amyloid peptide. 2009 , 74, 224-33	7

1157	Age matters. 2009 , 29, 997-1014	200
1156	Fenton chemistry and oxidative stress mediate the toxicity of the beta-amyloid peptide in a <i>Drosophila</i> model of Alzheimer's disease. 2009 , 29, 1335-47	142
1155	Inhibition of Alzheimer's amyloid toxicity with a tricyclic pyrone molecule in vitro and in vivo. 2009 , 108, 1097-1108	58
1154	Plasminogen activator activity is inhibited while neuroserpin is up-regulated in the Alzheimer disease brain. 2009 , 109, 303-15	66
1153	The amyloid hypothesis for Alzheimer's disease: a critical reappraisal. 2009 , 110, 1129-34	585
1152	NO-flurbiprofen reduces amyloid-beta, is neuroprotective in cell culture, and enhances cognition in response to cholinergic blockade. 2009 , 111, 766-76	18
1151	Amyloid beta serves as an NGF-like neurotrophic factor or acts as a NGF antagonist depending on its concentration. 2009 , 111, 1425-33	28
1150	Characterisation of two antibodies to oligomeric Abeta and their use in ELISAs on human brain tissue homogenates. 2009 , 176, 206-12	42
1149	The binding of pullulan modified cholesteryl nanogels to Abeta oligomers and their suppression of cytotoxicity. 2009 , 30, 5583-91	70
1148	Glutamate sensing with enzyme-modified floating-gate field effect transistors. 2009 , 24, 2384-9	19
1147	Amphotericin B interactions with soluble oligomers of amyloid Abeta1-42 peptide. 2009 , 17, 2366-70	17
1146	Syntheses of tricyclic pyrones and pyridinones and protection of Abeta-peptide induced MC65 neuronal cell death. 2009 , 19, 670-4	15
1145	A chemical screening approach reveals that indole fluorescence is quenched by pre-fibrillar but not fibrillar amyloid-beta. 2009 , 19, 4952-7	25
1144	Amyloid accomplices and enforcers. 2005 , 14, 1-12	110
1143	Increased expression of PAD2 after repeated intracerebroventricular infusions of soluble Abeta(25-35) in the Alzheimer's disease model rat brain: effect of memantine. 2009 , 14, 703-14	9
1142	Intrinsic Disorder in Proteins Associated with Neurodegenerative Diseases. 2009 , 21-75	6
1141	Neighboring amide participation in thioether oxidation: relevance to biological oxidation. 2009 , 131, 13791-805	40
1140	Abeta40, either soluble or aggregated, is a remarkably potent antioxidant in cell-free oxidative systems. 2009 , 48, 4354-70	83

1139	Morphology and secondary structure of stable beta-oligomers formed by amyloid peptide PrP(106-126). 2009 , 48, 5779-81	25
1138	Neural stem cells improve cognition via BDNF in a transgenic model of Alzheimer disease. 2009 , 106, 13594-9	644
1137	Protein Folding and Misfolding: Neurodegenerative Diseases. 2009 ,	5
1136	Dissociating beta-amyloid from alpha 7 nicotinic acetylcholine receptor by a novel therapeutic agent, S 24795, normalizes alpha 7 nicotinic acetylcholine and NMDA receptor function in Alzheimer's disease brain. 2009 , 29, 10961-73	91
1135	Current Hypotheses and Research Milestones in Alzheimer's Disease. 2009 ,	1
1134	Prevention of age-associated dementia. 2009 , 80, 315-25	23
1133	Protein aggregation as a paradigm of aging. 2009 , 1790, 980-96	78
1132	Effects of docosahexaenoic acid on in vitro amyloid beta peptide 25-35 fibrillation. 2009 , 1791, 289-96	30
1131	The interaction of beta-amyloid protein with cellular membranes stimulates its own production. 2009 , 1788, 964-72	69
1130	A protective role for lipid raft cholesterol against amyloid-induced membrane damage in human neuroblastoma cells. 2009 , 1788, 2204-16	54
1129	Amyloid beta peptides with an additional cysteine residue can enhance immunogenicity and reduce the amyloid beta burden in an Alzheimer's disease mouse model. 2009 , 382, 149-52	6
1128	Non-fibrillar amyloid-beta peptide reduces NMDA-induced neurotoxicity, but not AMPA-induced neurotoxicity. 2009 , 386, 734-8	4
1127	Ellagic acid promotes Abeta42 fibrillization and inhibits Abeta42-induced neurotoxicity. 2009 , 390, 1250-4	84
1126	Protection against beta-amyloid induced abnormal synaptic function and cell death by Ginkgolide J. 2009 , 30, 257-65	30
1125	Beta-amyloid deposition in brain is enhanced in mouse models of arterial hypertension. 2009 , 30, 222-8	95
1124	Deregulation of NMDA-receptor function and down-stream signaling in APP[V717I] transgenic mice. 2009 , 30, 241-56	83
1123	Insulin rescues amyloid beta-induced impairment of hippocampal long-term potentiation. 2009 , 30, 377-87	69
1122	Age-related accumulation of Reelin in amyloid-like deposits. 2009 , 30, 697-716	77

1121	Presenilin-1 mutation impairs cholinergic modulation of synaptic plasticity and suppresses NMDA currents in hippocampus slices. 2009 , 30, 1061-8	45
1120	Inhibition of LTP by beta-amyloid is prevented by activation of beta2 adrenoceptors and stimulation of the cAMP/PKA signalling pathway. 2009 , 30, 1608-13	44
1119	Amyloid precursor protein increases cortical neuron size in transgenic mice. 2009 , 30, 1238-44	38
1118	Abeta peptide conformation determines uptake and interleukin-1alpha expression by primary microglial cells. 2009 , 30, 1792-804	35
1117	Postsynaptic density-membrane associated guanylate kinase proteins (PSD-MAGUKs) and their role in CNS disorders. 2009 , 158, 324-33	55
1116	Synaptic transmission is impaired prior to plaque formation in amyloid precursor protein-overexpressing mice without altering behaviorally-correlated sharp wave-ripple complexes. 2009 , 162, 1081-90	41
1115	Granulocyte colony stimulating factor decreases brain amyloid burden and reverses cognitive impairment in Alzheimer's mice. 2009 , 163, 55-72	120
1114	Long-term green tea catechin administration prevents spatial learning and memory impairment in senescence-accelerated mouse prone-8 mice by decreasing Abeta1-42 oligomers and upregulating synaptic plasticity-related proteins in the hippocampus. 2009 , 163, 741-9	136
1113	Effects of memantine on soluble Alphabeta(25-35)-induced changes in peptidergic and glial cells in Alzheimer's disease model rat brain regions. 2009 , 164, 1199-209	27
1112	Lipoprotein receptors and cholesterol in APP trafficking and proteolytic processing, implications for Alzheimer's disease. 2009 , 20, 191-200	91
1111	Reduced oligomeric and vascular amyloid-beta following immunization of TgCRND8 mice with an Alzheimer's DNA vaccine. 2009 , 27, 1365-76	22
1110	Expression, purification, and characterization of recombinant human beta-amyloid42 peptide in Escherichia coli. 2009 , 64, 55-62	25
1109	Protective effect of S14G-humanin against beta-amyloid induced LTP inhibition in mouse hippocampal slices. 2009 , 30, 1197-202	21
1108	TrkA pathway activation induced by amyloid-beta (Abeta). 2009 , 40, 365-73	31
1107	Low molecular weight Abeta induces collapse of endoplasmic reticulum. 2009 , 41, 32-43	28
1106	Alzheimer beta-amyloid blocks epileptiform activity in hippocampal neurons. 2009 , 41, 420-8	17
1105	Amyloid-beta membrane binding and permeabilization are distinct processes influenced separately by membrane charge and fluidity. 2009 , 386, 81-96	131
1104	Characterization of oligomeric species on the aggregation pathway of human lysozyme. 2009 , 387, 17-27	77

1103	At low concentrations, 3,4-dihydroxyphenylacetic acid (DOPAC) binds non-covalently to alpha-synuclein and prevents its fibrillation. 2009 , 388, 597-610	43
1102	Oligomeric aggregates of amyloid beta peptide 1-42 activate ERK/MAPK in SH-SY5Y cells via the alpha7 nicotinic receptor. 2009 , 55, 796-801	38
1101	Biomarkers of oxidative and nitrosative damage in Alzheimer's disease and mild cognitive impairment. 2009 , 8, 285-305	178
1100	The sea urchin embryo: a model to study Alzheimer's beta amyloid induced toxicity. 2009 , 483, 120-6	15
1099	Metallo-complex activation of neuroprotective signalling pathways as a therapeutic treatment for Alzheimer's disease. 2009 , 5, 134-42	28
1098	RAGE and Alzheimer's disease: a progression factor for amyloid-beta-induced cellular perturbation?. 2009 , 16, 833-43	114
1097	Abeta oligomers and fibrillar aggregates induce different apoptotic pathways in LAN5 neuroblastoma cell cultures. 2009 , 96, 4200-11	83
1096	Human serum albumin inhibits Abeta fibrillization through a "monomer-competitor" mechanism. 2009 , 97, 2585-94	73
1095	Misfolded amyloid ion channels present mobile beta-sheet subunits in contrast to conventional ion channels. 2009 , 97, 3029-37	84
1094	Galantamine inhibits beta-amyloid aggregation and cytotoxicity. 2009 , 280, 49-58	74
1093	Copper(II) binding to amyloid-beta fibrils of Alzheimer's disease reveals a picomolar affinity: stoichiometry and coordination geometry are independent of Abeta oligomeric form. 2009 , 48, 4388-402	182
1092	Decreased brain-derived neurotrophic factor depends on amyloid aggregation state in transgenic mouse models of Alzheimer's disease. 2009 , 29, 9321-9	164
1091	Structure-neurotoxicity relationships of amyloid beta-protein oligomers. 2009 , 106, 14745-50	614
1090	On the nucleation of amyloid beta-protein monomer folding. 2005 , 14, 1581-96	270
1089	Beta amyloid oligomers and fibrils stimulate differential activation of primary microglia. 2009 , 6, 1	169
1088	Chapter 7: Cell protective functions of secretory Clusterin (sCLU). 2009 , 104, 115-38	20
1087	Beta-amyloid monomers are neuroprotective. 2009 , 29, 10582-7	289
1086	NMDA Receptors and Disease+C464. 2009 , 1177-1182	2

1085	Development of semagacestat (LY450139), a functional gamma-secretase inhibitor, for the treatment of Alzheimer's disease. 2009 , 10, 1657-64	122
1084	Interactions between heparan sulfate and proteins-design and functional implications. 2009 , 276, 105-59	206
1083	PET in the Evaluation of Alzheimer's Disease and Related Disorders. 2009 ,	6
1082	Neurofibrillary Tangle Formation as a Protective Response to Oxidative Stress in Alzheimer's Disease. 2009 , 103-113	3
1081	An improved screening model to identify inhibitors targeting zinc-enhanced amyloid aggregation. 2009 , 81, 6944-51	7
1080	Peptide Microarrays. 2009 ,	4
1079	Is Alzheimer's disease a result of presynaptic failure? Synaptic dysfunctions induced by oligomeric beta-amyloid. 2009 , 20, 1-12	103
1078	The quest for small molecules as amyloid inhibiting therapies for Alzheimer's disease. 2009 , 17, 33-47	56
1077	A recessive mutation in the APP gene with dominant-negative effect on amyloidogenesis. 2009 , 323, 1473-7	306
1076	Amyloid-beta(1-42) fibrillar precursors are optimal for inducing tumor necrosis factor-alpha production in the THP-1 human monocytic cell line. 2009 , 48, 9011-21	16
1075	Solid-phase synthesis of homodimeric peptides: preparation of covalently-linked dimers of amyloid beta peptide. 2009 , 6228-30	36
1074	MAPK, beta-amyloid and synaptic dysfunction: the role of RAGE. 2009 , 9, 1635-45	48
1073	Synaptic NMDA receptor activation stimulates alpha-secretase amyloid precursor protein processing and inhibits amyloid-beta production. 2009 , 29, 4442-60	148
1072	Angiotensin II AT2 receptor oligomers mediate G-protein dysfunction in an animal model of Alzheimer disease. 2009 , 284, 6554-65	66
1071	Soluble oligomers of amyloid Beta protein facilitate hippocampal long-term depression by disrupting neuronal glutamate uptake. 2009 , 62, 788-801	698
1070	The E693Delta mutation in amyloid precursor protein increases intracellular accumulation of amyloid beta oligomers and causes endoplasmic reticulum stress-induced apoptosis in cultured cells. 2009 , 174, 957-69	92
1069	Microglia activated with the toll-like receptor 9 ligand CpG attenuate oligomeric amyloid {beta} neurotoxicity in in vitro and in vivo models of Alzheimer's disease. 2009 , 175, 2121-32	110
1068	TDP-43 mutant transgenic mice develop features of ALS and frontotemporal lobar degeneration. 2009 , 106, 18809-14	519

1067	Risk factors for dementia. 2009 , 108, 754-64	144
1066	Protein Misfolding Diseases and the Key Role Played by the Interactions of Polypeptides with Water. 2009 , 241-265	
1065	Aging and Alzheimer's Disease. 2009 , 3049-3083	
1064	Amyloid-beta, tau, and dementia. 2009 , 17, 729-36	43
1063	Stimulation of neurogenesis and synaptogenesis by bilobalide and quercetin via common final pathway in hippocampal neurons. 2009 , 18, 787-98	122
1062	Animal models of dementia. 131-141	
1061	[Immunotherapy of Alzheimer's disease by Abeta vaccination]. 2009 , 134, 59-63	
1060	LRP1 and cerebral amyloid angiopathy. 2009 , 4, 55-65	2
1059	A potential role for alterations of zinc and zinc transport proteins in the progression of Alzheimer's disease. 2009 , 16, 471-83	63
1058	Modulating proteostasis: peptidomimetic inhibitors and activators of protein folding. 2009 , 15, 2488-507	12
1057	Analytical Tools for Detecting Amyloid Beta Oligomerisation and Assembly. 2009 , 5, 229-245	10
1056	Structural polymorphism of amyloid oligomers and fibrils underlies different fibrillization pathways: immunogenicity and cytotoxicity. 2010 , 11, 343-54	29
1055	Amyloid formation in surfactants and alcohols: membrane mimetics or structural switchers?. 2010 , 11, 355-71	63
1054	Metallopeptides [from Drug Discovery to Catalysis. 2010 , 57, 285-299	9
1053	Genetic ablation of luteinizing hormone receptor improves the amyloid pathology in a mouse model of Alzheimer disease. 2010 , 69, 253-61	32
1052	Histidine 14 modulates membrane binding and neurotoxicity of the Alzheimer's disease amyloid-beta peptide. 2010 , 19, 1387-400	27
1051	Neurotrophins enhance CaMKII activity and rescue amyloid- β -induced deficits in hippocampal synaptic plasticity. 2010 , 21, 823-31	80
1050	Amyloid-beta peptide and oligomers in the brain and cerebrospinal fluid of aged canines. 2010 , 20, 637-46	54

1049	[Current status of Alzheimer's disease immunotherapy and pharmacologic effect of BAN2401]. 2010 , 136, 21-5	1
1048	Co-localization of Reelin and proteolytic AbetaPP fragments in hippocampal plaques in aged wild-type mice. 2010 , 19, 1339-57	37
1047	Reduction in post-synaptic scaffolding PSD-95 and SAP-102 protein levels in the Alzheimer inferior temporal cortex is correlated with disease pathology. 2010 , 21, 795-811	66
1046	Approaches to Amyloid Therapies for the Treatment of Alzheimer's Disease. 2010 , 329-404	
1045	Dysfunction and recovery of synapses in prion disease: implications for neurodegeneration. 2010 , 38, 482-7	12
1044	Alzheimer's disease and amyloid beta-peptide deposition in the brain: a matter of 'aging'?. 2010 , 38, 539-44	14
1043	Hemoglobin-derived peptides as novel type of bioactive signaling molecules. 2010 , 12, 658-69	82
1042	Galantamine-induced amyloid- β clearance mediated via stimulation of microglial nicotinic acetylcholine receptors. 2010 , 285, 40180-91	115
1041	Chapter 1:The Amyloid Hypothesis of Alzheimer's Disease and Prospects for Therapeutics. 2010 , 3-18	
1040	Synapse elimination during development and disease: immune molecules take centre stage. 2010 , 38, 476-81	78
1039	Beta-amyloid oligomers and cellular prion protein in Alzheimer's disease. 2010 , 88, 331-8	63
1038	Lipid rafts are primary mediators of amyloid oxidative attack on plasma membrane. 2010 , 88, 597-608	32
1037	Toxic oligomers and islet beta cell death: guilty by association or convicted by circumstantial evidence?. 2010 , 53, 1046-56	143
1036	An enzyme-linked immunosorbent assay to compare the affinity of chemical compounds for β amyloid peptide as a monomer. 2010 , 396, 1745-54	4
1035	Separation and characterization of aggregated species of amyloid-beta peptides. 2010 , 397, 2357-66	9
1034	Intraneuronal beta-amyloid accumulation and synapse pathology in Alzheimer's disease. 2010 , 119, 523-41	267
1033	Neuropathology after active Abeta42 immunotherapy: implications for Alzheimer's disease pathogenesis. 2010 , 120, 369-84	105
1032	Generation of soluble oligomeric beta-amyloid species via copper catalyzed oxidation with implications for Alzheimer's disease: a DFT study. 2010 , 16, 1103-8	5

1031	Novel therapeutic approach for Alzheimer's disease by removing amyloid beta protein from the brain with an extracorporeal removal system. 2010 , 13, 31-7	21
1030	Calcium hypothesis of Alzheimer's disease. 2010 , 459, 441-9	236
1029	Dendritic vulnerability in neurodegenerative disease: insights from analyses of cortical pyramidal neurons in transgenic mouse models. 2010 , 214, 181-99	75
1028	Association of the RAGE G82S polymorphism with Alzheimer's disease. 2010 , 117, 861-7	36
1027	Neuroinflammatory processes in Alzheimer's disease. 2010 , 117, 919-47	321
1026	Generation of reactive oxygen species by beta amyloid fibrils and oligomers involves different intra/extracellular pathways. 2010 , 38, 1101-6	28
1025	A possible role of myristoylated alanine-rich C kinase substrate in endocytic pathway of Alzheimer's disease. 2010 , 26, 338-44	16
1024	Inflammation and Alzheimer's disease. 2010 , 33, 1539-56	306
1023	Outline and computational approaches of protein misfolding. 2010 , 5, 211-218	
1022	Alzheimer's disease amyloid beta-protein and synaptic function. 2010 , 12, 13-26	109
1021	Synaptic depression and aberrant excitatory network activity in Alzheimer's disease: two faces of the same coin?. 2010 , 12, 48-55	108
1020	Adverse stress, hippocampal networks, and Alzheimer's disease. 2010 , 12, 56-70	138
1019	Functional alterations in memory networks in early Alzheimer's disease. 2010 , 12, 27-43	389
1018	Thinking about HIV: the intersection of virus, neuroinflammation and cognitive dysfunction. 2010 , 48, 40-58	33
1017	Nicotinic receptors, amyloid-beta, and synaptic failure in Alzheimer's disease. 2010 , 40, 221-9	45
1016	Why pleiotropic interventions are needed for Alzheimer's disease. 2010 , 41, 392-409	124
1015	SSeCKS promote beta-amyloid-induced PC12 cells neurotoxicity by up-regulating tau phosphorylation in Alzheimer's disease. 2010 , 340, 257-63	5
1014	gamma-secretases: from cell biology to therapeutic strategies. 2010 , 9, 215-26	136

1013	Specific and efficient anti-A β 2 antibodies induced by sixteen tandem repeats of A β . 2010 , 227, 18-25	6
1012	Restricted V gene usage and VH/VL pairing of mouse humoral response against the N-terminal immunodominant epitope of the amyloid β peptide. 2010 , 48, 59-72	18
1011	Methylene blue fails to inhibit Tau and polyglutamine protein dependent toxicity in zebrafish. 2010 , 39, 265-71	67
1010	Linear and conformation specific antibodies in aged beagles after prolonged vaccination with aggregated Abeta. 2010 , 39, 301-10	15
1009	The roles of TNF in brain dysfunction and disease. 2010 , 128, 519-48	153
1008	A cellular perspective on conformational disease: the role of genetic background and proteostasis networks. 2010 , 20, 23-32	89
1007	Alzheimer's disease: insights from Drosophila melanogaster models. 2010 , 35, 228-35	88
1006	Characterization of the beta amyloid precursor protein-like gene in the central nervous system of the crab Chasmagnathus. Expression during memory consolidation. 2010 , 11, 109	2
1005	Sensitive detection of A β protofibrils by proximity ligation--relevance for Alzheimer's disease. 2010 , 11, 124	32
1004	Inhibition of AMPA receptor trafficking at hippocampal synapses by beta-amyloid oligomers: the mitochondrial contribution. 2010 , 3, 10	43
1003	Luteolin promotes long-term potentiation and improves cognitive functions in chronic cerebral hypoperfused rats. 2010 , 627, 99-105	50
1002	Amyloid beta and APP as biomarkers for Alzheimer's disease. 2010 , 45, 23-9	88
1001	Hydrogen-rich saline improves memory function in a rat model of amyloid-beta-induced Alzheimer's disease by reduction of oxidative stress. 2010 , 1328, 152-61	138
1000	Oligomerized Abeta25-35 induces increased tyrosine phosphorylation of NMDA receptor subunit 2A in rat hippocampal CA1 subfield. 2010 , 1343, 186-93	17
999	Aluminum does not enhance beta-amyloid toxicity in rat hippocampal cultures. 2010 , 1352, 265-76	10
998	Different electrophysiological actions of 24- and 72-hour aggregated amyloid-beta oligomers on hippocampal field population spike in both anesthetized and awake rats. 2010 , 1354, 227-35	19
997	Potential therapeutic effects of curcumin: relationship to microtubule-associated proteins 2 in A β -42 insult. 2010 , 1361, 115-23	20
996	Recovery of functional enzyme from amyloid fibrils. 2010 , 584, 1139-42	3

995	In vivo oxidative stress in brain of Alzheimer disease transgenic mice: Requirement for methionine 35 in amyloid beta-peptide of APP. 2010 , 48, 136-44	142
994	Intracellular calcium signalling in Alzheimer's disease. 2010 , 14, 30-41	46
993	Alzheimer Disease: Protein Misfolding, Model Systems, and Experimental Therapeutics. 2010 , 231-258	1
992	Chemistry and Biology of Amyloid Inhibition. 2010 , 903-915	
991	Atherosclerosis, dementia, and Alzheimer disease in the Baltimore Longitudinal Study of Aging cohort. 2010 , 68, 231-40	131
990	Controlling amyloid-beta peptide(1-42) oligomerization and toxicity by fluorinated nanoparticles. 2010 , 11, 1905-13	39
989	Quantifying prefibrillar amyloids in vitro by using a "thioflavin-like" spectroscopic method. 2010 , 11, 1889-95	22
988	Wechselwirkungen zwischen amyloidogenen Proteinen und Membranen: Modellsysteme liefern mechanistische Einblicke. 2010 , 122, 5760-5788	20
987	Amyloidogenic protein-membrane interactions: mechanistic insight from model systems. 2010 , 49, 5628-54	456
986	Binding of amyloid peptides to domain-swapped dimers of other amyloid-forming proteins may prevent their neurotoxicity. 2010 , 32, 1020-4	7
985	Memantine lowers amyloid-beta peptide levels in neuronal cultures and in APP/PS1 transgenic mice. 2010 , 88, 143-54	92
984	Dynamin 1 depletion and memory deficits in rats treated with Abeta and cerebral ischemia. 2010 , 88, 1908-17	17
983	Amyloid-beta oligomers impair fear conditioned memory in a calcineurin-dependent fashion in mice. 2010 , 88, 2923-32	75
982	Randomization of amyloid- β peptide(1-42) conformation by sulfonated and sulfated nanoparticles reduces aggregation and cytotoxicity. 2010 , 10, 1152-63	29
981	High-yield expression and purification of the transmembrane region of ion channel-forming amyloid- β protein for NMR structural studies. 2010 , 45, 682-688	4
980	A facile enantioselective synthesis of (S)-N-(5-chlorothiophene-2-sulfonyl)-L-diethylalaninol via proline-catalyzed asymmetric α -aminoxylation and α -amination of aldehyde. 2010 , 51, 6565-6567	21
979	Concanavalin A aggregation and toxicity on cell cultures. 2010 , 1804, 173-83	29
978	Improving the permeability of the hydroxyethylamine BACE-1 inhibitors: structure-activity relationship of P2' substituents. 2010 , 20, 4789-94	22

977	Design of an orally efficacious hydroxyethylamine (HEA) BACE-1 inhibitor in a preclinical animal model. 2010 , 20, 6231-6	39
976	Influence of the hydrophobic interface and transition metal ions on the conformation of amyloidogenic model peptides. 2010 , 150, 64-72	22
975	Phospholipase A2 inhibitors protect against prion and Abeta mediated synapse degeneration. 2010 , 5, 13	33
974	Endocytic pathways mediating oligomeric Abeta42 neurotoxicity. 2010 , 5, 19	36
973	Age-dependent changes in TDP-43 levels in a mouse model of Alzheimer disease are linked to A β oligomers accumulation. 2010 , 5, 51	25
972	Synuclein induced synapse damage is enhanced by amyloid- β -42. 2010 , 5, 55	35
971	Folding and membrane insertion of amyloid-beta (25-35) peptide and its mutants: implications for aggregation and neurotoxicity. 2010 , 78, 1909-25	22
970	Extending the PRIME model for protein aggregation to all 20 amino acids. 2010 , 78, 2950-60	98
969	Models of membrane-bound Alzheimer's Abeta peptide assemblies. 2010 , 78, 3473-87	52
968	[Gly(14)]-humanin rescues long-term potentiation from amyloid beta protein-induced impairment in the rat hippocampal CA1 region in vivo. 2010 , 64, 83-91	19
967	Inhibition of calpain prevents NMDA-induced cell death and beta-amyloid-induced synaptic dysfunction in hippocampal slice cultures. 2010 , 159, 1523-31	28
966	Inhibition of Abeta aggregation and neurotoxicity by the 39-kDa receptor-associated protein. 2010 , 112, 1199-209	7
965	Manganese chelation therapy extends survival in a mouse model of M1000 prion disease. 2010 , 114, 440-51	34
964	N-methyl-D-aspartate receptors are required for synaptic targeting of Alzheimer's toxic amyloid- β peptide oligomers. 2010 , 115, 1520-9	123
963	Amyloid oligomers: formation and toxicity of Abeta oligomers. 2010 , 277, 1348-58	423
962	Progressive accumulation of amyloid-beta oligomers in Alzheimer's disease and in amyloid precursor protein transgenic mice is accompanied by selective alterations in synaptic scaffold proteins. 2010 , 277, 3051-67	162
961	Mysterious oligomerization of the amyloidogenic proteins. 2010 , 277, 2940-53	151
960	Biochemical and biophysical features of both oligomer/fibril and cell membrane in amyloid cytotoxicity. 2010 , 277, 4602-13	144

959	Traumatic brain injury and amyloid- β pathology: a link to Alzheimer's disease?. 2010 , 11, 361-70	365
958	Structural conversion of neurotoxic amyloid-beta(1-42) oligomers to fibrils. 2010 , 17, 561-7	826
957	Neurotoxicity of Alzheimer's disease A β peptides is induced by small changes in the A β 2 to A β 0 ratio. 2010 , 29, 3408-20	376
956	Activation of Wnt signaling by lithium and rosiglitazone reduced spatial memory impairment and neurodegeneration in brains of an APP ^{swe} /PSEN1 ^{DeltaE9} mouse model of Alzheimer's disease. 2010 , 15, 272-85, 228	193
955	The prion protein as a receptor for amyloid-beta. <i>Nature</i> , 2010 , 466, E3-4; discussion E4-5	50.4 218
954	Laur β et al. reply. <i>Nature</i> , 2010 , 466, E4-E5	50.4 13
953	Differences in prion strain conformations result from non-native interactions in a nucleus. 2010 , 6, 225-230	63
952	Initiation and propagation of neurodegeneration. 2010 , 16, 1201-4	38
951	Amyloid beta from axons and dendrites reduces local spine number and plasticity. 2010 , 13, 190-6	241
950	Amyloid-beta-induced neuronal dysfunction in Alzheimer's disease: from synapses toward neural networks. 2010 , 13, 812-8	1106
949	Preparation and characterization of toxic A β aggregates for structural and functional studies in Alzheimer's disease research. 2010 , 5, 1186-209	198
948	Small molecule beta-amyloid inhibitors that stabilize protofibrillar structures in vitro improve cognition and pathology in a mouse model of Alzheimer's disease. 2010 , 31, 203-13	47
947	The turn formation at positions 22 and 23 in the 42-mer amyloid beta peptide: the emerging role in the pathogenesis of Alzheimer's disease. 2010 , 10 Suppl 1, S169-79	17
946	Self-organization of intrinsically disordered proteins with folded N-termini. 2010 ,	
945	Intracellular accumulation of amyloid-Beta - a predictor for synaptic dysfunction and neuron loss in Alzheimer's disease. 2010 , 2, 8	126
944	Role of grape seed polyphenols in Alzheimer's disease neuropathology. 2010 , 2010, 97-103	26
943	CSF Biomarkers for Alzheimer's Disease Diagnosis. 2010 , 2010,	61
942	Amyloid 1-42 oligomers impair function of human embryonic stem cell-derived forebrain cholinergic neurons. 2010 , 5, e15600	35

941	The concentration of soluble extracellular amyloid- β protein in acute brain slices from CRND8 mice. 2010 , 5, e15709	30
940	Cognitive deficits associated with alteration of synaptic metaplasticity precede plaque deposition in APP23 transgenic mice. 2010 , 21, 1367-81	34
939	Effective screen for amyloid β aggregation inhibitor using amyloid β -conjugated gold nanoparticles. 2010 , 6, 1-12	4
938	Centro de Biología Molecular "Severo Ochoa": a center for basic research into Alzheimer's disease. 2010 , 21, 325-35	
937	Anesthetics promoting in vitro APP metabolism and amyloid- β toxicity. 2010 , 22 Suppl 3, 21-6	2
936	Ubiquitin-Dependent Protein Degradation. 2010 , 699-752	
935	A novel transgenic rat model with a full Alzheimer's-like amyloid pathology displays pre-plaque intracellular amyloid-beta-associated cognitive impairment. 2010 , 20, 113-26	142
934	Polyglutamine diseases: where does toxicity come from? what is toxicity? where are we going?. 2010 , 2, 180-91	111
933	The monomer state of beta-amyloid: where the Alzheimer's disease protein meets physiology. 2010 , 21, 83-93	60
932	beta-Secretase inhibitor potency is decreased by aberrant beta-cleavage location of the "Swedish mutant" amyloid precursor protein. 2010 , 285, 1634-42	32
931	Ciliary neurotrophic factor cell-based delivery prevents synaptic impairment and improves memory in mouse models of Alzheimer's disease. 2010 , 30, 7516-27	100
930	Genetic reduction of striatal-enriched tyrosine phosphatase (STEP) reverses cognitive and cellular deficits in an Alzheimer's disease mouse model. 2010 , 107, 19014-9	138
929	N-terminal domain of myelin basic protein inhibits amyloid beta-protein fibril assembly. 2010 , 285, 35590-8	20
928	Substoichiometric levels of Cu ²⁺ ions accelerate the kinetics of fiber formation and promote cell toxicity of amyloid- β from Alzheimer disease. 2010 , 285, 41533-40	143
927	High-molecular-weight beta-amyloid oligomers are elevated in cerebrospinal fluid of Alzheimer patients. 2010 , 24, 2716-26	196
926	Complex environment experience rescues impaired neurogenesis, enhances synaptic plasticity, and attenuates neuropathology in familial Alzheimer's disease-linked APP ^{swe} /PS1 ^{DeltaE9} mice. 2010 , 24, 1667-81	136
925	The S100B/RAGE Axis in Alzheimer's Disease. 2010 , 2010, 539581	48
924	PI3 kinase signaling is involved in A β -induced memory loss in Drosophila. 2010 , 107, 7060-5	88

923	Generation and therapeutic efficacy of highly oligomer-specific beta-amyloid antibodies. 2010 , 30, 10369-79	88
922	Amyloid peptide pores and the beta sheet conformation. 2010 , 677, 150-67	50
921	Inhibition of calcineurin-mediated endocytosis and alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptors prevents amyloid beta oligomer-induced synaptic disruption. 2010 , 285, 7619-32	131
920	Oral treatment with a gamma-secretase inhibitor improves long-term potentiation in a mouse model of Alzheimer's disease. 2010 , 333, 110-9	39
919	Identification of low molecular weight pyroglutamate A{beta} oligomers in Alzheimer disease: a novel tool for therapy and diagnosis. 2010 , 285, 41517-24	75
918	Alzheimer's disease and the amyloid-beta peptide. 2010 , 19, 311-23	806
917	Inhibition of aggregate formation as therapeutic target in protein misfolding diseases: effect of tetracycline and trehalose. 2010 , 14, 1311-21	22
916	Fibrillar oligomers nucleate the oligomerization of monomeric amyloid beta but do not seed fibril formation. 2010 , 285, 6071-9	127
915	Expression of beta-amyloid induced age-dependent presynaptic and axonal changes in Drosophila. 2010 , 30, 1512-22	100
914	A mouse model of amyloid beta oligomers: their contribution to synaptic alteration, abnormal tau phosphorylation, glial activation, and neuronal loss in vivo. 2010 , 30, 4845-56	301
913	L-3-n-butylphthalide improves cognitive impairment and reduces amyloid-beta in a transgenic model of Alzheimer's disease. 2010 , 30, 8180-9	103
912	Binding of amyloid beta peptide to beta2 adrenergic receptor induces PKA-dependent AMPA receptor hyperactivity. 2010 , 24, 3511-21	61
911	Microglial receptor for advanced glycation end product-dependent signal pathway drives beta-amyloid-induced synaptic depression and long-term depression impairment in entorhinal cortex. 2010 , 30, 11414-25	78
910	Amyloid- β as a modulator of synaptic plasticity. 2010 , 22, 741-63	170
909	Loss of alpha7 nicotinic receptors enhances beta-amyloid oligomer accumulation, exacerbating early-stage cognitive decline and septohippocampal pathology in a mouse model of Alzheimer's disease. 2010 , 30, 2442-53	149
908	Amyloid-beta peptide oligomers disrupt axonal transport through an NMDA receptor-dependent mechanism that is mediated by glycogen synthase kinase 3beta in primary cultured hippocampal neurons. 2010 , 30, 9166-71	173
907	Phospholipase d2 ablation ameliorates Alzheimer's disease-linked synaptic dysfunction and cognitive deficits. 2010 , 30, 16419-28	140
906	Membrane localization of beta-amyloid 1-42 in lysosomes: a possible mechanism for lysosome labilization. 2010 , 285, 19986-96	44

905	Interaction between human prion protein and amyloid-beta (Abeta) oligomers: role OF N-terminal residues. 2010 , 285, 26377-83	211
904	Gelsolin as therapeutic target in Alzheimer's disease. 2010 , 14, 585-92	21
903	Selective translational control of the Alzheimer amyloid precursor protein transcript by iron regulatory protein-1. 2010 , 285, 31217-32	122
902	Amyloidogenic light chains induce cardiomyocyte contractile dysfunction and apoptosis via a non-canonical p38alpha MAPK pathway. 2010 , 107, 4188-93	214
901	Relationship between proteolytically cleaved gelsolin and levels of amyloid- β protein in the brains of Down syndrome subjects. 2010 , 22, 609-17	8
900	The hyperforin derivative IDN5706 occludes spatial memory impairments and neuropathological changes in a double transgenic Alzheimer's mouse model. 2010 , 7, 126-33	30
899	Protein conformational pathology in Alzheimer's and other neurodegenerative diseases; new targets for therapy. 2010 , 7, 74-83	21
898	ADF/Cofilin-actin rods in neurodegenerative diseases. 2010 , 7, 241-50	113
897	Targeted hydrolysis of Beta-amyloid with engineered antibody fragment. 2010 , 7, 214-22	10
896	Effects of the English (H6R) and Tottori (D7N) familial Alzheimer disease mutations on amyloid beta-protein assembly and toxicity. 2010 , 285, 23186-97	116
895	Amyloid β oligomers decrease hippocampal spontaneous network activity in an age-dependent manner. 2010 , 7, 453-62	19
894	Neurogenesis and Alzheimer's disease: Biology and pathophysiology in mice and men. 2010 , 7, 113-25	72
893	NEP-like endopeptidases and Alzheimer's disease [corrected]. 2010 , 7, 223-9	20
892	Proteases and proteolysis in Alzheimer disease: a multifactorial view on the disease process. 2010 , 90, 465-94	325
891	The role of STEP in Alzheimer's disease. 2010 , 4, 347-50	19
890	Are Abeta and its derivatives causative agents or innocent bystanders in AD?. 2010 , 7, 32-7	30
889	From alpha to omega with Abeta: targeting the multiple molecular appearances of the pathogenic peptide in Alzheimer's disease. 2010 , 17, 198-212	22
888	Amyloid PET Ligands for Dementia. 2010 , 5, 33-53	20

887 Force Fields. **2010**, 265-298

886 Abeta-mediated NMDA receptor endocytosis in Alzheimer's disease involves ubiquitination of the tyrosine phosphatase STEP61. **2010**, 30, 5948-57 154

885 Structural diversity of dimers of the Alzheimer amyloid-beta(25-35) peptide and polymorphism of the resulting fibrils. **2010**, 12, 3622-9 77

884 Preparation of oligomeric beta-amyloid 1-42 and induction of synaptic plasticity impairment on hippocampal slices. **2010**, 33

883 Inhibitors of class 1 histone deacetylases reverse contextual memory deficits in a mouse model of Alzheimer's disease. **2010**, 35, 870-80 53¹

882 Widespread protein aggregation as an inherent part of aging in *C. elegans*. **2010**, 8, e1000450 43¹

881 Small molecule microarrays enable the discovery of compounds that bind the Alzheimer's A β peptide and reduce its cytotoxicity. **2010**, 132, 17015-22 69

880 Retardation of Abeta fibril formation by phospholipid vesicles depends on membrane phase behavior. **2010**, 98, 2206-14 54

879 A yeast toxic mutant of HET-s((218-289)) prion displays alternative intermediates of amyloidogenesis. **2010**, 99, 1239-46 11

878 Measurement of the attachment and assembly of small amyloid- β oligomers on live cell membranes at physiological concentrations using single-molecule tools. **2010**, 99, 1969-75 60

877 Linking type 2 diabetes and Alzheimer's disease. **2010**, 107, 6557-8 68

876 Effects of Congo red on a β (1-40) fibril formation process and morphology. **2010**, 1, 315-24 42

875 Electric Field Effects on Short Fibrils of A β Amyloid Peptides. **2010**, 6, 3516-26 29

874 Calcium signaling and amyloid toxicity in Alzheimer disease. **2010**, 285, 12463-8 283

873 Human intravenous immunoglobulin provides protection against A β toxicity by multiple mechanisms in a mouse model of Alzheimer's disease. **2010**, 7, 90 76

872 A study of long-term potentiation in transgenic mice over-expressing mutant forms of both amyloid precursor protein and presenilin-1. **2010**, 3, 21 10

871 Prion-like disorders: blurring the divide between transmissibility and infectivity. **2010**, 123, 1191-201 23¹

870 Amyloid- β (1-40) inhibits amyloid- β (1-42) induced activation of cytoplasmic phospholipase A2 and synapse degeneration. **2010**, 21, 985-93 16

869	SORLA/SORL1, a neuronal sorting receptor implicated in Alzheimer's disease. 2010 , 21, 315-29	18
868	The mitochondrial secret(ase) of Alzheimer's disease. 2010 , 20 Suppl 2, S381-400	26
867	Monoclonal antibody against the turn of the 42-residue amyloid β protein at positions 22 and 23. 2010 , 1, 747-56	41
866	Temperature dependence of conjugation of amyloid beta protein on the surfaces of gold colloidal nanoparticles. 2010 , 114, 1521-8	8
865	Development of a proteolytically stable retro-inverso peptide inhibitor of beta-amyloid oligomerization as a potential novel treatment for Alzheimer's disease. 2010 , 49, 3261-72	120
864	Detection of elevated levels of β synuclein oligomers in CSF from patients with Parkinson disease. 2010 , 75, 1766-72	369
863	CNS expression of anti-inflammatory cytokine interleukin-4 attenuates Alzheimer's disease-like pathogenesis in APP+PS1 bigenic mice. 2010 , 24, 3093-102	154
862	EGCG remodels mature alpha-synuclein and amyloid-beta fibrils and reduces cellular toxicity. 2010 , 107, 7710-5	726
861	Silymarin attenuated the amyloid β plaque burden and improved behavioral abnormalities in an Alzheimer's disease mouse model. 2010 , 74, 2299-306	57
860	Structural convergence among diverse, toxic beta-sheet ion channels. 2010 , 114, 9445-51	60
859	HRMAS 1H NMR conformational study of the resin-bound amyloid-forming peptide GNNQQNY from the yeast prion Sup35. 2010 , 114, 3457-65	2
858	The Cu(II)/A β /human serum albumin model of control mechanism for copper-related amyloid neurotoxicity. 2010 , 23, 298-308	40
857	Memory impairment in transgenic Alzheimer mice requires cellular prion protein. 2010 , 30, 6367-74	328
856	Protective role of methylene blue in Alzheimer's disease via mitochondria and cytochrome c oxidase. 2010 , 20 Suppl 2, S439-52	91
855	Methionine-oxidized amyloid fibrils are poor substrates for human methionine sulfoxide reductases A and B2. 2010 , 49, 2981-3	13
854	Structural properties and dynamic behavior of nonfibrillar oligomers formed by PrP(106-126). 2010 , 132, 7684-95	42
853	Truncated beta-amyloid peptide channels provide an alternative mechanism for Alzheimer's Disease and Down syndrome. 2010 , 107, 6538-43	176
852	Time-course correlation of early toxic events in three models of striatal damage: modulation by proteases inhibition. 2010 , 56, 834-42	26

851	Tocopherol quinone inhibits β amyloid aggregation and cytotoxicity, disaggregates preformed fibrils and decreases the production of reactive oxygen species, NO and inflammatory cytokines. 2010 , 57, 914-22	58
850	No evidence for prion protein gene locus multiplication in Creutzfeldt-Jakob disease. 2010 , 472, 16-8	4
849	HIV-1 protein-mediated amyloidogenesis in rat hippocampal cell cultures. 2010 , 475, 174-8	45
848	Lead-induced accumulation of beta-amyloid in the choroid plexus: role of low density lipoprotein receptor protein-1 and protein kinase C. 2010 , 31, 524-32	33
847	Role of small oligomers on the amyloidogenic aggregation free-energy landscape. 2010 , 395, 134-54	25
846	Conversion of Abeta42 into a folded soluble native-like protein using a semi-random library of amphipathic helices. 2010 , 396, 1284-94	10
845	DHPC strongly affects the structure and oligomerization propensity of Alzheimer's A β (1-40) peptide. 2010 , 403, 643-59	24
844	Mechanism of fiber assembly: treatment of A β peptide aggregation with a coarse-grained united-residue force field. 2010 , 404, 537-52	74
843	β Barrel topology of Alzheimer's β amyloid ion channels. 2010 , 404, 917-34	101
842	sAPP α antagonizes dendritic degeneration and neuron death triggered by proteasomal stress. 2010 , 44, 386-93	56
841	In-vivo visualization of key molecular processes involved in Alzheimer's disease pathogenesis: Insights from neuroimaging research in humans and rodent models. 2010 , 1802, 373-88	16
840	Increased expression of the lysosomal cholesterol transporter NPC1 in Alzheimer's disease. 2010 , 1801, 831-8	28
839	Modulation of amyloid precursor protein processing by synthetic ceramide analogues. 2010 , 1801, 887-95	11
838	DGP-LA neutralizes mutant amyloid beta peptide-induced impairment of long-term potentiation and spatial learning. 2010 , 206, 151-4	9
837	RS-0406 arrests amyloid-beta oligomer-induced behavioural deterioration in vivo. 2010 , 210, 32-7	15
836	Effect size of reference memory deficits in the Morris water maze in Tg2576 mice. 2010 , 212, 115-20	28
835	Triazole-containing BODIPY dyes as novel fluorescent probes for soluble oligomers of amyloid Abeta1-42 peptide. 2010 , 391, 1455-8	41
834	Communication breaks-Down: from neurodevelopment defects to cognitive disabilities in Down syndrome. 2010 , 91, 1-22	86

833	Anti-ADDL antibodies differentially block oligomer binding to hippocampal neurons. 2010 , 31, 189-202	35
832	Heat shock treatment reduces beta amyloid toxicity in vivo by diminishing oligomers. 2010 , 31, 1055-8	39
831	Episodic memory deficits are not related to altered glutamatergic synaptic transmission and plasticity in the CA1 hippocampus of the APPswe/PS1E9-deleted transgenic mice model of Amyloidosis. 2010 , 31, 1173-87	113
830	Amyloid-related peptides potentiate K+-evoked glutamate release from adult rat hippocampal slices. 2010 , 31, 1164-72	42
829	Deleterious effects of amyloid beta oligomers acting as an extracellular scaffold for mGluR5. 2010 , 66, 739-54	347
828	Probing the biology of Alzheimer's disease in mice. 2010 , 66, 631-45	334
827	The Drosophila miR-310 cluster negatively regulates synaptic strength at the neuromuscular junction. 2010 , 68, 879-93	64
826	The functional neurophysiology of the amyloid precursor protein (APP) processing pathway. 2010 , 59, 243-67	50
825	ADDLs and the signaling web that leads to Alzheimer's disease. 2010 , 59, 230-42	90
824	Parahypteryside attenuates cognition deficits in d-galactose treated mice by increasing antioxidant capacity and improving long-term potentiation. 2010 , 94, 414-21	4
823	Size-dependent neurotoxicity of beta-amyloid oligomers. 2010 , 496, 84-92	133
822	Blood-borne amyloid-beta dimer correlates with clinical markers of Alzheimer's disease. 2010 , 30, 6315-22	65
821	Does the term 'trophic' actually mean anti-amyloidogenic? The case of NGF. 2010 , 17, 1126-33	24
820	Oligomers of beta-amyloid are sequestered into and seed new plaques in the brains of an AD mouse model. 2010 , 223, 394-400	29
819	The effects of parkin suppression on the behaviour, amyloid processing, and cell survival in APP mutant transgenic mice. 2010 , 221, 54-67	13
818	Soluble oligomeric forms of beta-amyloid (Abeta) peptide stimulate Abeta production via astrogliosis in the rat brain. 2010 , 223, 410-21	31
817	Memantine improves cognition and reduces Alzheimer's-like neuropathology in transgenic mice. 2010 , 176, 870-80	160
816	Evidence for proteotoxicity in beta cells in type 2 diabetes: toxic islet amyloid polypeptide oligomers form intracellularly in the secretory pathway. 2010 , 176, 861-9	172

815	Oligemic hypoperfusion differentially affects tau and amyloid- β . 2010 , 177, 300-10	94
814	Neuronal and axonal loss are selectively linked to fibrillar amyloid- β within plaques of the aged primate cerebral cortex. 2010 , 177, 325-33	32
813	Amyloid- β and mitochondria in aging and Alzheimer's disease: implications for synaptic damage and cognitive decline. 2010 , 20 Suppl 2, S499-512	175
812	Transmembrane structures for Alzheimer's A β (1-42) oligomers. 2010 , 132, 13300-12	116
811	Molecular interplay between mammalian target of rapamycin (mTOR), amyloid- β , and Tau: effects on cognitive impairments. 2010 , 285, 13107-20	625
810	Progressive age-related impairment of the late long-term potentiation in Alzheimer's disease presenilin-1 mutant knock-in mice. 2010 , 19, 1021-33	40
809	LPYFDa neutralizes amyloid- β -induced memory impairment and toxicity. 2010 , 19, 991-1005	25
808	[The role of cyclooxygenases in neurotoxicity of amyloid β peptides in Alzheimer's disease]. 2010 , 44, 65-79	4
807	The culprit behind amyloid β peptide related neurotoxicity in Alzheimer's disease: oligomer size or conformation?. 2010 , 2, 12	106
806	Transport of Alzheimer disease amyloid- β -binding D-amino acid peptides across an in vitro blood-brain barrier model. 2010 , 13, 210-3	25
805	Detecting a β 56 oligomers in brain tissues. 2011 , 670, 45-56	31
804	A noncompetitive BACE1 inhibitor TAK-070 ameliorates A β pathology and behavioral deficits in a mouse model of Alzheimer's disease. 2010 , 30, 11157-66	110
803	Soluble amyloid β -protein dimers isolated from Alzheimer cortex directly induce Tau hyperphosphorylation and neuritic degeneration. 2011 , 108, 5819-24	641
802	Amyloidogenesis highlighted by designed peptides forming supramolecular self-assemblies. 2011 , 2, 1293	9
801	Dissociation between the processivity and total activity of β -secretase: implications for the mechanism of Alzheimer's disease-causing presenilin mutations. 2011 , 50, 9023-35	87
800	Seed-dependent deposition behavior of A β peptides studied with wireless quartz-crystal-microbalance biosensor. 2011 , 83, 4982-8	19
799	Curcuminoid binds to amyloid- β 42 oligomer and fibril. 2011 , 24 Suppl 2, 33-42	72
798	Neuropathological alterations in Alzheimer disease. 2011 , 1, a006189	1682

797	Amyloid β peptides aggregation in a mixed membrane bilayer: a molecular dynamics study. 2011 , 115, 12247-56	61
796	Molecular engineering of a secreted, highly homogeneous, and neurotoxic $\alpha\beta$ dimer. 2011 , 2, 242-8	24
795	Molecular Imaging. 2011 ,	2
794	A study of the helical intermediate preceding the aggregation of the amino-terminal fragment of the amyloid peptide (A β 1-28)). 2011 , 115, 12978-83	46
793	Distinct effects of Zn ²⁺ , Cu ²⁺ , Fe ³⁺ , and Al ³⁺ on amyloid-beta stability, oligomerization, and aggregation: amyloid-beta destabilization promotes annular protofibril formation. 2011 , 286, 9646-56	144
792	La mayoría de edad de la potenciación de larga duración: plasticidad sináptica y diagnóstico temprano del Alzheimer. 2011 , 3, 117-119	
791	Fluctuation methods to study protein aggregation in live cells: concanavalin A oligomers formation. 2011 , 100, 774-783	39
790	Insulin Inhibits A β 2 Aggregation and Prevents A β 2-Induced Membrane Disruption. 2019 , 58, 4519-4529	8
789	A β Seeding as a Tool to Study Cerebral Amyloidosis and Associated Pathology. 2019 , 12, 233	16
788	Trends of Protein Aggregation in Neurodegenerative Diseases. 2019 ,	6
787	Age-Dependent Modification of Intracellular Zn Buffering in the Hippocampus and Its Impact. 2019 , 42, 1070-1075	5
786	History and progress of hypotheses and clinical trials for Alzheimer's disease. 2019 , 4, 29	182
785	Brain Iron Metabolism and CNS Diseases. 2019 ,	9
784	Template-Mediated Detoxification of Low-Molecular-Weight Amyloid Oligomers and Regulation of Their Nucleation Pathway.. 2019 , 2, 5306-5312	4
783	Aggregation dynamics of charged peptides in water: Effect of salt concentration. 2019 , 151, 074901	1
782	Case report: a giant arachnoid cyst masking Alzheimer's disease. 2019 , 19, 274	4
781	Intraneuronal Tau Misfolding Induced by Extracellular Amyloid- β Oligomers. 2019 , 71, 1125-1138	8
780	Amyloid- β and Synaptic Vesicle Dynamics: A Cacophonous Orchestra. 2019 , 72, 1-14	15

- 779 Molecular Modulation of Human α 7 Nicotinic Receptor by Amyloid- β Peptides. **2019**, 13, 37 18
- 778 Simultaneous Monitoring of Amyloid- β Oligomers and Fibrils for Effectively Evaluating the Dynamic Process of A β Aggregation. **2019**, 4, 471-478 15
- 777 Effective connectivity in the default mode network is distinctively disrupted in Alzheimer's disease-A simultaneous resting-state FDG-PET/fMRI study. **2021**, 42, 4134-4143 23
- 776 Difference in ability for extracellular Zn influx between human and rat amyloid β and its significance. **2019**, 72, 1-5 5
- 775 Influence of fulleranol on hIAPP aggregation: amyloid inhibition and mechanistic aspects. **2019**, 21, 4022-4031 19
- 774 Amyloid- β Peptide Targeting Peptidomimetics for Prevention of Neurotoxicity. **2019**, 10, 1462-1477 5
- 773 Synthesis and biochemical characterization of quasi-stable trimer models of full-length amyloid β 0 with a toxic conformation. **2018**, 55, 182-185 13
- 772 Infection-induced endothelial amyloids impair memory. **2019**, 33, 10300-10314 8
- 771 Do We Need Anti-Prion Compounds to Treat Alzheimer's Disease?. **2019**, 24, 11
- 770 Amyloid Beta-Related Alterations to Glutamate Signaling Dynamics During Alzheimer's Disease Progression. **2019**, 11, 1759091419855541 43
- 769 Assessing Neuroprotective Agents for A β -Induced Neurotoxicity. **2019**, 25, 685-695 10
- 768 Oral Immunization with Soybean Storage Protein Containing Amyloid- β -10 Prevents Spatial Learning Decline. **2019**, 70, 487-503 2
- 767 Intertwined Pathologies of Amyloid- β and Metal Ions in Alzheimer's Disease: Metal-Amyloid- β **2019**, 48, 951-960 12
- 766 Influx of Tau and Amyloid- β Proteins into the Blood During Hemodialysis as a Therapeutic Extracorporeal Blood Amyloid- β Removal System for Alzheimer's Disease. **2019**, 69, 687-707 7
- 765 Vanadyl acetylacetonate attenuates A β pathogenesis in APP/PS1 transgenic mice depending on the intervention stage. **2019**, 43, 17588-17594 3
- 764 Extracellular Zn-independently attenuated LTP by human amyloid β and rat amyloid β **2019**, 514, 888-892 7
- 763 Force clamp approach for characterization of nano-assembly in amyloid beta 42 dimer. **2019**, 11, 12259-12265 8
- 762 Proteomic signatures of brain regions affected by tau pathology in early and late stages of Alzheimer's disease. **2019**, 130, 104509 25

761	Molecular dynamics simulations reveal the mechanism of graphene oxide nanosheet inhibition of A β peptide aggregation. 2019 , 21, 10981-10991	26
760	Endophilin 1 knockdown prevents synaptic dysfunction induced by oligomeric amyloid β 2019 , 19, 4897-4905	3
759	Hsp60 Protects against Amyloid β Oligomer Synaptic Toxicity via Modification of Toxic Oligomer Conformation. 2019 , 10, 2858-2867	9
758	Fat and Lipid Metabolism and the Involvement of Apolipoprotein E in Alzheimer's Disease. 2019 , 189-231	1
757	A quantitative model of human neurodegenerative diseases involving protein aggregation. 2019 , 80, 46-55	13
756	A clinical dose of angiotensin-converting enzyme (ACE) inhibitor and heterozygous ACE deletion exacerbate Alzheimer's disease pathology in mice. 2019 , 294, 9760-9770	16
755	High molecular weight amyloid β oligomers induce neurotoxicity plasma membrane damage. 2019 , 33, 9220-9234	36
754	Label-free distribution of anti-amyloid D-AIP in Drosophila melanogaster: prevention of A β 2-induced toxicity without side effects in transgenic flies. 2019 , 150, 74-87	5
753	Simultaneous Live Imaging of Multiple Endogenous Proteins Reveals a Mechanism for Alzheimer's-Related Plasticity Impairment. 2019 , 27, 658-665.e4	20
752	Neurochemical Aspects of Poststroke Dementia. 2019 , 39-72	
751	Use of a Stereochemical Strategy To Probe the Mechanism of Phenol-Soluble Modulin β Toxicity. 2019 , 141, 7660-7664	23
750	S100 Proteins in Alzheimer's Disease. 2019 , 13, 463	46
749	Amyloid- β Oligomers Regulate ADAM10 Synaptic Localization Through Aberrant Plasticity Phenomena. 2019 , 56, 7136-7143	3
748	What Is the "Relevant" Amyloid β 2 Concentration?. 2019 , 20, 1725-1726	10
747	Emergence of synaptic and cognitive impairment in a mature-onset APP mouse model of Alzheimer's disease. 2019 , 7, 25	12
746	Nanoscale structure of amyloid- β plaques in Alzheimer's disease. 2019 , 9, 5181	28
745	The anti-prion RNA aptamer R12 disrupts the Alzheimer's disease-related complex between prion and amyloid β 2019 , 286, 2355-2365	4
744	Extracellular Vesicles from Mesenchymal Stem Cells Exert Pleiotropic Effects on Amyloid- β Inflammation, and Regeneration: A Spark of Hope for Alzheimer's Disease from Tiny Structures?. 2019 , 41, e1800199	18

743	A method of predicting the in vitro fibril formation propensity of A β 0 mutants based on their inclusion body levels in E. coli. 2019 , 9, 3680	4
742	Role of GIRK Channels in Long-Term Potentiation of Synaptic Inhibition in an In Vivo Mouse Model of Early Amyloid- Pathology. 2019 , 20,	14
741	Jujuboside A prevents sleep loss-induced disturbance of hippocampal neuronal excitability and memory impairment in young APP/PS1 mice. 2019 , 9, 4512	11
740	Mechanism of amyloid protein aggregation and the role of inhibitors. 2019 , 91, 211-229	38
739	Amyloid- β oligomers have a profound detergent-like effect on lipid membrane bilayers, imaged by atomic force and electron microscopy. 2019 , 294, 7566-7572	59
738	The anaesthetic xenon partially restores an amyloid beta-induced impairment in murine hippocampal synaptic plasticity. 2019 , 151, 21-32	4
737	Calcitonin native prefibrillar oligomers but not monomers induce membrane damage that triggers NMDA-mediated Ca-influx, LTP impairment and neurotoxicity. 2019 , 9, 5144	8
736	Nanoparticle Assisted Regulation of Nucleation Pathway of Amyloid Tetramer and Inhibition of Their Fibrillation Kinetics.. 2019 , 2, 2137-2142	9
735	Metabolic resistance of the D-peptide RD2 developed for direct elimination of amyloid- β oligomers. 2019 , 9, 5715	15
734	Treatment with the glutamate modulator riluzole prevents early life stress-induced cognitive deficits and impairments in synaptic plasticity in APP ^{swe} /PS1 ^{dE9} mice. 2019 , 150, 175-183	16
733	Systematic and standardized comparison of reported amyloid- β receptors for sufficiency, affinity, and Alzheimer's disease relevance. 2019 , 294, 6042-6053	28
732	Cerebrospinal fluid biomarkers for understanding multiple aspects of Alzheimer's disease pathogenesis. 2019 , 76, 1833-1863	46
731	Unravelling protein aggregation as an ageing related process or a neuropathological response. 2019 , 51, 67-77	9
730	Effects of Reducing Norepinephrine Levels via DSP4 Treatment on Amyloid- β Pathology in Female Rhesus Macaques (Macaca Mulatta). 2019 , 68, 115-126	6
729	The Role of NMDA Receptors in Alzheimer's Disease. 2019 , 13, 43	126
728	Glial Contribution to Excitatory and Inhibitory Synapse Loss in Neurodegeneration. 2019 , 13, 63	44
727	The amyloid cascade and Alzheimer's disease therapeutics: theory versus observation. 2019 , 99, 958-970	50
726	Pharmacological Interventions to Attenuate Alzheimer's Disease Progression: The Story So Far. 2019 , 16, 261-277	19

725	Synaptic Elimination in Neurological Disorders. 2019 , 17, 1071-1095	25
724	In search of pathogenic amyloid β peptide in familial Alzheimer's disease. 2019 , 168, 71-78	4
723	Molecular mechanisms of 33-mer gliadin peptide oligomerisation. 2019 , 21, 22539-22552	8
722	Resistance to autosomal dominant Alzheimer's disease in an APOE3 Christchurch homozygote: a case report. 2019 , 25, 1680-1683	171
721	MKP-1 reduces A β generation and alleviates cognitive impairments in Alzheimer's disease models. 2019 , 4, 58	31
720	[D-enantiomeric peptides could be a new therapeutic approach in Alzheimer's disease]. 2019 , 35, 897-900	
719	Emerging roles of N- and C-terminally truncated A β species in Alzheimer's disease. 2019 , 23, 991-1004	24
718	Redox proteomics and amyloid β peptide: insights into Alzheimer disease. 2019 , 151, 459-487	44
717	Amyloid β Peptide Interaction with Membranes: Can Chaperones Change the Fate?. 2019 , 123, 631-638	8
716	Prenylated Curcumin Analogues as Multipotent Tools To Tackle Alzheimer's Disease. 2019 , 10, 1420-1433	9
715	Estimating the concentration of therapeutic range using disease-specific iPS cells: Low-dose rapamycin therapy for Pendred syndrome. 2019 , 10, 54-63	11
714	Concentration-dependent effects of mercury and lead on A β 2: possible implications for Alzheimer's disease. 2019 , 48, 173-187	23
713	Evaluating the Role of Microglial Cells in Clearance of A β from Alzheimer's Brain. 2019 , 10, 1149-1156	7
712	Vascular Risk and β Amyloid Are Synergistically Associated with Cortical Tau. 2019 , 85, 272-279	44
711	Electrochemical Detection of Isoform-Specific Interaction between Apolipoprotein E and Amyloid- β 2019 , 6, 834-840	2
710	Deceleration of the neurodegenerative phenotype in pyroglutamate-A β accumulating transgenic mice by oral treatment with the A β oligomer eliminating compound RD2. 2019 , 124, 36-45	8
709	Carbenoxolone Reverses the Amyloid Beta 1-42 Oligomer-Induced Oxidative Damage and Anxiety-Related Behavior in Rats. 2019 , 35, 654-667	13
708	Zebrafish models of diabetes-related CNS pathogenesis. 2019 , 92, 48-58	12

707	The Anti-amyloid Compound DO1 Decreases Plaque Pathology and Neuroinflammation-Related Expression Changes in 5xFAD Transgenic Mice. 2019 , 26, 109-120.e7	6
706	Prestimulation of Microglia Through TLR4 Pathway Promotes Interferon Beta Expression in a Rat Model of Alzheimer's Disease. 2019 , 67, 495-503	13
705	Emerging pathways to neurodegeneration: Dissecting the critical molecular mechanisms in Alzheimer's disease, Parkinson's disease. 2019 , 111, 765-777	53
704	An exercise-induced messenger boosts memory in Alzheimer's disease. 2019 , 25, 20-21	8
703	Combined treatment with the phenolics (-)-epigallocatechin-3-gallate and ferulic acid improves cognition and reduces Alzheimer-like pathology in mice. 2019 , 294, 2714-2731	44
702	IGF-II-Conjugated Nanocarrier for Brain-Targeted Delivery of p11 Gene for Depression. 2019 , 20, 50	5
701	Molecular dynamics simulation on the effect of transition metal binding to the -terminal fragment of amyloid- β 2019 , 37, 4590-4600	6
700	Alzheimer's Disease Risk Factor Pyk2 Mediates Amyloid- β -Induced Synaptic Dysfunction and Loss. 2019 , 39, 758-772	37
699	Disrupted-in-schizophrenia-1 protects synaptic plasticity in a transgenic mouse model of Alzheimer's disease as a mitophagy receptor. 2019 , 18, e12860	37
698	Functions and dysfunctions of nitric oxide in brain. 2019 , 1865, 1949-1967	80
697	Clusterin contributes to early stage of Alzheimer's disease pathogenesis. 2019 , 29, 217-231	25
696	High detection sensitivity with antibody-based PET radioligand for amyloid beta in brain. 2019 , 184, 881-888	25
695	A β oligomers trigger and accelerate A β seeding. 2020 , 30, 36-45	31
694	Hibiscus sabdariffa L. extract prolongs lifespan and protects against amyloid- β toxicity in <i>Caenorhabditis elegans</i> : involvement of the FoxO and Nrf2 orthologues DAF-16 and SKN-1. 2020 , 59, 137-150	24
693	Effect of catechins and high-temperature-processed green tea extract on scavenging reactive oxygen species and preventing A β fibrils' formation in brain microvascular endothelium. 2020 , 23, 363-373	11
692	New diagnostic method for Alzheimer's disease based on the toxic conformation theory of amyloid β 2020 , 84, 1-16	20
691	Glut4: A central player in hippocampal memory and brain insulin resistance. 2020 , 323, 113076	32
690	Systemic Amyloidosis: a Contemporary Overview. 2020 , 59, 304-322	10

689	The Interaction Between Contactin and Amyloid Precursor Protein and Its Role in Alzheimer's Disease. 2020 , 424, 184-202	10
688	Memory and cerebrovascular deficits recovered following angiotensin IV intervention in a mouse model of Alzheimer's disease. 2020 , 134, 104644	20
687	Self-powered, wireless-control, neural-stimulating electronic skin for in vivo characterization of synaptic plasticity. 2020 , 67, 104182	35
686	Reelin reverts biochemical, physiological and cognitive alterations in mouse models of Tauopathy. 2020 , 186, 101743	7
685	Diabetes as a risk factor for Alzheimer's disease in the Middle East and its shared pathological mediators. 2020 , 27, 736-750	21
684	A Focused Chiral Mutant Library of the Amyloid β 42 Central Electrostatic Cluster as a Tool To Stabilize Aggregation Intermediates. 2020 , 85, 1385-1391	13
683	MA-[D-Leu-4]-OB3, a Small Molecule Synthetic Peptide Leptin Mimetic, Normalizes Glucose Tolerance and Episodic Memory in a Mouse Model of Type 2 Diabetes Mellitus and Alzheimer's Disease-Like Cognitive Impairment. 2020 , 26, 1981-1990	4
682	Polysaccharides from <i>Lycium barbarum</i> ameliorate amyloid pathology and cognitive functions in APP/PS1 transgenic mice. 2020 , 144, 1004-1012	14
681	Stabilization Mechanism for a Nonfibrillar Amyloid β Oligomer Based on Formation of a Hydrophobic Core Determined by Dissipative Particle Dynamics. 2020 , 11, 385-394	7
680	Design, Synthesis, and Properties of a Chemically Tethered Amyloid- β Segment Trimer Resistant to Intertrimer Mis-aggregation. 2020 , 85, 1635-1643	2
679	Mapping pathogenic processes contributing to neurodegeneration in <i>Drosophila</i> models of Alzheimer's disease. 2020 , 10, 338-350	3
678	Amyloid, APP, and Electrical Activity of the Brain. 2020 , 26, 231-251	16
677	Alzheimer's Disease and Diabetes: Insulin Signaling as the Bridge Linking Two Pathologies. 2020 , 57, 1966-1977	27
676	The effect of insomnia on development of Alzheimer's disease. 2020 , 17, 289	13
675	Design and synthesis of novel pyrazolo[3,4-d]pyrimidin-4-one bearing quinoline scaffold as potent dual PDE5 inhibitors and apoptotic inducers for cancer therapy. 2020 , 105, 104352	2
674	Dysfunctional proteins in neuropsychiatric disorders: From neurodegeneration to autism spectrum disorders. 2020 , 141, 104853	4
673	Kinetic fingerprints differentiate the mechanisms of action of anti-A β antibodies. 2020 , 27, 1125-1133	35
672	Sequence and structure-based peptides as potent amyloid inhibitors: A review. 2020 , 695, 108614	10

671	Involvement of endoplasmic reticulum stress in amyloid β -induced Alzheimer's like neuropathological process in rat brain. 2020 , 165, 108-117	8
670	Synaptic Loss in Primary Tauopathies Revealed by [C]UCB-J Positron Emission Tomography. 2020 , 35, 1834-1842	28
669	Caspase Activation and Caspase-Mediated Cleavage of APP Is Associated with Amyloid β -Protein-Induced Synapse Loss in Alzheimer's Disease. 2020 , 31, 107839	18
668	Age-related decline of neuroplasticity to intermittent theta burst stimulation of the lateral prefrontal cortex and its relationship with late-life memory performance. 2020 , 131, 2181-2191	6
667	Therapeutic Strategies to Reduce the Toxicity of Misfolded Protein Oligomers. 2020 , 21,	12
666	Acetylation of AMPA Receptors Regulates Receptor Trafficking and Rescues Memory Deficits in Alzheimer's Disease. 2020 , 23, 101465	1
665	Association of Odor Identification Ability With Amyloid- β and Tau Burden: A Systematic Review and Meta-Analysis. 2020 , 14, 586330	4
664	Phenylalanine Mutation to Cyclohexylalanine Facilitates Triangular Trimer Formation by β -Hairpins Derived from A β . 2020 , 142, 20708-20716	3
663	Prodromal Alzheimer's Disease: Constitutive Upregulation of Neuroglobin Prevents the Initiation of Alzheimer's Pathology. 2020 , 14, 562581	3
662	Amyloid- β Peptide Impact on Synaptic Function and Neuroepigenetic Gene Control Reveal New Therapeutic Strategies for Alzheimer's Disease. 2020 , 13, 577622	11
661	Extracellular vesicles from amyloid- β -exposed cell cultures induce severe dysfunction in cortical neurons. 2020 , 10, 19656	8
660	Signaling via the p75 neurotrophin receptor facilitates amyloid- β -induced dendritic spine pathology. 2020 , 10, 13322	7
659	Treating Protein Misfolding Diseases: Therapeutic Successes Against Systemic Amyloidoses. 2020 , 11, 1024	10
658	The physiological roles of tau and A β implications for Alzheimer's disease pathology and therapeutics. 2020 , 140, 417-447	88
657	Involvement of p38 MAPK in Synaptic Function and Dysfunction. 2020 , 21,	25
656	Coenzyme Q in Aging. 2020 ,	1
655	Amyloid Beta Secreted during Consolidation Prevents Memory Malleability. 2020 , 30, 1934-1940.e4	6
654	Noncanonical function of an autophagy protein prevents spontaneous Alzheimer's disease. 2020 , 6, eabb9036	28

653	Age-Dependent Shift of AMPA Receptors From Synapses to Intracellular Compartments in Alzheimer's Disease: Immunocytochemical Analysis of the CA1 Hippocampal Region in APP/PS1 Transgenic Mouse Model. 2020 , 12, 577996	6
652	Embryonic proteoglycans regulate monoamines in the rat frontal cortex and hippocampus in Alzheimer's disease-like pathology. 2020 , 140, 104838	2
651	Computational Investigation of Gantenerumab and Crenezumab Recognition of A β Fibrils in Alzheimer's Disease Brain Tissue. 2020 , 11, 3233-3244	4
650	Fluorescent Dopamine-Tryptophan Nanocomposites as Dual-Imaging and Antiaggregation Agents: New Generation of Amyloid Theranostics with Trimeric Effects. 2020 , 12, 44180-44194	3
649	Increased levels of Stress-inducible phosphoprotein-1 accelerates amyloid- β deposition in a mouse model of Alzheimer's disease. 2020 , 8, 143	7
648	Glucosylpolyphenols as Inhibitors of A β -induced Fyn Kinase Activation and Tau Phosphorylation: Synthesis, Membrane Permeability, and Exploratory Target Assessment within the Scope of Type 2 Diabetes and Alzheimer's Disease. 2020 , 63, 11663-11690	3
647	Thermodynamic and kinetic design principles for amyloid-aggregation inhibitors. 2020 , 117, 24251-24257	15
646	Fluid Biomarkers for Synaptic Dysfunction and Loss. 2020 , 15, 1177271920950319	23
645	Gallic acid is a dual β -secretase modulator that reverses cognitive impairment and remediates pathology in Alzheimer mice. 2020 , 295, 16251-16266	15
644	From Seeds to Fibrils and Back: Fragmentation as an Overlooked Step in the Propagation of Prions and Prion-Like Proteins. 2020 , 10,	1
643	A Pentacyclic Triterpene from Targets β -Secretase. 2020 , 11, 2827-2835	2
642	The retinal toxicity profile towards assemblies of Amyloid- β indicate the predominant pathophysiological activity of oligomeric species. 2020 , 10, 20954	6
641	Novel PET Biomarkers to Disentangle Molecular Pathways across Age-Related Neurodegenerative Diseases. 2020 , 9,	12
640	Modulation of Brain Hyperexcitability: Potential New Therapeutic Approaches in Alzheimer's Disease. 2020 , 21,	17
639	Celecoxib Exerts Neuroprotective Effects in β -Amyloid-Treated SH-SY5Y Cells Through the Regulation of Heme Oxygenase-1: Novel Insights for an Old Drug. 2020 , 8, 561179	9
638	The Role of Synaptic Dysfunction in Alzheimer's Disease. 2020 , 76, 49-62	6
637	Humanin Blocks the Aggregation of Amyloid- β Induced by Acetylcholinesterase, an Effect Abolished in the Presence of IGFBP-3. 2020 , 59, 1981-2002	8
636	A 3D human brain-like tissue model of herpes-induced Alzheimer's disease. 2020 , 6, eaay8828	90

635	Amyloid Metabolism and Amyloid-Targeting Blood-Based Biomarkers of Alzheimer's Disease. 2020 , 75, 685-696	4
634	Selenium Restores Synaptic Deficits by Modulating NMDA Receptors and Selenoprotein K in an Alzheimer's Disease Model. 2021 , 35, 863-884	12
633	Proteomic Profiling of Plasma and Brain Tissue from Alzheimer's Disease Patients Reveals Candidate Network of Plasma Biomarkers. 2020 , 76, 349-368	9
632	Alzheimer's Disease "Non-amyloidogenic" p3 Peptide Revisited: A Case for Amyloid- β 2020 , 11, 1539-1544	10
631	Out-of-Register Parallel β -Sheets and Antiparallel β -Sheets Coexist in 150-kDa Oligomers Formed by Amyloid- β (1-42). 2020 , 432, 4388-4407	15
630	Can Reduce Amyloid Beta and Reverse Cognitive Impairment and Memory Dysfunction in Alzheimer's Disease Mouse Model. 2020 , 9,	4
629	Integrin adhesion in brain assembly: From molecular structure to neuropsychiatric disorders. 2021 , 53, 3831-3850	10
628	Muscone Ameliorates Synaptic Dysfunction and Cognitive Deficits in APP/PS1 Mice. 2020 , 76, 491-504	3
627	Alzheimer's disease-related dysregulation of mRNA translation causes key pathological features with ageing. 2020 , 10, 192	12
626	Tipping the Scales: Peptide-Dependent Dysregulation of Neural Circuit Dynamics in Alzheimer's Disease. 2020 , 107, 417-435	30
625	Effects of N-Terminal Residues on the Assembly of Constrained β -Hairpin Peptides Derived from A β 2020 , 142, 11593-11601	9
624	Biosensing: The best alternative for conventional methods in detection of Alzheimer's disease biomarkers. 2020 , 161, 59-71	11
623	Dimerization of A β 40 inside dipalmitoylphosphatidylcholine bilayer and its effect on bilayer integrity: Atomistic simulation at three temperatures. 2020 , 88, 1540-1552	3
622	Identification of on- and off-pathway oligomers in amyloid fibril formation. 2020 , 11, 6236-6247	23
621	designed 13 mer hairpin-peptide arrests insulin and inhibits its aggregation: role of OH- π interactions between water and hydrophobic amino acids.. 2020 , 10, 14991-14999	
620	Is the p3 Peptide (A β 7-40, A β 7-42) Relevant to the Pathology of Alzheimer's Disease?1. 2020 , 74, 43-53	7
619	A mechanistic hypothesis for the impairment of synaptic plasticity by soluble A β oligomers from Alzheimer's brain. 2020 , 154, 583-597	68
618	SERP1 is an assembly regulator of β -secretase in metabolic stress conditions. 2020 , 13,	5

617	The clinical promise of biomarkers of synapse damage or loss in Alzheimer's disease. 2020 , 12, 21	69
616	Control of the toxic conformation of amyloid β 2 by intramolecular disulfide bond formation. 2020 , 56, 4118-4121	7
615	Computational studies of protein aggregation mediated by amyloid: Fibril elongation and secondary nucleation. 2020 , 170, 461-504	4
614	Safety and pharmacokinetics of the orally available antiprionic compound PRI-002: A single and multiple ascending dose phase I study. 2020 , 6, e12001	12
613	Molecular Pathogenesis and Interventional Strategies for Alzheimer's Disease: Promises and Pitfalls. 2020 , 3, 472-488	6
612	Removal of A β oligomers from the Blood: A Potential Therapeutic System for Alzheimer's Disease. 2020 , 16, 607-627	1
611	Destruction of ERP responses to deviance in an auditory oddball paradigm in amyloid infusion mice with memory deficits. 2020 , 15, e0230277	3
610	Z-ligustilide: A review of its pharmacokinetics and pharmacology. 2020 , 34, 1966-1991	18
609	Novel huperzine A based NMDA antagonists: insights from molecular docking, ADME/T and molecular dynamics simulation studies.. 2020 , 10, 25446-25455	0
608	Recombinant Bri3 BRICHOS domain is a molecular chaperone with effect against amyloid formation and non-fibrillar protein aggregation. 2020 , 10, 9817	2
607	Heavy Tau Burden with Subtle Amyloid β Accumulation in the Cerebral Cortex and Cerebellum in a Case of Familial Alzheimer's Disease with APP Osaka Mutation. 2020 , 21,	3
606	Multidimensional protein characterisation using microfluidic post-column analysis. 2020 , 20, 2663-2673	2
605	Mixing A β (1-40) and A β (1-42) peptides generates unique amyloid fibrils. 2020 , 56, 8830-8833	13
604	Proximity ligation assay reveals both pre- and postsynaptic localization of the APP-processing enzymes ADAM10 and BACE1 in rat and human adult brain. 2020 , 21, 6	8
603	APP Osaka Mutation in Familial Alzheimer's Disease-Its Discovery, Phenotypes, and Mechanism of Recessive Inheritance. 2020 , 21,	12
602	Enhanced self-assembly of the 7 β 2 sequence of amyloid- β peptide by tyrosine bromination. 2020 , 32, 247-255	3
601	Deletion of a conserved Gata2 enhancer impairs haemogenic endothelium programming and adult Zebrafish haematopoiesis. 2020 , 3, 71	7
600	Effects of Boron Nitride Nanotube on the Secondary Structure of A β (1-42) Trimer: Possible Inhibitory Effect on Amyloid Formation. 2020 , 124, 1928-1940	8

599	Cyanidin-3-O-glucoside inhibits A β 0 fibrillogenesis, disintegrates preformed fibrils, and reduces amyloid cytotoxicity. 2020 , 11, 2573-2587	13
598	Activated Bone Marrow-Derived Macrophages Eradicate Alzheimer's-Related A β Oligomers and Protect Synapses. 2020 , 11, 49	17
597	miR-181a negatively modulates synaptic plasticity in hippocampal cultures and its inhibition rescues memory deficits in a mouse model of Alzheimer's disease. 2020 , 19, e13118	19
596	Altered dorsal CA1 neuronal population coding in the APP/PS1 mouse model of Alzheimer's disease. 2020 , 10, 1077	3
595	Dissociation of somatostatin and parvalbumin interneurons circuit dysfunctions underlying hippocampal theta and gamma oscillations impaired by amyloid β oligomers in vivo. 2020 , 225, 935-954	13
594	study of the mechanism of intraneuronal amyloid aggregation in Alzheimer's disease. 2020 , 1-8	7
593	β Amyloid redirects norepinephrine signaling to activate the pathogenic GSK3 β /tau cascade. 2020 , 12,	43
592	Optogenetic activation of parvalbumin and somatostatin interneurons selectively restores theta-nested gamma oscillations and oscillation-induced spike timing-dependent long-term potentiation impaired by amyloid β oligomers. 2020 , 18, 7	19
591	Pine Bark Polyphenolic Extract Attenuates Amyloid- β and Tau Misfolding in a Model System of Alzheimer's Disease Neuropathology. 2020 , 73, 1597-1606	4
590	Sodium Butyrate Reduces Brain Amyloid- β Levels and Improves Cognitive Memory Performance in an Alzheimer's Disease Transgenic Mouse Model at an Early Disease Stage. 2020 , 74, 91-99	25
589	Amyloids in Site-Specific Autoimmune Reactions and Inflammatory Responses. 2019 , 10, 2980	2
588	Misfolded amyloid- β 42 impairs the endosomal-lysosomal pathway. 2020 , 77, 5031-5043	14
587	Assessing Reproducibility in Amyloid β Research: Impact of A β Sources on Experimental Outcomes. 2020 , 21, 2425-2430	3
586	Peroxidase activity of heme bound amyloid β peptides associated with Alzheimer's disease. 2020 , 56, 4505-4518	10
585	Obesity and Alzheimer's disease: Molecular bases. 2020 , 52, 3944-3950	13
584	Going the Extra (Synaptic) Mile: Excitotoxicity as the Road Toward Neurodegenerative Diseases. 2020 , 14, 90	52
583	Hippocampal Deficits in Amyloid- β -Related Rodent Models of Alzheimer's Disease. 2020 , 14, 266	16
582	Amyloid- β oligomers in cellular models of Alzheimer's disease. 2020 , 155, 348-369	19

- 581 Hollow Mesoporous Carbon Nanospheres Loaded with Pt Nanoparticles for Colorimetric Detection of Ascorbic Acid and Glucose. **2020**, 3, 4586-4598 18
- 580 A Path Toward Precision Medicine for Neuroinflammatory Mechanisms in Alzheimer's Disease. **2020**, 11, 456 87
- 579 Acute Pannexin 1 Blockade Mitigates Early Synaptic Plasticity Defects in a Mouse Model of Alzheimer's Disease. **2020**, 14, 46 9
- 578 Modulation of tau protein aggregation using 'Trojan' sequences. **2020**, 1864, 129569 5
- 577 Abelson Kinases Mediate the Depression of Spontaneous Synaptic Activity Induced by Amyloid Beta 1-42 Peptides. **2021**, 41, 431-448 1
- 576 Future avenues for Alzheimer's disease detection and therapy: liquid biopsy, intracellular signaling modulation, systems pharmacology drug discovery. **2021**, 185, 108081 12
- 575 Anti-aging Klotho Protects SH-SY5Y Cells Against Amyloid β -42 Neurotoxicity: Involvement of Wnt1/pCREB/Nrf2/HO-1 Signaling. **2021**, 71, 19-27 7
- 574 β -Secretase-cleaved Tau stimulates $A\beta$ production via upregulating STAT1-BACE1 signaling in Alzheimer's disease. **2021**, 26, 586-603 31
- 573 Enhanced neprilysin-mediated degradation of hippocampal $A\beta$ 2 with a somatostatin peptide that enters the brain. **2021**, 11, 789-804 8
- 572 A multitude of signaling pathways associated with Alzheimer's disease and their roles in AD pathogenesis and therapy. **2021**, 41, 2689-2745 3
- 571 Detergent-insoluble inclusion constitutes the first pathology in PFN1 transgenic rats. **2021**, 157, 1244-1252 3
- 570 Nutraceuticals in neurodegenerative diseases. **2021**, 249-270 2
- 569 Circulating levels of Irisin in obese individuals at genetic risk for Alzheimer's disease: Correlations with amyloid- β metabolic, and neurocognitive indices. **2021**, 400, 113013 5
- 568 The Aggregation Pattern of $A\beta$ s Altered by the Presence of N-Truncated $A\beta$ and/or Cu in a Similar Way through Ionic Interactions. **2021**, 27, 2798-2809 5
- 567 Implications of Oligomeric Amyloid-Beta ($\alpha A\beta$) Signaling through $\alpha A\beta$ -Nicotinic Acetylcholine Receptors (nAChRs) on Basal Forebrain Cholinergic Neuronal Intrinsic Excitability and Cognitive Decline. **2021**, 41, 555-575 12
- 566 Oral absorption enhancement of the amyloid- β oligomer eliminating compound RD2 by conjugation with folic acid. **2021**, 156, 105581 1
- 565 β -Amyloid: The known unknowns. **2021**, 65, 101212 13
- 564 Inhibition of human amylin aggregation by Flavonoid Chrysin: An and approach. **2021**, 18, 199-206 3

563	The Role of Toll-Like Receptor 4 in Infectious and Non Infectious Inflammation. 2021 ,	1
562	Systems-based proteomics to resolve the biology of Alzheimer's disease beyond amyloid and tau. 2021 , 46, 98-115	18
561	Early life stress amplifies fear responses and hippocampal synaptic potentiation in the APPswe/PS1dE9 Alzheimer mouse model. 2021 , 454, 151-161	2
560	Modified Glutamatergic Postsynapse in Neurodegenerative Disorders. 2021 , 454, 116-139	4
559	Identifying the key residues instrumental in imparting stability to amyloid beta protofibrils - a comparative study using MD simulations of 17-42 residues. 2021 , 39, 431-456	5
558	The Hunt for Ancient Prions: Archaeal Prion-Like Domains Form Amyloid-Based Epigenetic Elements. 2021 , 38, 2088-2103	6
557	Kinetic and thermodynamic stability comparison for the fibrillar form of small amyloid- β (1-42) oligomers using scaled molecular dynamics. 2021 , 23, 16897-16908	0
556	Soluble amyloid beta-containing aggregates are present throughout the brain at early stages of Alzheimer's disease. 2021 , 3, fcab147	2
555	microRNAs as Early Biomarkers of Alzheimer's Disease: A Synaptic Perspective. 2021 , 10,	13
554	Alzheimer's disease neuropathology is exacerbated following traumatic brain injury. Neuroprotection by co-administration of nanowired mesenchymal stem cells and cerebrolysin with monoclonal antibodies to amyloid beta peptide. 2021 , 265, 1-97	0
553	Association of neurogranin gene expression with Alzheimer's disease pathology in the perirhinal cortex. 2021 , 7, e12162	0
552	The p38-MK2 Signaling Axis as a Critical Link Between Inflammation and Synaptic Transmission. 2021 , 9, 635636	3
551	Identification of biomarkers for diagnosing and monitoring therapy in the treatment of neurologic disorders. 2021 , 291-310	
550	Staphylococcus aureus N-terminus formylated β -toxin tends to form amyloid fibrils, while the deformylated β -toxin tends to form functional oligomer complexes. 2021 , 12, 1418-1437	1
549	A continuous-time mathematical model and discrete approximations for the aggregation of β -Amyloid. 2021 , 15, 109-136	0
548	The biological pathways of Alzheimer disease: a review. 2021 , 8, 86-132	33
547	The A β (1-38) peptide is a negative regulator of the A β (1-42) peptide implicated in Alzheimer disease progression. 2021 , 11, 431	9
546	Management of Alzheimer's Disease with nutraceuticals. 2021 , 391-408	

545	Immunotherapy for Alzheimer's Disease: Current Scenario and Future Perspectives. 2021 , 8, 534-551	1
544	3D-visualization of amyloid- β oligomer interactions with lipid membranes by cryo-electron tomography. 2021 , 12, 6896-6907	6
543	Pathobiology and Management of Alzheimer's Disease. 2021 , 57, 108-117	1
542	Quantifying misfolded protein oligomers as drug targets and biomarkers in Alzheimer and Parkinson diseases. 2021 , 5, 277-294	10
541	Binding of Amyloid β (1-42)-Calmodulin Complexes to Plasma Membrane Lipid Rafts in Cerebellar Granule Neurons Alters Resting Cytosolic Calcium Homeostasis. 2021 , 22,	3
540	Accumulation of cellular prion protein within β amyloid oligomer plaques in aged human brains. 2021 , 31, e12941	5
539	Reactive astrocytes as treatment targets in Alzheimer's disease-Systematic review of studies using the APPswePS1dE9 mouse model. 2021 , 69, 1852-1881	12
538	A circulating, disease-specific, mechanism-linked biomarker for ATTR polyneuropathy diagnosis and response to therapy prediction. 2021 , 118,	4
537	Synthesis of Alkyl Bridged-Tris- β -Amino Acids as C3-Symmetric and Linear Linkers. 2021 , 2021, 1370-1377	1
536	Insight into the role of phosphatidylserine in complement-mediated synapse loss in Alzheimer's disease. 2021 , 10, 19	4
535	Apoptotic neurons and amyloid-beta clearance by phagocytosis in Alzheimer's disease: Pathological mechanisms and therapeutic outlooks. 2021 , 895, 173873	10
534	Membrane Interactions and Toxicity by Misfolded Protein Oligomers. 2021 , 9, 642623	10
533	Rapid initiation of cell cycle reentry processes protects neurons from amyloid- β toxicity. 2021 , 118,	3
532	Neuronal Network Excitability in Alzheimer's Disease: The Puzzle of Similar versus Divergent Roles of Amyloid β and Tau. 2021 , 8,	10
531	Discovery of a Highly Selective and Potent TRPC3 Inhibitor with High Metabolic Stability and Low Toxicity. 2021 , 12, 572-578	1
530	Fluorine-19 Magnetic Resonance Imaging for Detection of Amyloid β Oligomers Using a Keto Form of Curcumin Derivative in a Mouse Model of Alzheimer's Disease. 2021 , 26,	5
529	Unraveling the Speciation of β Amyloid Peptides during the Aggregation Process by Taylor Dispersion Analysis. 2021 , 93, 6523-6533	1
528	Alzheimer's pathology causes impaired inhibitory connections and reactivation of spatial codes during spatial navigation. 2021 , 35, 109008	3

527	Shexiang Baoxin Pill, a Proprietary Multi-Constituent Chinese Medicine, Prevents Locomotor and Cognitive Impairment Caused by Brain Ischemia and Reperfusion Injury in Rats: A Potential Therapy for Neuropsychiatric Sequelae of Stroke. 2021 , 12, 665456	2
526	The Neuroprotective Beta Amyloid Hexapeptide Core Reverses Deficits in Synaptic Plasticity in the 5xFAD APP/PS1 Mouse Model. 2021 , 14, 576038	0
525	Evaluation of the prevention and treatment effects of acupuncture-moxibustion for Alzheimer disease based on various mouse models. 2021 , 19, 147-156	0
524	Temporal Lobe Epilepsy and Alzheimer's Disease: From Preclinical to Clinical Evidence of a Strong Association. 2021 , 5, 243-261	8
523	Overexpression of protein kinase M $\kern-0.05em\text{̄}$ in the hippocampal dentate gyrus rescues amyloid- β -induced synaptic dysfunction within entorhinal-hippocampal circuit. 2021 , 101, 160-171	2
522	Amyloids: The History of Toxicity and Functionality. 2021 , 10,	3
521	Annexin A1 restores cerebrovascular integrity concomitant with reduced amyloid- β and tau pathology. 2021 , 144, 1526-1541	6
520	The Relevance of Amyloid β -Calmodulin Complexation in Neurons and Brain Degeneration in Alzheimer's Disease. 2021 , 22,	2
519	The synthesis and characterization of Bri2 BRICHOS coated magnetic particles and their application to protein fishing: Identification of novel binding proteins. 2021 , 198, 113996	0
518	Regulation of amyloid- β levels by matrix metalloproteinase-2/9 (MMP2/9) in the media of lung cancer cells. 2021 , 11, 9708	3
517	VEGF counteracts amyloid- β -induced synaptic dysfunction. 2021 , 35, 109121	2
516	Promoted Aggregation of A β in Lipid Bilayers in an Open Flowing System. 2021 , 12, 4453-4460	1
515	Re-emphasizing early Alzheimer's disease pathology starting in select entorhinal neurons, with a special focus on mitophagy. 2021 , 67, 101307	18
514	A signal amplification strategy based on peptide self-assembly for the identification of amyloid- β oligomer. 2021 , 335, 129697	5
513	Selective Regional Loss of Cortical Synapses Lacking Presynaptic Mitochondria in the 5xFAD Mouse Model. 2021 , 15, 690168	3
512	Amyloid Prefibrillar Oligomers: The Surprising Commonalities in Their Structure and Activity. 2021 , 22,	4
511	Reversible GABAergic dysfunction involved in hippocampal hyperactivity predicts early-stage Alzheimer disease in a mouse model. 2021 , 13, 114	5
510	An Unbalanced Synaptic Transmission: Cause or Consequence of the Amyloid Oligomers Neurotoxicity?. 2021 , 22,	4

509	Synaptic Plasticity and Oscillations in Alzheimer's Disease: A Complex Picture of a Multifaceted Disease. 2021 , 14, 696476	3
508	Bacterial Extracellular DNA Promotes β Amyloid Aggregation. 2021 , 9,	5
507	Structural Features and Toxicity of β Synuclein Oligomers Grown in the Presence of DOPAC. 2021 , 22,	0
506	Overexpression of LIMK1 in hippocampal excitatory neurons improves synaptic plasticity and social recognition memory in APP/PS1 mice. 2021 , 14, 121	1
505	PEGylated superparamagnetic iron oxide nanoparticles (SPIONs) ameliorate learning and memory deficit in a rat model of Alzheimer's disease: Potential participation of STIMs. 2021 , 85, 145-159	3
504	Sorting nexin-27 regulates AMPA receptor trafficking through the synaptic adhesion protein LRFN2. 2021 , 10,	5
503	Blockage of Drp1 phosphorylation at Ser579 protects neurons against A β -induced degeneration. 2021 , 24,	2
502	Development of grape polyphenols as multi-targeting strategies for Alzheimer's disease. 2021 , 147, 105046	5
501	Age-Related Transcriptional Deregulation of Genes Coding Synaptic Proteins in Alzheimer's Disease Murine Model: Potential Neuroprotective Effect of Fingolimod. 2021 , 14, 660104	1
500	Impairment of visual cortical plasticity by amyloid-beta species. 2021 , 154, 105344	1
499	N-Truncated A β -Starting at Position Four-Biochemical Features, Preclinical Models, and Potential as Drug Target in Alzheimer's Disease. 2021 , 13, 710579	4
498	Basal forebrain cholinergic system in the dementias: Vulnerability, resilience, and resistance. 2021 , 158, 1394-1411	2
497	Significance of Oligomeric and Fibrillar Species in Amyloidosis: Insights into Pathophysiology and Treatment. 2021 , 26,	2
496	Neprilysin-sensitive amyloidogenic A β versus IDE-sensitive soluble A β a probable mechanistic cause for sporadic Alzheimer's disease.	
495	Noradrenaline in the aging brain: Promoting cognitive reserve or accelerating Alzheimer's disease?. 2021 , 116, 108-124	6
494	Long-term depression links amyloid- β to the pathological hyperphosphorylation of tau. 2021 , 36, 109638	1
493	Planar cell polarity signaling components are a direct target of β Amyloid-associated degeneration of glutamatergic synapses. 2021 , 7,	4
492	Looking at Alzheimer's Disease Pathogenesis from the Nuclear Side. 2021 , 11,	0

491	Soluble Amyloid- β Consumption in Alzheimer's Disease. 2021 , 82, 1403-1415	16
490	The Amyloid- β Pathway in Alzheimer's Disease. 2021 ,	63
489	Prediction and verification of the AD-FTLD common pathomechanism based on dynamic molecular network analysis. 2021 , 4, 961	1
488	A Comprehensive Insight into the Mechanisms of Dopamine in Disrupting A β Protofibrils and Inhibiting A β Aggregation. 2021 , 12, 4007-4019	4
487	Oligomeric and Fibrillar Species of A β 2 Diversely Affect Human Neural Stem Cells. 2021 , 22,	0
486	Novel strategies for the fight of Alzheimer's disease targeting amyloid- β protein. 2021 , 1-10	1
485	Alzheimer's Disease: A Molecular View of β Amyloid Induced Morbific Events. 2021 , 9,	5
484	On the Common Journey of Neural Cells through Ischemic Brain Injury and Alzheimer's Disease. 2021 , 22,	4
483	Role of amber extract in protecting SHSY5Y cells against amyloid β -42-induced neurotoxicity. 2021 , 141, 111804	1
482	Palmitoylated prolactin-releasing peptide reduced A β plaques and microgliosis in the cerebellum: APP/PS1 mice study. 2021 ,	1
481	Endoplasmic reticulum tubules limit the size of misfolded protein condensates. 2021 , 10,	6
480	Novel multivalent design of a monoclonal antibody improves binding strength to soluble aggregates of amyloid beta. 2021 , 10, 38	0
479	Human cerebral vascular amyloid contains both antiparallel and parallel in-register A β 0 fibrils. 2021 , 297, 101259	0
478	Inflammatory Cascade in Alzheimer's Disease Pathogenesis: A Review of Experimental Findings. 2021 , 10,	9
477	Insulin and Insulin Resistance in Alzheimer's Disease. 2021 , 22,	7
476	Lovastatin attenuates sevoflurane-induced cognitive disorder in aged rats via reducing A β accumulation. 2021 , 148, 105078	3
475	Monitoring the early aggregatory behaviour and size of A β in the absence & presence of metal ions using dynamic light scattering. 2021 , 67, 126766	0
474	Potential of amyloid beta phagocytosis and amelioration of synaptic dysfunction upon FAAH deletion in a mouse model of Alzheimer's disease. 2021 , 18, 223	1

- 473 Astrocytic C-X-C motif chemokine ligand-1 mediates β -amyloid-induced synaptotoxicity.
- 472 Improvement of cognitive performance by a nutraceutical formulation: Underlying mechanisms revealed by laboratory studies. **2021**, 174, 281-304 1
- 471 Effect of involuntary chronic physical exercise on beta-amyloid protein in experimental models of Alzheimer's disease: Systematic review and meta-analysis. **2021**, 153, 111502 0
- 470 Three new alkaloids from *Portulaca oleracea* L. and their bioactivities. **2021**, 154, 105020 6
- 469 Icariin ameliorate Alzheimer's disease by influencing SIRT1 and inhibiting A β cascade pathogenesis. **2021**, 117, 102014 1
- 468 Cholesterol in Membranes Facilitates Aggregation of Amyloid β Protein at Physiologically Relevant Concentrations. **2021**, 12, 506-516 8
- 467 STEP inhibition prevents A β -mediated damage in dendritic complexity and spine density in Alzheimer's disease. **2021**, 239, 881-890 3
- 466 Preclinical and clinical biomarker studies of CT1812: A novel approach to Alzheimer's disease modification. **2021**, 17, 1365-1382 11
- 465 Protein Aggregation and the UPS: A Two-Way Street. **2006**, 39-55 1
- 464 Early Onset Familial Alzheimer's Disease: Is a Mutation Predictive of Pathology?. **2005**, 45-59 1
- 463 A β -Degradation. **2007**, 157-178 1
- 462 Free Radicals, Metal Ions, and A β -Aggregation and Neurotoxicity. **2007**, 31-47 3
- 461 Overview of the Alzheimer's Disease Pathology and Potential Therapeutic Targets. **2007**, 1-27 2
- 460 Amyloid Imaging with PET in Alzheimer's Disease, Mild Cognitive Impairment, and Clinically Unimpaired Subjects. **2009**, 119-147 4
- 459 Zinc and Zinc Transport and Sequestration Proteins in the Brain in the Progression of Alzheimer's Disease. **2011**, 669-693 1
- 458 The Glutamatergic System in Alzheimer's Disease Brain: Dysfunction Associated with Amyloid β -Peptide and Oxidative Stress. **2004**, 251-262 2
- 457 MPTP Neurotoxicity: Actions, Mechanisms, and Animal Modeling of Parkinson's Disease. **2014**, 237-275 2
- 456 Amyloid-Beta, BDNF, and the Mechanism of Neurodegeneration in Alzheimer's Disease. **2014**, 1597-1620 2

455	Metabolic Syndrome as a Risk Factor for Alzheimer Disease. 2013 , 281-341	3
454	Flow cytometric evaluation of crude synaptosome preparation as a way to study synaptic alteration in neurodegenerative diseases. 2018 , 141, 297-310	3
453	Normal and Pathological Aging: From Animals to Humans. 2009 , 1-28	3
452	Molecular simulations of peptides: a useful tool for the development of new drugs and for the study of molecular recognition. 2009 , 570, 77-153	6
451	Protein aggregation diseases: toxicity of soluble prefibrillar aggregates and their clinical significance. 2010 , 648, 25-41	19
450	A β Infusion and Related Models of Alzheimer Dementia. 2011 , 347-370	5
449	The 3xTg-AD Mouse Model: Reproducing and Modulating Plaque and Tangle Pathology. 2011 , 469-482	3
448	Quantitative approaches to amyloid imaging. 2011 , 680, 201-25	3
447	Amyloid β peptide neurotoxicity assay using cultured rat cortical neurons. 2012 , 846, 57-65	4
446	Establishing the links between A β aggregation and cytotoxicity in vitro using biophysical approaches. 2012 , 849, 227-43	1
445	The A β entric Pathway of Alzheimer's Disease. 2007 , 5-36	1
444	Amyloid Diseases at the Molecular Level: General Overview and Focus on AL Amyloidosis. 2015 , 9-29	3
443	Polymorphism of Alzheimer's A β Amyloid Fibrils and Oligomers. 2017 , 1-15	1
442	Role of Phosphodiesterases in Huntington's Disease. 2017 , 17, 285-304	8
441	Molecules that Disrupt Memory Circuits in Alzheimer's Disease: The Attack on Synapses by A β Oligomers (ADDLs). 2007 , 155-179	7
440	Why Alzheimer's is a Disease of Memory: Synaptic Targeting by Pathogenic A β Oligomers (ADDLs). 2008 , 103-132	4
439	Application of Discrete Molecular Dynamics to Protein Folding and Aggregation. 2009 , 97-131	12
438	Protein Aggregation, Unfolded Protein Response and Delayed Neuronal Death after Brain Ischemia. 2004 , 225-237	7

437	Modelle zum Wirkmechanismus der Elektrokrampftherapie. 2003 , 90-106	1
436	Overview of Fibrillar and Oligomeric Assemblies of Amyloidogenic Proteins. 2012 , 1-36	2
435	Preparation and Structural Characterization of Pre-fibrillar Assemblies of Amyloidogenic Proteins. 2012 , 61-102	1
434	The Role of A β and Tau Oligomers in the Pathogenesis of Alzheimer's Disease. 2012 , 135-188	5
433	Role of phosphoinositides at the neuronal synapse. 2012 , 59, 131-75	31
432	Removal of Blood Amyloid As a Therapeutic Strategy for Alzheimer's Disease: The Influence of Smoking and Nicotine. 2018 , 173-191	1
431	Iron Pathophysiology in Alzheimer's Diseases. 2019 , 1173, 67-104	22
430	Protein Microgels from Amyloid Fibril Networks. 2019 , 1174, 223-263	2
429	Protein Nanofibrils as Storage Forms of Peptide Drugs and Hormones. 2019 , 1174, 265-290	8
428	Amyloid- β and Tau at the Crossroads of Alzheimer's Disease. 2019 , 1184, 187-203	48
427	Cofilin-mediated neurodegeneration in alzheimer's disease and other amyloidopathies. 2007 , 35, 21	2
426	Nicotinamide mononucleotide administration after sever hypoglycemia improves neuronal survival and cognitive function in rats. 2020 , 160, 98-106	10
425	Single-subject gray matter networks predict future cortical atrophy in preclinical Alzheimer's disease. 2020 , 94, 71-80	7
424	Ensemencement et propagation des lésions dans les maladies neurodégénératives: un nouveau paradigme. 2015 , 199, 809-819	3
423	Alzheimer's disease. 80-108	1
422	Scara1 deficiency impairs clearance of soluble amyloid- β by mononuclear phagocytes and accelerates Alzheimer's-like disease progression. 2013 , 4, 2030	122
421	Ultrastructural evidence for self-replication of Alzheimer-associated A β 2 amyloid along the sides of fibrils. 2020 , 117, 11265-11273	16
420	The role of fibril structure and surface hydrophobicity in secondary nucleation of amyloid fibrils. 2020 , 117, 25272-25283	21

419	Grey matter network trajectories across the Alzheimer's disease continuum and relation to cognition. 2020 , 2, fcaa177	3
418	DNAJ Proteins in neurodegeneration: essential and protective factors. 2018 , 373,	54
417	Alzheimer's disease-related dysregulation of protein synthesis causes key pathological features with ageing.	2
416	Synaptic loss in primary tauopathies revealed by [11C]UCB-J positron emission tomography.	2
415	Transcranial in vivo detection of amyloid-beta at single plaque resolution with large-field multifocal illumination fluorescence microscopy.	6
414	The Neuroprotective Beta Amyloid Hexapeptide Core Reverses Deficits in Synaptic Plasticity in the 5FAD APP/PS1 Mouse Model.	1
413	The hunt for ancient prions: Archaeal prion-like domains form amyloids and substitute for yeast prion domains.	1
412	3D-Visualization of Amyloid- β Oligomer and Fibril Interactions with Lipid Membranes by Cryo-Electron Tomography.	1
411	Heterogeneous aggregation of amyloid- β 42 from single-molecule spectroscopy.	2
410	Drosophila p38 MAPK Interacts with BAG-3/starvin to Regulate Age-dependent Protein Homeostasis.	2
409	Kinetic fingerprints differentiate anti-A β therapies.	5
408	Membrane permeabilization: a common mechanism in protein-misfolding diseases. 2005 , 2005, pe28	29
407	Neuropathology in Alzheimer's disease: awaking from a hundred-year-old dream. 2006 , 2006, pe10	10
406	Activation of CaMKIV by soluble amyloid- β impedes trafficking of axonal vesicles and impairs activity-dependent synaptogenesis. 2017 , 10,	23
405	Series Introduction: The cellular response to aggregated proteins associated with human disease. 2002 , 110, 1219-1220	19
404	Protein aggregation in disease: a role for folding intermediates forming specific multimeric interactions. 2002 , 110, 1221-1232	154
403	Deciphering the genesis and fate of amyloid β protein yields novel therapies for Alzheimer disease. 2002 , 110, 1375-1381	133
402	Protein aggregation in disease: a role for folding intermediates forming specific multimeric interactions. 2002 , 110, 1221-32	60

401	Deciphering the genesis and fate of amyloid beta-protein yields novel therapies for Alzheimer disease. 2002 , 110, 1375-81	69
400	Persistent improvement in synaptic and cognitive functions in an Alzheimer mouse model after rolipram treatment. 2004 , 114, 1624-34	330
399	Drusen deposits associated with aging and age-related macular degeneration contain nonfibrillar amyloid oligomers. 2006 , 116, 378-85	135
398	Cholinergic dysfunction in a mouse model of Alzheimer disease is reversed by an anti-A beta antibody. 2006 , 116, 825-32	92
397	Inhibition of calpains improves memory and synaptic transmission in a mouse model of Alzheimer disease. 2008 , 118, 2796-807	160
396	FcRIIb mediates amyloid- β neurotoxicity and memory impairment in Alzheimer's disease. 2013 , 123, 2791-802	91
395	Morphology and Growth Kinetics of Alzheimer's Amyloid β -Peptides, A β and the Arctic Mutation A β (E22G). 2004 , 408-410	2
394	Reducing amyloid plaque burden via ex vivo gene delivery of an Abeta-degrading protease: a novel therapeutic approach to Alzheimer disease. 2007 , 4, e262	95
393	Metabolites of cerebellar neurons and hippocampal neurons play opposite roles in pathogenesis of Alzheimer's disease. 2009 , 4, e5530	12
392	Opposite effects of low and high doses of Abeta42 on electrical network and neuronal excitability in the rat prefrontal cortex. 2009 , 4, e8366	24
391	Lowering beta-amyloid levels rescues learning and memory in a Down syndrome mouse model. 2010 , 5, e10943	60
390	Amyloid-like aggregates of the yeast prion protein ure2 enter vertebrate cells by specific endocytotic pathways and induce apoptosis. 2010 , 5, e12529	16
389	Distinct transcriptome expression of the temporal cortex of the primate <i>Microcebus murinus</i> during brain aging versus Alzheimer's disease-like pathology. 2010 , 5, e12770	22
388	Amyloid- β triggers the release of neuronal hexokinase 1 from mitochondria. 2010 , 5, e15230	70
387	The nuclear inclusion a (Nia) protease of turnip mosaic virus (TuMV) cleaves amyloid- β 2010 , 5, e15645	11
386	Calcium ions promote formation of amyloid β peptide (1-40) oligomers causally implicated in neuronal toxicity of Alzheimer's disease. 2011 , 6, e18250	84
385	Non-esterified fatty acids generate distinct low-molecular weight amyloid- β (A β 2) oligomers along pathway different from fibril formation. 2011 , 6, e18759	29
384	PrP(Sc)-specific antibodies with the ability to immunodetect prion oligomers. 2011 , 6, e19998	15

383	Blockade of gap junction hemichannel suppresses disease progression in mouse models of amyotrophic lateral sclerosis and Alzheimer's disease. 2011 , 6, e21108	105
382	Amitriptyline-mediated cognitive enhancement in aged 3Tg Alzheimer's disease mice is associated with neurogenesis and neurotrophic activity. 2011 , 6, e21660	71
381	S100B and APP promote a gliocentric shift and impaired neurogenesis in Down syndrome neural progenitors. 2011 , 6, e22126	54
380	Reversal of fragile X phenotypes by manipulation of ABP/Al levels in Fmr1KO mice. 2011 , 6, e26549	90
379	Natural amyloid- β oligomers acutely impair the formation of a contextual fear memory in mice. 2012 , 7, e29940	23
378	BACE1 inhibition induces a specific cerebrospinal fluid β amyloid pattern that identifies drug effects in the central nervous system. 2012 , 7, e31084	60
377	Excitability and synaptic alterations in the cerebellum of APP/PS1 mice. 2012 , 7, e34726	29
376	Model Hirano bodies protect against tau-independent and tau-dependent cell death initiated by the amyloid precursor protein intracellular domain. 2012 , 7, e44996	15
375	A peptide binding to the β site of APP improves spatial memory and attenuates A β burden in Alzheimer's disease transgenic mice. 2012 , 7, e48540	7
374	Ferulic acid is a nutraceutical β secretase modulator that improves behavioral impairment and alzheimer-like pathology in transgenic mice. 2013 , 8, e55774	118
373	NMDA-receptor activation but not ion flux is required for amyloid-beta induced synaptic depression. 2013 , 8, e65350	47
372	Evaluating amyloid- β oligomers in cerebrospinal fluid as a biomarker for Alzheimer's disease. 2013 , 8, e66381	93
371	Continuation of exercise is necessary to inhibit high fat diet-induced β amyloid deposition and memory deficit in amyloid precursor protein transgenic mice. 2013 , 8, e72796	27
370	A generic method for design of oligomer-specific antibodies. 2014 , 9, e90857	34
369	EphA4 activation of c-Abl mediates synaptic loss and LTP blockade caused by amyloid- β oligomers. 2014 , 9, e92309	55
368	Amyloid- β and proinflammatory cytokines utilize a prion protein-dependent pathway to activate NADPH oxidase and induce cofilin-actin rods in hippocampal neurons. 2014 , 9, e95995	45
367	Multiplex assay for live-cell monitoring of cellular fates of amyloid- β precursor protein (APP). 2014 , 9, e98619	9
366	Di-tyrosine cross-link decreases the collisional cross-section of a β peptide dimers and trimers in the gas phase: an ion mobility study. 2014 , 9, e100200	16

365	Interplay between short- and long-term plasticity in cell-assembly formation. 2014 , 9, e101535	14
364	Methyllycaconitine alleviates amyloid- β peptides-induced cytotoxicity in SH-SY5Y cells. 2014 , 9, e111536	24
363	Aggregation of A β (25-35) on DOPC and DOPC/DHA bilayers: an atomic force microscopy study. 2014 , 9, e115780	14
362	Amyloid β mediated Zn ²⁺ influx into dentate granule cells transiently induces a short-term cognitive deficit. 2014 , 9, e115923	30
361	Neuronal Cx3cr1 Deficiency Protects against Amyloid β Induced Neurotoxicity. 2015 , 10, e0127730	16
360	Virtual and In Vitro Screens Reveal a Potential Pharmacophore that Avoids the Fibrillization of A β -42. 2015 , 10, e0130263	9
359	Tetrahydrohyperforin Inhibits the Proteolytic Processing of Amyloid Precursor Protein and Enhances Its Degradation by Atg5-Dependent Autophagy. 2015 , 10, e0136313	25
358	Traditional Chinese Nootropic Medicine Radix Polygalae and Its Active Constituent Onjisaponin B Reduce β Amyloid Production and Improve Cognitive Impairments. 2016 , 11, e0151147	17
357	Analyzing and Modeling the Dysfunction of Inhibitory Neurons in Alzheimer's Disease. 2016 , 11, e0168800	7
356	Wnt Signaling Prevents the A β Oligomer-Induced Mitochondrial Permeability Transition Pore Opening Preserving Mitochondrial Structure in Hippocampal Neurons. 2017 , 12, e0168840	35
355	Ligand field molecular dynamics simulation of Pt(II)-phenanthroline binding to N-terminal fragment of amyloid- β peptide. 2018 , 13, e0193668	5
354	Selectively reduced expression of synaptic plasticity-related genes in amyloid precursor protein + presenilin-1 transgenic mice. 2003 , 23, 5219-26	196
353	Effect of A β Oligomers on Neuronal APP Triggers a Vicious Cycle Leading to the Propagation of Synaptic Plasticity Alterations to Healthy Neurons. 2020 , 40, 5161-5176	4
352	Protective Effects of Proline-Rich Peptide in a Rat Model of Alzheimer Disease: An Electrophysiological Study. 2017 , 8, 5-12	1
351	Alzheimer's disease: amyloid-based pathogenesis and potential therapies. 2018 , 2, 150-161	11
350	Inhibition of A β Oligomerization in yeast by a PICALM ortholog and certain FDA approved drugs. 2016 , 3, 53-64	12
349	Yeast screening platform identifies FDA-approved drugs that reduce A β Oligomerization. 2016 , 3, 97-100	6
348	Compensatory mechanisms to heal neuroplasticity impairment under Alzheimer's disease neurodegeneration. I: The role of amyloid beta and its' precursor protein. 2012 , 58, 385-399	2

347	Innate immune activation in Alzheimer's disease. 2018 , 6, 177	33
346	Protein aggregation in the brain: the molecular basis for Alzheimer's and Parkinson's diseases. 2008 , 14, 451-64	362
345	Key Peptides and Proteins in Alzheimer's Disease. 2019 , 20, 577-599	14
344	Cyclic Nucleotides Signaling and Phosphodiesterase Inhibition: Defying Alzheimer's Disease. 2020 , 21, 1371-1384	11
343	MiR-335-5p Inhibits β Amyloid (A β) Accumulation to Attenuate Cognitive Deficits Through Targeting c-jun-N-terminal Kinase 3 in Alzheimer's Disease. 2020 , 17, 93-101	7
342	Amyloid- β Aggregation Inhibitory and Neuroprotective Effects of Xanthohumol and its Derivatives for Alzheimer's Diseases. 2019 , 16, 836-842	6
341	Brain Arrhythmias Induced by Amyloid Beta and Inflammation: Involvement in Alzheimer's Disease and Other Inflammation-related Pathologies. 2019 , 16, 1108-1131	8
340	Reversal of Calcium Dysregulation as Potential Approach for Treating Alzheimer's Disease. 2020 , 17, 344-354	5
339	Advances in Studies on Stroke-Induced Secondary Neurodegeneration (SND) and Its Treatment. 2020 , 20, 1154-1168	4
338	Anti-Amyloid Effects of Small Molecule A β Binding Agents in PS1/APP Mice. 2009 , 6, 437	19
337	Biphasic mechanisms of neurovascular unit injury and protection in CNS diseases. 2013 , 12, 302-15	77
336	Spatiotemporal Regulation of Signaling in and out of Dendritic Spines: CaMKII and Ras. 2009 , 3, 117-127	16
335	Kisspeptin-13 Improves Spatial Memory Consolidation and Retrieval against Amyloid- β Pathology. 2019 , 18, 169-181	3
334	Imaging of Neurotransmitter Systems in Dementia. 2016 , 271-296	9
333	Biochemical aspects of dementias. 2003 , 5, 27-33	4
332	Extracellular Amyloid Deposits in Alzheimer's and Creutzfeldt-Jakob Disease: Similar Behavior of Different Proteins?. 2020 , 22,	6
331	A current view of Alzheimer's disease. 2009 , 1, 54	6
330	NKX6.3 protects against gastric mucosal atrophy by downregulating β amyloid production. 2019 , 25, 330-345	2

329	Challenges in understanding the structure/activity relationship of A β oligomers. 2019 , 6, 1-22	2
328	Is Stroke a Neurodegenerative Condition? A Critical Review of Secondary Neurodegeneration and Amyloid-beta Accumulation after Stroke. 2017 , 4, 1-16	22
327	Chronic pre-treatment with memantine prevents amyloid-beta protein-mediated long-term potentiation disruption. 2013 , 8, 49-55	2
326	Amyloid Beta annular protofibrils in cell processes and synapses accumulate with aging and Alzheimer-associated genetic modification. 2009 , 2009,	16
325	Amynin Ameliorates Alzheimer's Disease-Like Aberrant Synaptic Plasticity in the Mouse Hippocampus. 2020 , 28, 74-82	7
324	Polyphenolic Biflavonoids Inhibit Amyloid-Beta Fibrillation and Disaggregate Preformed Amyloid-Beta Fibrils. 2020 , 28, 145-151	15
323	Effects of turmeric on Alzheimer's disease with behavioral and psychological symptoms of dementia. 2012 , 33, 499-504	86
322	Synaptic dysfunction in Alzheimer's disease: the effects of amyloid beta on synaptic vesicle dynamics as a novel target for therapeutic intervention. 2018 , 13, 616-623	57
321	Cognitive deficits and Alzheimer-like neuropathological impairments during adolescence in a rat model of type 2 diabetes mellitus. 2018 , 13, 1995-2004	11
320	Glutamate receptor delocalization in postsynaptic membrane and reduced hippocampal synaptic plasticity in the early stage of Alzheimer's disease. 2019 , 14, 1037-1045	13
319	Physiological and pathological effects of amyloid- β species in neural stem cell biology. 2019 , 14, 2035-2042	12
318	Human Pentraxins Bind to Misfolded Proteins and Inhibit Production of Type I Interferon Induced by Nucleic Acid-Containing Amyloid. 2015 , 6,	2
317	Spatial structure of beta-amyloid A β 1-40 in complex with a biological membrane model. 2012 , 01, 22-29	2
316	Therapeutic Effects of Curcumin on Alzheimer's Disease. 2014 , 03, 145-159	13
315	A Lysozyme Concentration, pH, and Time-Dependent Isothermal Transformation Diagram Reveals Fibrous Amyloid and Non-Fibrous, Amorphous Aggregate Species. 2014 , 04, 39-50	9
314	Spectroscopic Investigations of β -Amyloid Interactions with Propofol and L-Arginine. 2015 , 05, 50-67	3
313	Toxic oligomer species of amyloid- β in Alzheimer's disease, a timing issue. 2014 , 144, w14021	24
312	Computational Study of Human Calcitonin (hCT) Oligomer. 2009 , 30, 3006-3010	2

311	Amyloid pore-channel hypothesis: effect of ethanol on aggregation state using frog oocytes for an Alzheimer's disease study. 2015 , 48, 13-8	9
310	Effect of Aggregated β Amyloid (1-42) on Synaptic Plasticity of Hippocampal Dentate Gyrus Granule Cells in Vivo. 2012 , 2, 189-94	10
309	Nicotine alters the proteome of two human pancreatic duct cell lines. 2014 , 15, 465-74	16
308	Intrinsically aggregation-prone proteins form amyloid-like aggregates and contribute to tissue aging in. 2019 , 8,	25
307	TREM2-H157Y Increases Soluble TREM2 Production and Reduces Amyloid Pathology.	0
306	Inhalational Anesthetics Do Not Deteriorate Amyloid- β Derived Pathophysiology in Alzheimer's Disease: Investigations on the Molecular, Neuronal, and Behavioral Level. 2021 , 84, 1193-1218	
305	C9orf72-derived poly-GA DPRs undergo endocytic uptake in iNPC-derived astrocytes and spread to motor neurons.	
304	Neurogranin and Neuronal Pentraxin Receptor as Synaptic Dysfunction Biomarkers in Alzheimer's Disease. 2021 , 10,	1
303	Combined High-Pressure and Multiquantum NMR and Molecular Simulation Propose a Role for N-Terminal Salt Bridges in Amyloid-Beta. 2021 , 12, 9933-9939	1
302	The effect of sodium channels on neurological/neuronal disorders: A systematic review. 2021 , 81, 669-685	0
301	Drosophila p38 MAPK interacts with BAG-3/starvin to regulate age-dependent protein homeostasis. 2021 , 20, e13481	1
300	Interactions of the A β (1-42) Peptide with Boron Nitride Nanoparticles of Varying Curvature in an Aqueous Medium: Different Pathways to Inhibit β Sheet Formation. 2021 , 125, 11159-11178	3
299	Smoking gun found for Alzheimer's. <i>Nature</i> ,	50.4
298	Antibody Therapy Against β Amyloid to Treat Alzheimer's Disease. 2003 , 75-83	
297	The Role of NF- κ B in Inflammatory Diseases. 2003 , 295-323	0
296	Cytotoxicity of PrP Peptides. 2004 , 176-197	1
295	Protein Misfolding as a Disease Determinant. 2004 , 1009-1036	2
294	Genetic and molecular aspects of Alzheimer's disease shed light on new mechanisms of transcriptional regulation. 2005 , 051213091414049	

293 Correlation between Stability and Propensity to Form Amyloid-like Fibrils. **2004**, 21-23

292 Studying Amyloid b-Protein Assembly. **2004**,

291 Amyloid Therapeutic Strategies for Alzheimer's Disease.

0

290 Amyloid- β and τ in Alzheimer's Disease. **2005**, 121-129

289 Amyloid- β Peptide, a Therapeutic Target for Alzheimer's Disease?. **2005**, 395-408

288 Methionine Sulfoxide Reductase System. **2005**, 199-212

287 Drugs from Molecular Targets for CNS and Neurodegenerative Diseases. **2006**, 225-241

286 Design of Artificial Proteins and Peptides Targeting to Amyloid β -Peptide (A β) and Control of A β Aggregation. **2007**, 47, 228-234

285 The Rationale for an Immunological Approach to Alzheimer's Therapeutics. **2007**, 141-148

284 ANTI-AMYLOID- β IMMUNOTHERAPY AS A TREATMENT FOR ALZHEIMER'S DISEASE. **2008**, 295-318

1

283 Long-Term Potentiation and A β -Targeting A β -Species, Cellular Mechanisms and Putative Receptors. **2008**, 157-167

282 An Overview of Protein Misfolding Diseases.

281 Heat Shock Proteins, Unfolded Protein Response Chaperones and Alzheimer's Disease. **2008**, 25-50

280 Prion Protein. 493

279 Cellular Toxicity of Protein Aggregates. 319

278 Protein Misfolding and Disease. 1

277 Impact of A β and Tau on Cognition in Mouse Models of Alzheimer's Disease. **2009**, 1-15

276 Inhibition of Protein Amyloidosis by Glycomaterials. **2009**, 21, 324-334

275 Drosophila Model of Alzheimer's Amyloidosis. **2009**, 197-206

274 Proteases In Amyloid Metabolism: Potential Therapeutic Targets Against Alzheimer's Disease. **2009**, 385-402

273 ??????????????. **2010**, 56, 447-451

272 One-Compound-Multi-Targets at Amyloid Cascade Offered By Bis(7)-Cognitin, a Novel Anti-Alzheimer's Dimer. **2010**, 165-183

271 Synaptic Dysfunction in Huntington's Disease. **2011**, 233-255

270 Synapses and Alzheimer's Disease: Effect of Immunotherapy?. **2011**, 269-287

269 DHEA and Alzheimer's Disease. **2011**, 433-445

268 Biological Targeting and Activity of Pre-fibrillar A β Assemblies. **2012**, 103-133

267 Oligomers of Synuclein in the Pathogenesis of Parkinson's Disease. **2012**, 189-216

266 Pathogenesis of Alzheimer's Disease with Special Reference to Amyloid β Protein. **2012**, 8, 285-290

265 Amyloid Diseases at the Molecular Level: General Overview and Focus on AL Amyloidosis. **2012**, 9-29

264 The Amyloid β -Protein and Alzheimer's Disease. **2012**, 1-85

263 New Small Molecule Drug Discovery for Alzheimer's Disease. **2012**, 163-210

262 Protein Misfolding and Disease. 379-400

261 Role of Cellular Prion Protein in the Amyloid- β Oligomer Pathophysiology of Alzheimer's Disease. **2013**, 35-48

260 Ubiquitin-Dependent Protein Degradation. **2013**,

259 Amyloid- β Transmissibility. **2013**, 71-86

258 Regulatory Crosstalk Analysis of Biochemical Networks in the Hippocampus and Nucleus Accumbens. **2013**, 95-127

257 Correlati neurobiologici nell'anziano con malattia di alzheimer e altre demenze. **2013**, 389-406

256 Alzheimer Disease. **2013**,

255 Animal Models of Alzheimer's Disease. **2014**, 527-540

254 Controlling Reversible Self-Assembly Path of Amyloid Beta Peptide over Gold Colloidal Nanoparticles Surfaces. **2013**, 279-304

1

253 A Mini Review on A β Oligomers and its Pathogenicity. **2014**, 7, 79-86

252 Introduction. **2015**, 1-28

251 Alzheimer's Disease and Other Neurodegenerative Disorders. **2015**, 329-351

250 Immunotherapeutic Approaches Against Amyloid- β In Drug Discovery for Alzheimer's Disease. **2015**, 395-415

249 Enhanced neuronal degradation of amyloid- β oligomers allows synapse regeneration. **2015**, 10, 700-1

1

248 Protein Misfolding and Aggregation. **2015**, 95-127

247 The Application of Biophysical Techniques to the Study of the Inhibition of Aggregation of A β Using PINPs Liposomes. **2016**, 121-137

246 Pathological Consequences of A β From Extracellular to Intraneuronal. **2016**, 69-113

245 SARS Vaccines. **2016**, 942-954

244 New Insight into Metallomics in Cognition. **2017**, 315-339

243 Human brain-derived A β oligomers bind to synapses and disrupt synaptic activity in a manner that requires APP.

o

242 Unexpected Early Proteomic Changes in Alzheimer's Disease Model Mice Synaptosomes.

241 Effects of Force Fields on the Conformational and Dynamic Properties of Amyloid (1-40) Dimer Explored by Replica Exchange Molecular Dynamics Simulations.

240 Intrinsically aggregation-prone proteins form amyloid-like aggregates and contribute to tissue aging in *C. elegans*.

- 239 Deletion of a conserved Gata2 enhancer impairs haemogenic endothelium programming and adult haematopoiesis. 1
- 238 Immunotherapy in Alzheimer's Disease. **2019**, 271-293
- 237 Dysregulation of Heat Shock Proteins in Neurodegenerative Diseases: Restorative Roles of Small Molecules and Natural Compounds. **2019**, 85-114 1
- 236 A quantitative model of human neurodegenerative diseases involving protein aggregation.
- 235 Differential Inhibition of E-S Potentiation and Long-term Potentiation by Cell-derived and Arctic Amyloid Beta.
- 234 Misfolded amyloid β 2 induced impairment of the endosomal-lysosomal pathway revealed by real-time optical monitoring.
- 233 Aggregation dynamics of charged peptides in water: effect of salt concentration.
- 232 Altered dorsal CA1 neuronal population coding in the APP/PS1 mouse model of Alzheimer's disease.
- 231 CAP2 is a novel regulator of Cofilin in synaptic plasticity and Alzheimer's disease.
- 230 Fruit bromelain derived peptides destabilize growth of amyloid fibrils.
- 229 The autophagy activator Spermidine reduces neuroinflammation and soluble amyloid beta in an Alzheimer's disease mouse model.
- 228 Removal of blood amyloid- β s an effective and safe therapeutic strategy for Alzheimer's disease. **2020**, 647-662
- 227 Coenzyme Q and Age-Related Neurodegenerative Disorders: Parkinson and Alzheimer Diseases. **2020**, 241-268
- 226 Alzheimer's Disease: Etiology, Neuropathology and Pathogenesis. 1-22 5
- 225 Deep Brain Stimulation for Alzheimer's Disease: Tackling Circuit Dysfunction. **2021**, 24, 171-186 9
- 224 The Role of A β in the Development of Alzheimer's Disease and its Mechanisms. **2020**, 218, 03041
- 223 Synaptosomal bioenergetic defects in Alzheimer's disease. **2020**, 473-490
- 222 Phosphatidylethanolamine accelerates aggregation of the amyloidogenic N-terminal fragment of apoA-I. **2020**, 594, 1443-1452 0

221	Thermodynamic and kinetic design principles for protein aggregation inhibitors.	2
220	Out-of-register parallel β -sheets and antiparallel β -sheets coexist in 150 kDa oligomers formed by A β (1-42).	
219	Asymptomatic neurotoxicity of amyloid β -peptides (A β 1-42 and A β 5-35) on mouse embryonic stem cell-derived neural cells. 2021 , 21, 98-110	0
218	STEP inhibition prevents A β -mediated damage in dendritic complexity and spine density in Alzheimer's disease..	0
217	Consequences of endogenous and virally-induced hyperphosphorylated tau on behavior and cognition in a rat model of Alzheimer's disease.	
216	Plaque-Associated Oligomeric Amyloid-Beta Drives Early Synaptotoxicity in APP/PS1 Mice Hippocampus: Ultrastructural Pathology Analysis. 2021 , 15, 752594	5
215	A β -induced synaptic injury is mediated by presynaptic expression of amyloid precursor protein (APP) in hippocampal neurons.	
214	Differential Effect of Amyloid Beta1-40 on Short-term and Long-term Plasticity in Dentate Gyrus of a Rat Model of Alzheimer Disease. 2020 , 11, 517-524	0
213	A β -Monomer, Oligomer and Fibril in Alzheimer's Disease. 1557-1563	
212	A β -Monomer, Oligomer and Fibril in Alzheimer's Disease. 125-131	
211	β -Secretase: Physiological Role and Target Validation. 59-76	
210	Beta Amyloid and Excitatory Synapses. 151-156	
209	Cell Models of Tauopathy. 2008 , 325-336	
208	Dendritic Organelles for Postsynaptic Trafficking. 2008 , 205-249	1
207	The cellular response to aggregated proteins associated with human disease. 2002 , 110, 1219-20	10
206	Structure, Function, and Regulation of the Microtubule Associated Protein Tau. 2008 , 559-576	
205	Physiologic and Neurotoxic Properties of A β -Peptides. 2007 , 179-197	
204	Mouse Models of Alzheimer's Disease. 2007 , 259-273	

203	Copper Coordination by β -Amyloid and the Neuropathology of Alzheimer's Disease. 2007 , 125-141	
202	Protein Folding, Unfolding and Aggregation Studied Using an All-Atom Model with a Simplified Interaction Potential. 2008 , 269-291	
201	Synapse Loss, Synaptic Plasticity and the Postsynaptic Density. 2008 , 51-62	
200	TLR4 in Neurodegenerative Diseases: Alzheimer's and Parkinson's Diseases. 2021 , 105-118	
199	Protecting synapses from amyloid β -associated degeneration by manipulations of Wnt/planar cell polarity signaling.	0
198	Perphenazine-macrocyclic conjugates rapidly sequester the A β 2 monomer and inhibit amyloid formation.	
197	Formation of amyloid fibrils in vitro by human gammaD-crystallin and its isolated domains. 2008 , 14, 81-9	60
196	BRAIN MYELINATION IN PREVALENT NEUROPSYCHIATRIC DEVELOPMENTAL DISORDERS: PRIMARY AND COMORBID ADDICTION. 2005 , 29, 55-96	23
195	[Not Available]. 2009 , 3, 13	4
194	Evaluation of neprilysin sequence variation in relation to CSF β -Amyloid levels and Alzheimer disease risk. 2010 , 1, 47-52	6
193	Alzheimer's Disease: Fatty Acids We Eat may be Linked to a Specific Protection via Low-dose Aspirin. 2010 , 1, 37-59	7
192	Reelin-mediated Signaling during Normal and Pathological Forms of Aging. 2010 , 1, 12-29	15
191	Alzheimer's disease biomarkers in animal models: closing the translational gap. 2013 , 2, 108-20	13
190	Evaluation of neural damage in Duchenne muscular dystrophy patients. 2014 , 33, 13-8	5
189	Construction of human Fab library and screening of a single-domain antibody of amyloid-beta 42 oligomers. 2013 , 8, 3107-15	5
188	Protective effects of luteolin against cognitive impairment induced by infusion of A β peptide in rats. 2015 , 8, 6740-7	14
187	Effect of Cinnamomum Verum Extract on the Amyloid Formation of Hen Egg-white Lysozyme and Study of its Possible Role in Alzheimer's Disease. 2015 , 6, 29-37	13
186	The characteristics of astrocyte on A β clearance altered in Alzheimer's disease were reversed by anti-inflammatory agent (+)-2-(1-hydroxyl-4-oxocyclohexyl) ethyl caffeate. 2016 , 8, 4082-4094	13

185	Alzheimer's Toxic Amyloid Beta Oligomers: Unwelcome Visitors to the Na/K ATPase alpha3 Docking Station. 2017 , 90, 45-61	17
184	Taming Alzheimer's disease: New perspectives, newer horizons. 2017 , 16, 146-155	4
183	Lynx1 Prevents Long-Term Potentiation Blockade and Reduction of Neuromodulator Expression Caused by A β -42 and JNK Activation. 2018 , 10, 57-61	3
182	Alzheimer's Pathogenesis, Metal-Mediated Redox Stress, and Potential Nanotheranostics. 2019 , 7, 547-558	
181	Neurodegeneration and axonal mRNA transportation. 2021 , 10, 1-12	1
180	An ultra-sensitive immunoassay detects and quantifies soluble A β oligomers in human plasma. 2021 ,	3
179	Mechanical Stretching-Induced Traumatic Brain Injury Is Mediated by the Formation of GSK-3 β /Tau Complex to Impair Insulin Signaling Transduction. 2021 , 9,	
178	Revisit the Cellular Transmission and Emerging Techniques in Understanding the Mechanisms of Proteinopathies. 2021 , 15, 781722	
177	Coassembled Chitosan-Hyaluronic Acid Nanoparticles as a Theranostic Agent Targeting Alzheimer's β Amyloid. 2021 , 13, 55879-55889	2
176	Precision Mapping of Amyloid- β Binding Reveals Perisynaptic Localization and Spatially Restricted Plasticity Deficits. 2021 ,	1
175	Structural biology of cell surface receptors implicated in Alzheimer's disease.. 2022 , 14, 233-255	0
174	Proteotoxicity and Autophagy in Neurodegenerative and Cardiovascular Diseases. 2022 , 219-237	
173	Role of Receptors in Relation to Plaques and Tangles in Alzheimer's Disease Pathology. 2021 , 22,	2
172	Non-invasive visualization of amyloid-beta deposits in Alzheimer amyloidosis mice using magnetic resonance imaging and fluorescence molecular tomography.	2
171	Discovery of a novel pseudo β hairpin structure of N-truncated amyloid- β for use as a vaccine against Alzheimer's disease. 2021 ,	4
170	Biological and methodological complexities of beta-amyloid peptide: Implications for Alzheimer's disease research. 2021 ,	2
169	Tau Biomarkers in Dementia: Positron Emission Tomography Radiopharmaceuticals in Tauopathy Assessment and Future Perspective. 2021 , 22,	0
168	Time-Dependent Analysis of Plasmalogens in the Hippocampus of an Alzheimer's Disease Mouse Model: A Role of Ethanolamine Plasmalogen.. 2021 , 11,	0

167 [Alzheimer disease and epilepsy]. **2021**, 121, 23-29

166 Global fitting and parameter identifiability for amyloid- β aggregation with competing pathways. **2020**, 0

165 Synaptic dysfunction in early phases of Alzheimer's Disease.. **2022**, 184, 417-438 2

164 Effects of Lipoic Acid on Phagocytosis of Oligomeric Beta-Amyloid in BV-2 Mouse Microglial Cells.. **2021**, 13, 788723 0

163 The Amyloid- β oligomer interacting peptide D-AIP possesses favorable biostability, pharmacokinetics, and brain region distribution.. **2021**, 101483 1

162 Reactive Astrocytes Contribute to Alzheimer's Disease-Related Neurotoxicity and Synaptotoxicity in a Neuron-Astrocyte Co-culture Assay.. **2021**, 15, 739411 1

161 Role of proline-rich tyrosine kinase 2 (Pyk2) in the pathogenesis of Alzheimer's Disease.. **2021**, 0

160 Controllable signal molecule release from Au NP-gated MSNs for photocathodic detection of ultralow level A β .. **2021**, 1

159 Pathway-specific TNF-mediated metaplasticity in hippocampal area CA1.. **2022**, 12, 1746 0

158 Consequences of Hyperphosphorylated Tau in the Locus Coeruleus on Behavior and Cognition in a Rat Model of Alzheimer's Disease.. **2022**, 0

157 Heparan sulfate from porcine mucosa promotes amyloid-beta clearance in APP/PS1 mice and alleviates Alzheimer's pathology.. **2022**, 285, 119205 2

156 Design and Experimental Evaluation of a Peptide Antagonist against Amyloid β (1-42) Interactions with Calmodulin and Calbindin-D28k.. **2022**, 23, 0

155 A β -Induced Alterations in Membrane Lipids Occur before Synaptic Loss Appears.. **2022**, 23, 0

154 An Essential Role for Alzheimer's-Linked Amyloid Beta Oligomers in Neurodevelopment: Transient Expression of Multiple Proteoforms during Retina Histogenesis.. **2022**, 23, 1

153 Alzheimer's disease amyloid- β pathology in the lens of the eye.. **2022**, 108974 1

152 Spatial Training Attenuates Long-Term Alzheimer's Disease-Related Pathogenic Processes in APP/PS1 Mice.. **2021**, 0

151 Optogenetics: implications for Alzheimer's disease research and therapy.. **2022**, 15, 20 1

150 Application of LSPR-based optical biosensors. **2022**, 0

149	Amyloidosis in Alzheimer's Disease: Pathogeny, Etiology, and Related Therapeutic Directions.. 2022 , 27,	7
148	Advances in stem cell therapy in Alzheimer's disease: a comprehensive clinical trial review.. 2022 , 9, 2	0
147	Supramolecular Copolymers of Peptides and Lipidated Peptides and Their Therapeutic Potential.. 2022 , 144, 5562-5574	0
146	Structure optimization of the toxic conformation model of amyloid β 2 by intramolecular disulfide bond formation.. 2022 ,	1
145	Commercial and Instant Coffees Effectively Lower A β -40 and A β -42 in N2a/APPswe Cells.. 2022 , 9, 850523	1
144	Mechanistic Kinetic Model Reveals How Amyloidogenic Hydrophobic Patches Facilitate the Amyloid-Fibril Elongation.. 2022 ,	
143	Pattern of Otitis Externa in ENT Outpatient Department. 9,	
142	Microglial large extracellular vesicles propagate early synaptic dysfunction in Alzheimer's disease.. 2022 ,	4
141	PCSK9 acts as a key regulator of A β clearance across the blood-brain barrier.. 2022 , 79, 212	1
140	Impairments of glutamatergic synaptic transmission in Alzheimer's disease.. 2022 ,	0
139	Association of Emerging β Amyloid and Tau Pathology With Early Cognitive Changes in Clinically Normal Older Adults.. 2022 ,	1
138	Differential vulnerability of hippocampal CA3-CA1 synapses to A β 2022 , 10, 45	
137	Structural basis of FPR2 in recognition of A β and neuroprotection by humanin.. 2022 , 13, 1775	1
136	The Homer1 family of proteins at the crossroad of dopamine-glutamate signaling: an emerging molecular "Lego" in the pathophysiology of psychiatric disorders. A systematic review and translational insight.. 2022 , 104596	2
135	Astrocytic C-X-C motif chemokine ligand-1 mediates β amyloid-induced synaptotoxicity.. 2021 , 18, 306	1
134	Friend or Foe? The Varied Faces of Homeostatic Synaptic Plasticity in Neurodegenerative Disease.. 2021 , 15, 782768	1
133	Pathogenesis of Alzheimer's Disease. 2021 , 1-20	
132	Deep Learning Assisted Stratification of Amyloid Beta Mutants Using Drying Droplet Patterns.. 2022 , e2110404	1

- 131 Amyloid- β Induces Cdh1-Mediated Rock2 Stabilization Causing Neurodegeneration.. **2022**, 13, 884470 o
- 130 Lipid Rafts Act as a Common Platform for Amyloid- β Oligomer-Induced Alzheimer's Disease Pathology.. **2022**, o
- 129 Inhibition of Nogo-A rescues synaptic plasticity and associativity in APP/PS1 animal model of Alzheimer's disease.. **2022**, o
- 128 The synapse as a treatment avenue for Alzheimer's Disease.. **2022**, 1
- 127 Ganglioside enriched phospholipid vesicles induce cooperative A β oligomerization and membrane disruption.
- 126 Data_Sheet_1.pdf. **2020**,
- 125 Data_Sheet_1.pdf. **2020**,
- 124 Image1.JPEG. **2018**,
- 123 Image2.JPEG. **2018**,
- 122 Image3.JPEG. **2018**,
- 121 Data_Sheet_1.pdf. **2020**,
- 120 Data_Sheet_1.docx. **2020**,
- 119 Data_Sheet_1.PDF. **2019**,
- 118 DataSheet_1.pdf. **2019**,
- 117 DataSheet_2.pdf. **2019**,
- 116 DataSheet_3.pdf. **2019**,
- 115 DataSheet_1.zip. **2019**,
- 114 Involvement of cholesterol and β amyloid in the initiation and progression of Alzheimer's disease. **2022**, 715-745

113	ACU193: An Immunotherapeutic Poised to Test the Amyloid β Oligomer Hypothesis of Alzheimer's Disease.. 2022 , 16, 848215	1
112	Bioactive human Alzheimer brain soluble A β pathophysiology and therapeutic opportunities.. 2022 , 16, 866434	2
111	Vagus Nerve Stimulation as a Potential Therapy in Early Alzheimer's Disease: A Review.. 2022 , 16, 866434	1
110	A β Induced synaptic impairments require CaMKII activity that is stimulated by indirect signaling events. 2022 , 104368	
109	Amyloid- β Oligomers: Multiple Moving Targets. 2022 , 2, 91-110	2
108	A β Oligomer concentration in mouse and human brain and its drug-induced reduction ex vivo.. 2022 , 3, 100630	0
107	An aggregation inhibitor specific to oligomeric intermediates of A β 2 derived from phage display libraries of stable, small proteins.. 2022 , 119, e2121966119	1
106	Aptamer-Induced-Dimerization Strategy Attenuates A β Toxicity through Modulating the Trophic Activity of PrP Signaling.. 2022 , 119, e2121966119	2
105	The Small Molecule GAL-201 Efficiently Detoxifies Soluble Amyloid β Oligomers: New Approach towards Oral Disease-Modifying Treatment of Alzheimer's Disease. 2022 , 23, 5794	1
104	Non-invasive visualization of amyloid-beta deposits in Alzheimer amyloidosis mice using magnetic resonance imaging and fluorescence molecular tomography.	1
103	GW5074 Increases Microglial Phagocytic Activities: Potential Therapeutic Direction for Alzheimer's Disease. 16,	1
102	Microglia in Alzheimer's Disease: A Favorable Cellular Target to Ameliorate Alzheimer's Pathogenesis. 2022 , 2022, 1-17	
101	Physiological Roles of Monomeric Amyloid- β and Implications for Alzheimer's Disease Therapeutics. 2022 , 31, 65-88	3
100	Restoring synapse integrity and memory in Alzheimer's disease by downregulation of the Wnt antagonist Dickkopf-3.	
99	Insulin and Its Key Role for Mitochondrial Function/Dysfunction and Quality Control: A Shared Link between Dysmetabolism and Neurodegeneration. 2022 , 11, 943	1
98	NMDA and AMPA Receptors at Synapses: Novel Targets for Tau and β Synuclein Proteinopathies. 2022 , 10, 1550	0
97	Effect of Cholesterol on C99 Dimerization: Revealed by Molecular Dynamics Simulations. 9,	1
96	Reducing fibrosis progression of biliary atresia by continuous administration of aducanumab at low dose: A potential treatment. 2022 , 165, 110901	

- 95 Aβ oligomers from human brain impair mossy fiber LTP in CA3 of hippocampus, but activating cAMP-PKA and cGMP-PKG prevents this. **2022**, 172, 105816
- 94 Inhibition of Rac1 in ventral hippocampal excitatory neurons improves social recognition memory and synaptic plasticity. 14,
- 93 Coumarin derivatives against amyloid-beta 40/42 peptide and tau protein. **2022**,
- 92 Synaptic Disruption by Soluble Oligomers in Patients with Alzheimer's and Parkinson's Disease. **2022**, 10, 1743 0
- 91 Salt-Inducing Assembly Polymorphism Strategy for Cytotoxicity Differentiation of Phenol-Soluble Modulin B Assemblies. **2022**, 23, 3318-3328 1
- 90 SorCS1 inhibits amyloid-β binding to neurexin and rescues amyloid-β induced synaptic pathology.
- 89 Treatment of Alzheimer's disease by promoting the aggregation of small β-amyloid peptides. **2022**, 52, 1184-1191
- 88 Extracellular vesicles and Alzheimer's disease in the novel era of Precision Medicine: Implications for disease progression, diagnosis and treatment. **2022**, 114183 0
- 87 Modeling the early stages of Alzheimer's disease by administering intracerebroventricular injections of human native Aβ oligomers to rats. **2022**, 10, 0
- 86 Synthesis and Characterization of Propeller- and Parallel-Type Full-Length Amyloid β0 Trimer Models. **2022**, 13, 2517-2528 1
- 85 Oligomeropathies, inflammation and prion protein binding. 16, 1
- 84 Effects of pramipexole on beta-amyloid1β2 memory deficits and evaluation of oxidative stress and mitochondrial function markers in the hippocampus of Wistar rat. **2022**, 92, 91-101 1
- 83 Astrocyte energy and neurotransmitter metabolism in Alzheimer's disease: Integration of the glutamate/GABA-glutamine cycle. **2022**, 217, 102331 2
- 82 An adjustable amyloid-β oligomers aptasensor based on the synergistic effect of self-enhanced metal-organic gel luminophore and triple-helix DNA system. **2022**, 0
- 81 A systematic review on drugs for synaptic plasticity in the treatment of dementia. **2022**, 81, 101726 1
- 80 PEDF-Derived Peptide Protects Against Amyloid-β Toxicity in vitro and Prevents Retinal Dysfunction in Rats. 0
- 79 Therapeutic nanosweepers promote β amyloid removal from the brain for Alzheimer's disease treatment. 0
- 78 Biologically Active Fragment of the Receptor for Advanced Glycation End Products (RAGE) Is Able to Inhibit Oligomerization of the Beta-Amyloid. **2022**, 48, 731-738 0

- 77 The Antioxidative Effects of Picein and Its Neuroprotective Potential: A Review of the Literature. **2022**, 27, 6189 ○
- 76 Elevated ganglioside GM2 activator (GM2A) in human brain tissue reduces neurite integrity and spontaneous neuronal activity. **2022**, 17, ○
- 75 A long-term high-fat diet influences brain damage and is linked to the activation of HIF-1 α /AMPK/mTOR/p70S6K signalling. 16, ○
- 74 Optimization of the Linker Length in the Dimer Model of E22P-A β 0 Tethered at Position 38. **2022**, 13, 2913-2923 ○
- 73 Ganglioside-Enriched Phospholipid Vesicles Induce Cooperative A β Oligomerization and Membrane Disruption. ○
- 72 Characterization of the Conformations of Amyloid Beta 42 in Solution That May Mediate Its Initial Hydrophobic Aggregation. ○
- 71 The BACE1-generated C-terminal fragment of the neural cell adhesion molecule 2 (NCAM2) promotes BACE1 targeting to Rab11-positive endosomes. **2022**, 79, ○
- 70 APP Knock-In Mice Produce E22P-A β Exhibiting an Alzheimer's Disease-like Phenotype with Dysregulation of Hypoxia-Inducible Factor Expression. **2022**, 23, 13259 1
- 69 Internalized Amyloid- β (1-42) Peptide Inhibits the Store-Operated Calcium Entry in HT-22 Cells. **2022**, 23, 12678 ○
- 68 Amyloid A β 5-35 Aggregates Say NO to Long-Term Potentiation in the Hippocampus through Activation of Stress-Induced Phosphatase 1 and Mitochondrial Na⁺/Ca²⁺ Exchanger. **2022**, 23, 11848 ○
- 67 Amyloid- β 42 oligomers enhance mGlu5R-dependent synaptic weakening via NMDAR activation and complement C3aR/C5aR signaling. ○
- 66 STUDY ON THE AMYLOIDOGENIC POTENTIAL OF NON-SPECIFIC YERSINIA PSEUDOTUBERCULOSIS PORINS. **2022**, 7, 273-279 ○
- 65 Linking the Amyloid, Tau, and Mitochondrial Hypotheses of Alzheimer's Disease and Identifying Promising Drug Targets. **2022**, 12, 1676 3
- 64 Correlative cryo-soft X-ray tomography reveals defective lysosomes in amyloid- β oligomer treated hippocampal neurons. ○
- 63 Cryo-EM Structures of Amyloid- β Filaments With the Arctic Mutation (E22G) From Human and Mouse Brains. ○
- 62 Toward the Identification of Neurophysiological Biomarkers for Alzheimer's Disease in Down Syndrome: A Potential Role for Cross-Frequency Phase-Amplitude Coupling Analysis. **2022**, 0 ○
- 61 Current understanding of metal-dependent amyloid- β aggregation and toxicity. ○
- 60 Non-competitive AMPA glutamate receptors antagonism by perampanel as a strategy to counteract hippocampal hyper-excitability and cognitive deficits in cerebral amyloidosis. **2023**, 225, 109373 ○

- 59 The Protective and Therapeutic Anti-Alzheimer Potential of *Olea europaea* L. cv. Picual: An In Silico and In Vivo Study. **2022**, 12, 1178 0
- 58 Physiological Roles of β -Amyloid in Regulating Synaptic Function: Implications for AD Pathophysiology. 1
- 57 Swollen axons impair neuronal circuits in Alzheimer's disease. **2022**, 612, 218-220 0
- 56 Synthetic, Cell-Derived, Brain-Derived, and Recombinant β -Amyloid: Modelling Alzheimer's Disease for Research and Drug Development. **2022**, 23, 15036 0
- 55 Role of Hydrophobicity at the N-Terminal Region of A β 2 in Secondary Nucleation. **2022**, 13, 3477-3487 0
- 54 Biomarkers in the diagnosis of neurodegenerative diseases. **2022**, 26, 431-440 0
- 53 Perphenazine-Macrocycle Conjugates Rapidly Sequester the A β 2 Monomer and Prevent Formation of Toxic Oligomers and Amyloid. 0
- 52 Leptin-based hexamers facilitate memory and prevent amyloid-driven AMPA receptor internalisation and neuronal degeneration. 0
- 51 Synaptic degeneration in Alzheimer disease. 3
- 50 Simple, Reliable Protocol for High-Yield Solubilization of Seedless Amyloid- β Monomer. 0
- 49 Putative Structures of Membrane-Embedded Amyloid β -Oligomers. 1
- 48 Elucidation of Amyloid-Beta's Gambit in Oligomerization: Truncated A β fragments of residues A β 1-23, A β 1-24 and A β 1-25 rapidly seed to form SDS-stable, LMW A β oligomers that impair synaptic plasticity. 0
- 47 Zebrafish: A Model Deciphering the Impact of Flavonoids on Neurodegenerative Disorders. **2023**, 12, 252 0
- 46 Cryo-EM structures of amyloid- β filaments with the Arctic mutation (E22G) from human and mouse brains. 0
- 45 Neuroprotective Effects of a Multi-Herbal Extract on Axonal and Synaptic Disruption in Vitro and Cognitive Impairment in Vivo. 1-26 0
- 44 The Anaesthetics Isoflurane and Xenon Reverse the Synaptotoxic Effects of A β 2 on Megf10-Dependent Astrocytic Synapse Elimination and Spine Density in Ex Vivo Hippocampal Brain Slices. **2023**, 24, 912 0
- 43 Hydroxychloroquine lowers Alzheimer's disease and related dementias risk and rescues molecular phenotypes related to Alzheimer's disease. 0
- 42 Enhanced delivery of a low dose of aducanumab via FUS in 5FAD mice, an AD model. **2022**, 11, 3

- 41 The Apparent Organ-Specificity of Amyloidogenic ApoA-I Variants Is Linked to Tissue-Specific Extracellular Matrix Components. **2023**, 24, 318 1
- 40 The Contribution of Transgenic Models to the Understanding of Alzheimer's Disease Progression and Therapeutic Development. **2011**, 1-14 0
- 39 Animal Models of Amyloid/PS-1 Pathology. **2011**, 15-38 0
- 38 Adipokines and Alzheimer's Disease. **2011**, 130-148 0
- 37 A Function of Amyloid- β Mediating Activity-Dependent Axon/Synapse Competition May Unify Its Roles in Brain Physiology and Pathology. **2023**, 1-29 0
- 36 Modulation of A β 2 aggregation kinetics and pathway by low molecular weight inhibitors. 1
- 35 SorCS1 inhibits amyloid- β binding to neuexin and rescues amyloid- β induced synaptic pathology. **2023**, 6, e202201681 1
- 34 A β 56 is a stable oligomer that correlates with age-related memory loss in Tg2576 mice. 0
- 33 Structural Polymorphism and Cytotoxicity of Brain-derived β Amyloid Extracts. 0
- 32 Comprehensive review on pharmacological effects and mechanism of actions of taxifolin: A bioactive flavonoid. **2023**, 7, 100240 0
- 31 Pathogenesis of Alzheimer's Disease. **2022**, 1709-1728 0
- 30 DNAzyme-driven bipedal DNA walker triggered to hybridize silver nanoparticle probes for electrochemical detection of amyloid- β oligomer. **2023**, 1246, 340889 0
- 29 Plantainoside B in *Bacopa monniera* Binds to A β Aggregates Attenuating Neuronal Damage and Memory Deficits Induced by A β **2023**, 46, 320-333 0
- 28 Aberrant protein S-nitrosylation contributes to hyperexcitability-induced synaptic damage in Alzheimer's disease: Mechanistic insights and potential therapies. 17, 0
- 27 β Amyloid monomer scavenging by an anticalin protein prevents neuronal hyperactivity. 0
- 26 Phospholipase D1 Attenuation Therapeutics Promotes Resilience against Synaptotoxicity in 12-Month-Old 3xTg-AD Mouse Model of Progressive Neurodegeneration. **2023**, 24, 3372 0
- 25 Aquaporin-4 mediated aggregation of Alzheimer's amyloid β peptide. 0
- 24 Oxidative Stress in Brain in Amnesic Mild Cognitive Impairment. **2023**, 12, 462 0

- 23 Interictal epileptiform discharges affect memory in an Alzheimer's Disease mouse model. ○
- 22 Thymol in *Trachyspermum ammi* seed extract exhibits neuroprotection, learning, and memory enhancement in scopolamine-induced Alzheimer's disease mouse model. ○
- 21 Targeting BACE1-mediated production of amyloid beta improves hippocampal synaptic function in an experimental model of ischemic stroke. 0271678X2311595 ○
- 20 Soluble and insoluble protein aggregates, endoplasmic reticulum stress, and vascular dysfunction in Alzheimer's disease and cardiovascular diseases. ○
- 19 Imaging Amyloid-Membrane Interactions: Ion-Channel Pores and Lipid-Bilayer Permeability in Alzheimer's Disease. ○
- 18 Imaging Amyloid-Membrane Interactions: Ion-Channel Pores and Lipid-Bilayer Permeability in Alzheimer's Disease. ○
- 17 Sex differences in hippocampal β amyloid accumulation in the triple-transgenic mouse model of Alzheimer's disease and the potential role of local estrogens. 17, ○
- 16 Deficiency in neprilysin causes laminar impairments in the visual cortex. ○
- 15 Alleviating the unwanted effects of oxidative stress on A β clearance: a review of related concepts and strategies for the development of computational modelling. **2023**, 12, ○
- 14 Functional aberration of cortical neuronal network induced by A β 2 oligomer. ○
- 13 Learnings about A β from human brain recommend the use of a live-neuron bioassay for the discovery of next generation Alzheimer's disease immunotherapeutics. **2023**, 11, ○
- 12 Sigma-2 Receptors—from Basic Biology to Therapeutic Target: A Focus on Age-Related Degenerative Diseases. **2023**, 24, 6251 ○
- 11 Unravelling the mechanotransduction pathways in Alzheimer's disease. **2023**, 17, ○
- 10 Iron response elements (IREs)-mRNA of Alzheimer's amyloid precursor protein binding to iron regulatory protein (IRP1): a combined molecular docking and spectroscopic approach. **2023**, 13, ○
- 9 Exploring the Pathological Effect of A β 2 Oligomers on Neural Networks in Primary Cortical Neuron Culture. **2023**, 24, 6641 ○
- 8 Stem cells in the treatment of Alzheimer's disease [Promises and pitfalls. **2023**, 1869, 166712 ○
- 7 Exosomes as mediators of chemical-induced toxicity. **2023**, 97-112 ○
- 6 Artemisin and human endometrial-derived stem cells improve cognitive function and synaptic plasticity in a rat model of Alzheimer disease and diabetes. ○

- 5 Recent Development in the Understanding of Molecular and Cellular Mechanisms Underlying the Etiopathogenesis of Alzheimer's Disease. **2023**, 24, 7258 ○
- 4 Hearing loss and impaired short-term memory in an Alzheimer's disease mouse model of amyloid-beta pathology. **2023**, 365, 114413 ○
- 3 Discoveries and future significance of research into amyloid-beta/ τ -containing nicotinic acetylcholine receptor (nAChR) interactions. **2023**, 106743 ○
- 2 Peptide aptamer targeting A β /P τ axis reduces Alzheimer's disease pathologies in 5XFAD transgenic mouse model. **2023**, 80, ○
- 1 Antibodies Raised Against an A β Oligomer Mimic Recognize Pathological Features in Alzheimer's Disease and Associated Amyloid-Disease Brain Tissue. ○